<!DOCTYPE html><html>
<head>
<title></title>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body>
<a name=1></a><img src="chapter2-1_1.jpg"/><br/>
<b>C</b><br/>
<b>H</b><br/>
<b>A</b><br/>
<b>P</b><br/>
<b>T</b><br/>
<b>E</b><br/>
<b>R</b><br/>
<b>&#160; Genetic&#160;&#160;Disease&#160;</b><br/>
<b>&#160;Gregory&#160;Barsh, MD, PhD&#160;&#160;</b><br/>
<b>2</b><br/>
&#160;<br/>
Mechanisms of&#160;cellular and tissue dysfunction&#160;in genetic&#160;<br/>
Several genetic conditions have&#160;been found to&#160;depend not&#160;<br/>
&#160;<br/>
diseases are as varied as the organs&#160;they&#160;aff&#160;ect. To&#160;some&#160;<br/>
only&#160;on&#160;the gene being inherited&#160;but also on&#160;the phenotype&#160;or&#160;<br/>
extent, these mechanisms are similar to&#160;those that&#160;occur in&#160;<br/>
the sex of&#160;the parent. As&#160;an&#160;example of&#160;a condition&#160;that&#160;exhib-<br/>
nonheritable disorders. For example, a fracture&#160;resulting&#160;from&#160;<br/>
its nontraditional inheritance, &#160;<b>fragile X–associated mental&#160;</b><br/>
decreased bone density in osteoporosis heals in much&#160;the same&#160;<br/>
<b>retardation&#160;syndrome</b>&#160;&#160;is discussed. Th<br/>
&#160;&#160;is syndrome not only&#160;<br/>
way as one caused by&#160;a defective&#160;collagen gene in osteogen-<br/>
is the most common inherited&#160;cause of&#160;mental retardation but&#160;<br/>
esis imperfecta, and the response&#160;to&#160;coronary&#160;atherosclerosis&#160;<br/>
also illustrates how diff&#160;erent types of&#160;mutations&#160;can explain&#160;<br/>
in most individuals does not depend on&#160;whether they&#160;have&#160;<br/>
the perplexing phenomenon of&#160;&#160;<b>genetic anticipation</b>, &#160;&#160;where&#160;<br/>
inherited a defective&#160;low-density lipoprotein (LDL) receptor.&#160;<br/>
the severity of&#160;a mendelian syndrome appears to&#160;progress with&#160;<br/>
Th<br/>
&#160;&#160;us, the pathophysiologic principles that&#160;distinguish genetic&#160;<br/>
every generation of&#160;inheritance. Another group of&#160;disorders&#160;<br/>
disease&#160;focus not so&#160;much on&#160;the aff&#160;ected organ system as&#160;<br/>
that&#160;depend on&#160;the phenotype&#160;and sex of&#160;the parent&#160;consists&#160;<br/>
on&#160;the mechanisms of&#160;mutation, inheritance, and molecular&#160;<br/>
of&#160;those that&#160;aff&#160;ect the mitochondrial genome. As&#160;examples,&#160;<br/>
pathways from&#160;genotype to&#160;phenotype.&#160;<br/>
&#160;<b>Leber hereditary optic&#160;neuropathy</b>&#160;&#160;&#160;(&#160;<b>LHON</b>&#160;) and &#160;<b>myoclonic&#160;</b><br/>
&#160;Th<br/>
&#160;is chapter begins with&#160;a discussion of&#160;the terminol-<br/>
<b>epilepsy with ragged red fi&#160;bers</b>&#160;&#160;&#160;(&#160;<b>MERRF</b>&#160;) are considered.&#160;<br/>
ogy used to&#160;describe inherited&#160;conditions, the prevalence of&#160;<br/>
Th<br/>
&#160;&#160;ese illustrate&#160;the principles of&#160;mitochondrial inheritance&#160;<br/>
genetic disease, and some major principles and considerations&#160;<br/>
and its pathophysiology.&#160;&#160;<b>Aneuploidy</b>&#160;&#160;is discussed&#160;as one of&#160;the&#160;<br/>
in medical genetics. Important terms and key words used&#160;<br/>
most common types of&#160;human genetic disease&#160;that&#160;does not&#160;<br/>
throughout&#160;the chapter are defi&#160;ned in &#160;Table 2–1&#160;.&#160;<br/>
aff&#160;ect DNA structure&#160;but instead alters&#160;the normal chromo-<br/>
&#160;Next, a group of&#160;disorders caused by&#160;mutations&#160;in collagen&#160;<br/>
some content per cell. Th<br/>
&#160;&#160;e example that&#160;is considered, &#160;<b>Down&#160;</b><br/>
genes is discussed&#160;(ie, &#160;<b>osteogenesis imperfecta</b>&#160;).&#160;&#160;Although&#160;<br/>
<b>syndrome</b>,&#160;&#160;has had a major impact on&#160;reproductive&#160;medicine&#160;<br/>
osteogenesis imperfecta&#160;is oft&#160;en considered a single entity, dif-<br/>
and reproductive&#160;decision making and serves to&#160;illustrate&#160;<br/>
ferent&#160;mutations&#160;and diff&#160;erent genes subject to&#160;mutation lead&#160;<br/>
general principles that&#160;apply&#160;to&#160;many&#160;aneuploid conditions.&#160;<br/>
to&#160;a wide spectrum of&#160;clinical phenotypes. Th<br/>
&#160;e&#160;diff&#160;erent&#160;types&#160;<br/>
Finally,&#160;I consider how genome sequences and sequencing are&#160;<br/>
of&#160;osteogenesis imperfecta&#160;exhibit&#160;typical patterns&#160;of&#160;auto-<br/>
improving our understanding of&#160;pathophysiology for many&#160;<br/>
somal dominant&#160;or&#160;autosomal recessive&#160;inheritance and are,&#160;<br/>
diseases. With&#160;the completion of&#160;the human genome sequence&#160;<br/>
therefore,&#160;examples of&#160;so-called &#160;<b>mendelian conditions</b>. &#160;&#160;To&#160;<br/>
and technological advances that&#160;allow individual genomes to&#160;<br/>
show how environmental factors&#160;can infl&#160;uence the relationship&#160;<br/>
be&#160;sequenced rapidly and inexpensively, prospects are at&#160;hand&#160;<br/>
between genotype and phenotype, I discuss another mende-<br/>
to&#160;identify genetic components of&#160;any human phenotype&#160;and&#160;<br/>
lian condition, &#160;<b>phenylketonuria</b>. &#160;&#160;Th<br/>
&#160;&#160;is serves as a paradigm for&#160;<br/>
to&#160;provide medical care&#160;that&#160;is truly personalized.&#160;<br/>
newborn screening programs&#160;and treatment of&#160;genetic disease.&#160;<br/>
<b>&#160;UNIQUE&#160;PATHOPHYSIOLOGIC&#160;ASPECTS&#160;OF&#160;GENETIC&#160;DISEASES&#160;&#160;&#160;</b><br/>
&#160;Although&#160;the phenotypes of&#160;genetic diseases are diverse,&#160;their&#160;<br/>
ultimately&#160;deranges gene expression. Most genetic diseases&#160;<br/>
causes are not. Th<br/>
&#160;&#160;e primary&#160;cause of&#160;any genetic disease&#160;is&#160;<br/>
are caused by&#160;an&#160;alteration in DNA sequence that&#160;alters&#160;the&#160;<br/>
a change&#160;in the sequence or&#160;cellular content of&#160;DNA that&#160;<br/>
synthesis of&#160;a single gene product. However,&#160;some genetic&#160;<br/>
3<br/>
<hr/>
<a name=2></a>4 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
<b>&#160;TABLE&#160;&#160;21&#160;&#160;Glossary of terms and keywords.&#160;</b><br/>
<b>Term</b><br/>
<b>Deﬁ&#160;nition</b><br/>
Acrocentric<br/>
Refers to&#160;the terminal location of the centromere on chromosomes 13, 14, 15, 21, and 22.<br/>
Allelic&#160;<br/>
The situation in which multiple alleles at a single locus can produce one or more disease phenotypes.<br/>
heterogeneity<br/>
Amorphic<br/>
Refers to&#160;mutations that cause a complete loss of function for the respective gene, and therefore yield the same phenotype&#160;<br/>as a complete gene deletion.<br/>
Aneuploidy<br/>
A general term used to&#160;denote any unbalanced chromosome complement.<br/>
Antimorphic<br/>
Refers to&#160;mutations that when present in heterozygous form opposite a nonmutant allele will result in a phenotype similar&#160;<br/>to&#160;homozygosity for loss-of-function alleles.<br/>
Ascertainment&#160;<br/>
The situation in which individuals or families in a genetic study are not representative of the general population because&#160;<br/>
bias<br/>
of the way in which they are identiﬁ&#160;ed.<br/>
Autosomal<br/>
Located on chromosomes 1–22 rather than X or&#160;Y.<br/>
CpG island<br/>
A segment of DNA that contains a relatively high density of 5′- CG-3′&#160;dinucleotides. Such segments are frequently unmethylated&#160;<br/>and located close to&#160;ubiquitously expressed genes.<br/>
Dictyotene<br/>
The end of prophase during female meiosis I in which fetal oocytes are arrested prior to&#160;ovulation.<br/>
Dominant<br/>
A pattern of inheritance or mechanism of gene action in which the eﬀ&#160;ects of a variant allele can be observed in the presence&#160;<br/>of a nonmutant allele.<br/>
Dominant&#160;<br/>
A type of pathophysiologic mechanism that occurs when a mutant allele interferes with the normal function of the nonmutant&#160;<br/>
negative<br/>
gene product.<br/>
Dosage&#160;<br/>
Mechanism by&#160;which a diﬀ&#160;erence in gene dosage between two cells is equalized. For XX&#160;cells in mammals, decreased expression&#160;<br/>
compensation<br/>
from one of the two X chromosomes results in a concentration of gene product similar to&#160;an XY cell.<br/>
End-product&#160;<br/>
A pathologic mechanism in which absence or reduction in the product of a particular enzymatic reaction leads to&#160;disease.<br/>
deﬁ&#160;ciency<br/>
Epigenetic<br/>
Refers to&#160;a phenotypic eﬀ&#160;ect that is heritable, through somatic cell division and/or across organismal generations, but that does&#160;<br/>not depend on variation in DNA sequence.&#160;Instead, epigenetic inheritance is associated with alterations in chromatin structure&#160;<br/>such as DNA methylation or histone modiﬁ&#160;cation that can be transmitted during cell division.<br/>
Expressivity<br/>
The extent to&#160;which a mutant genotype aﬀ&#160;ects phenotype, including the tissues that are aﬀ&#160;ected,&#160;and the severity of those&#160;<br/>eﬀ&#160;ects.<br/>
Fitness<br/>
The eﬀ&#160;ect of a mutant allele on an individual’s&#160;ability to&#160;produce oﬀ&#160;spring.<br/>
Founder eﬀ&#160;ect<br/>
One of several possible explanations for an unexpectedly high frequency of a deleterious gene in a population. If&#160;the population&#160;<br/>was founded by&#160;a small ancestral group, it may have, by&#160;chance,&#160;contained a large number of carriers for the deleterious gene.<br/>
Gamete<br/>
The egg or sperm cell that represents a potential reproductive contribution to&#160;the next generation. Gametes have&#160;undergone&#160;<br/>meiosis and so contain half the normal number of chromosomes found in zygotic cells.<br/>
Gene dosage<br/>
The principle that the amount of product expressed for a particular gene is proportionate to&#160;the number of gene copies present&#160;<br/>per cell.<br/>
Genetic&#160;<br/>
A clinical phenomenon in which the phenotype observed in individuals carrying a deleterious gene appears more severe in&#160;<br/>
anticipation<br/>
successive generations. Possible explanations include ascertainment bias or a multistep mutational mechanism such as expansion&#160;<br/>of triplet repeats.<br/>
Haplotype<br/>
A set of closely linked DNA sequence variants on a single chromosome.<br/>
Hemizygous<br/>
A term referring to&#160;the presence of only one allele at a locus, either because the other allele is deleted or because&#160;it is normally&#160;<br/>not present, e.g., X-linked genes in males.<br/>
Heterochromatin<br/>
One of two alternative forms of chromosomal material (the other is euchromatin) in which chromosomal DNA is highly condensed&#160;<br/>and, usually, devoid of genes that are actively transcribed.<br/>
Heteroplasmy<br/>
The mixture of mutant and nonmutant mitochondrial DNA molecules in a single cell.<br/>
(<i>continued&#160;</i>)<br/>
<hr/>
<a name=3></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 5<br/>
<b>TABLE&#160;21&#160;&#160;Glossary of terms and keywords.&#160;&#160;(Continued)</b><br/>
<b>Term</b><br/>
<b>Deﬁ&#160;nition</b><br/>
Heterozygote&#160;<br/>
One way to&#160;explain an unexpectedly high frequency of a recessively inherited mutation in a particular population. During recent&#160;<br/>
advantage<br/>
evolution, carriers (i.e., heterozygotes) are postulated to&#160;have&#160;had a higher ﬁ&#160;tness than homozygous nonmutant individuals.<br/>
Heterozygous<br/>
Having two alleles at the same locus that are diﬀ&#160;erent.<br/>
Homozygous<br/>
Having two alleles at the same locus that are the same.<br/>
Hypermorphic<br/>
Refers to&#160;a mutation that has an eﬀ&#160;ect similar to&#160;increasing the number of normal gene copies per cell.<br/>
Hypomorphic<br/>
Refers to&#160;a mutation that reduces but does not eliminate the activity of a particular gene product.<br/>
Imprinting<br/>
Most commonly, the process whereby expression of a gene depends on whether it was inherited from the mother or the father.<br/>
Linkage&#160;<br/>
A condition in which certain combinations of closely linked alleles, or haplotypes, are present in a population at frequencies&#160;not&#160;<br/>
disequilibrium<br/>
predicted by&#160;their individual allele frequencies.<br/>
Locus&#160;<br/>
A situation in which mutations of diﬀ&#160;erent genes produce similar or identical phenotypes. Also referred to&#160;as genetic&#160;<br/>
heterogeneity<br/>
heterogeneity.<br/>
Mendelian<br/>
A form of inheritance that obeys Mendel laws, ie, autosomal dominant, autosomal recessive,&#160;X-linked dominant, or X-linked&#160;<br/>recessive.<br/>
Mosaicism<br/>
A situation in which a genetic alteration is present in some but not all of the cells of a single individual. In&#160;germline or gonadal&#160;<br/>mosaicism, the alteration is present in germ cells but not somatic cells. In&#160;somatic mosaicism, the genetic alteration is present in&#160;<br/>some but not all of the somatic cells (and is generally not present in the germ cells).<br/>
Monosomy<br/>
A&#160;reduction in zygotic cells from two to&#160;one in the number of copies for a particular chromosomal segment or chromosome.<br/>
Neomorphic<br/>
Refers to&#160;a mutation that imparts a novel function to&#160;its gene product and consequently results in a phenotype distinct&#160;from an&#160;<br/>alteration in gene dosage.<br/>
Nondisjunction<br/>
Failure of two homologous chromosomes to&#160;separate,&#160;or disjoin, at metaphase of meiosis I, or the failure of two sister chromatids&#160;<br/>to&#160;disjoin at metaphase of meiosis II or mitosis.<br/>
Penetrance<br/>
In a single individual of a variant genotype, penetrance refers to&#160;whether or not the variant genotype can be inferred based on&#160;<br/>deﬁ&#160;ned phenotypic criteria. In&#160;a population, reduced penetrance refers to&#160;the rate at which individuals of a variant genotype&#160;<br/>cannot be recognized according to&#160;speciﬁ&#160;c phenotypic criteria.<br/>
Phenotypic&#160;<br/>
The situation that pertains when mutations of a single gene produce multiple diﬀ&#160;erent&#160;phenotypes.<br/>
heterogeneity<br/>
Postzygotic<br/>
A mutational event that occurs after fertilization and that commonly gives rise to&#160;mosaicism.<br/>
Premutation<br/>
A genetic change that does not result in a phenotype itself but has a high probability of developing a second alteration—a full&#160;<br/>mutation—which does cause a phenotype.<br/>
Primordial germ&#160;<br/>
The group of cells set aside early in development that go on to&#160;give&#160;rise to&#160;gametes.<br/>
cell<br/>
Recessive<br/>
A&#160;pattern of inheritance or mechanism of gene action in which a particular mutant allele causes a phenotype only in the absence&#160;<br/>of a nonmutant allele.&#160;Thus, for autosomal conditions, the variant or disease phenotype is manifest when two copies of the&#160;<br/>mutant allele are present. For X-linked conditions, the variant or disease phenotype is manifest in cells, tissues, or individuals in&#160;<br/>which the nonmutant allele is either inactivated (a heterozygous female) or not present (a hemizygous male).<br/>
Robertsonian&#160;<br/>
A type of translocation in which two acrocentric chromosomes are fused together with a single functional centromere.&#160;A carrier&#160;<br/>
translocation<br/>
of a robertsonian translocation with 45 chromosomes has a normal amount of chromosomal material and is said to&#160;be euploid.<br/>
SNP<br/>
Single nucleotide polymorphism—one of the most common types of genetic variation.&#160;There are approximately 1 million common&#160;<br/>SNPs in the human genome (those that exist at a frequency&#160;&gt;1%), and billions of rare single-nucleotide variants (at a frequency&#160;<br/>
&gt;0.001%). Most do not aﬀ&#160;ect protein structure,&#160;but the common SNPs may serve&#160;as valuable markers for determining the eﬀ&#160;ect&#160;<br/>of genetic variation on complex and common diseases and disorders such as diabetes, heart disease, hypertension, and obesity.<br/>
Structural variant&#160;A deletion, insertion, or more complex rearrangement, usually caused by&#160;recombination between repetitive elements. Also&#160;<br/>
referred to&#160;as copy&#160;number variant (CNV) and the most common type of genomic variation. Most structural variants involve&#160;<br/>deletions or insertions that are relatively small (&lt;10 kb) and do not cause any clinical phenotype. Larger structural variants&#160;<br/>(&gt;100 kb) are increasingly likely to&#160;have&#160;clinical eﬀ&#160;ects.<br/>
Substrate&#160;<br/>
A pathogenetic mechanism in which deﬁ&#160;ciency of a particular enzyme causes disease because the substrate of that enzyme&#160;<br/>
accumulation<br/>
accumulates in tissue or blood.<br/>
Triplet repeat<br/>
A three-nucleotide sequence that is tandemly repeated many times—ie, (XYZ)&#160;&#160;&#160;. Alterations in length of such simple types of&#160;<br/>
n<br/>
repeats (dinucleotide and tetranucleotide as well) occur much more frequently than most other kinds of mutations; in addition,&#160;<br/>alteration in the length of trinucleotide repeats is the molecular basis for several heritable disorders.<br/>
Trisomy<br/>
An abnormal situation in which there are three instead of two copies of a chromosomal segment or chromosome per cell.<br/>
<hr/>
<a name=4></a>6 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
diseases are caused by&#160;(1) structural rearrangements that&#160;<br/>
amino acids, do not aff&#160;ect the structure&#160;or&#160;expression of&#160;the&#160;<br/>
result in deletion or&#160;duplication&#160;of&#160;a group of&#160;closely linked&#160;<br/>
gene product; therefore,&#160;although&#160;all mutations&#160;result in a&#160;<br/>
genes or&#160;(2) abnormalities during&#160;mitosis or&#160;meiosis that&#160;<br/>
biochemical or&#160;molecular&#160;biologic phenotype&#160;(ie, a change&#160;<br/>
result in an&#160;abnormal number of&#160;chromosomes per cell. In&#160;<br/>
in DNA), only&#160;some of&#160;them result in a clinically abnormal&#160;<br/>
most genetic diseases, every cell in an&#160;aff&#160;ected individual car-<br/>
phenotype.&#160;<br/>
ries the mutated gene or&#160;genes as a consequence of&#160;its inheri-<br/>
&#160;At&#160;the molecular&#160;level,&#160;variant alleles are usually recognized&#160;<br/>
tance via a mutant&#160;egg or&#160;sperm cell (&#160;<b>gamete</b>&#160;).&#160;&#160;However,&#160;<br/>
by&#160;DNA sequencing and are referred to&#160;as a single nucleotide&#160;<br/>
mutation of&#160;the gametic cell may have&#160;arisen during&#160;its devel-<br/>
polymorphism (SNP) if a single base pair change&#160;has occurred.&#160;<br/>
opment, in which case somatic cells of&#160;the parent&#160;do not carry&#160;<br/>
As&#160;originally coined, the word&#160;&#160;<b>polymorphism</b>&#160;&#160;referred&#160;to&#160;an&#160;<br/>
the&#160;mutation&#160;and&#160;the&#160;aff&#160;ected individual is said to&#160;have&#160;a “new&#160;<br/>
allele present in 1% or&#160;more&#160;of&#160;a population; today,&#160;the ter-<br/>
mutation.” In&#160;addition, some mutations&#160;may arise during&#160;early&#160;<br/>
minology tends to&#160;be&#160;less rigid and is oft&#160;en described quali-<br/>
embryogenesis, in which case tissues of&#160;the aff&#160;ected&#160;individ-<br/>
tatively, ie, rare&#160;and common variants. At&#160;the clinical level,&#160;<br/>
ual contain a mixture,&#160;or&#160;&#160;<b>mosaic</b>,&#160;&#160;of&#160;mutant&#160;and nonmutant&#160;<br/>
variant alleles are recognized by&#160;their eff&#160;ect on&#160;a phenotype&#160;<br/>
cells. Depending on&#160;the time of&#160;embryogenesis and cell type&#160;<br/>
such as human leukocyte antigen (HLA) type or&#160;hair color.&#160;<br/>
in which a new mutation arises, an&#160;individual may carry the&#160;<br/>
For an&#160;autosomal gene (those that&#160;lie on&#160;chromosomes 1–22,&#160;<br/>
mutation in some but not all of&#160;their germ&#160;cells (&#160;<b>germline&#160;</b><br/>
carried in two copies per cell), individuals carrying identical&#160;<br/>
<b>mosaicism</b>&#160;), some but not all of&#160;their somatic cells (&#160;<b>somatic&#160;</b><br/>
copies are &#160;<b>homozygous</b>,&#160;&#160;whereas individuals whose two cop-<br/>
<b>mosaicism</b>&#160;), or&#160;both.&#160;<br/>
ies diff&#160;er from&#160;each&#160;other are &#160;<b>heterozygous</b>. &#160;&#160;Th<br/>
&#160;ese&#160;terms—&#160;<br/>
&#160;It&#160;is helpful to&#160;begin with&#160;a brief review of&#160;terms that&#160;are&#160;<br/>
homozygous and heterozygous—can apply&#160;to&#160;the DNA&#160;<br/>
commonly used in discussing genetic disease&#160;with&#160;patients&#160;<br/>
sequence, the protein product, or&#160;the clinical phenotype. In&#160;<br/>
and their families. Although&#160;genes were&#160;recognized and&#160;<br/>
other words, an&#160;individual may be&#160;heterozygous for a SNP that&#160;<br/>
studied long&#160;before&#160;the structure&#160;of&#160;DNA was known, it&#160;has&#160;<br/>
does not alter the protein product, heterozygous for a dele-<br/>
become common usage to regard&#160;a &#160;<b>gene</b>&#160;&#160;as a short&#160;stretch&#160;<br/>
tion that&#160;causes a genetic disease, or&#160;heterozygous for a DNA&#160;<br/>
of&#160;DNA, usually but not always&#160;&lt;100,000 base pairs (bp) in&#160;<br/>
sequence alteration that&#160;causes a change&#160;in protein structure&#160;<br/>
length, that&#160;encodes a product (usually protein) responsible&#160;<br/>
but does not cause disease.&#160;<br/>
for a measurable trait. DNA length is typically measured in&#160;<br/>
&#160;Th<br/>
&#160;is discussion helps to&#160;illustrate&#160;the use of&#160;the word&#160;<br/>
base pairs, kilobase pairs (kb), or&#160;megabase pairs (Mb); chro-<br/>
&#160;<b>phenotype</b>,&#160;&#160;which refers&#160;simply&#160;to&#160;any characteristic that&#160;can&#160;<br/>
mosomes vary&#160;in length from&#160;about 46 Mb to&#160;245 Mb. Th<br/>
&#160;e&#160;<br/>
be&#160;measured, with&#160;the type of&#160;measurement depending on&#160;the&#160;<br/>
&#160;<b>locus</b>&#160;&#160;is the place where a particular gene lies on&#160;its chromo-<br/>
characteristic. Hair color and height&#160;are phenotypes readily&#160;<br/>
some. A gene’s&#160;DNA sequence nearly&#160;always shows slight&#160;dif-<br/>
apparent&#160;to&#160;a casual observer that&#160;are not obviously&#160;associ-<br/>
ferences when many&#160;unrelated individuals are compared, and&#160;<br/>
ated with&#160;disease, diabetes and coronary&#160;artery&#160;disease&#160;are&#160;<br/>
the variant sequences are described as &#160;<b>alleles</b>.&#160;&#160;A &#160;<b>mutation</b>&#160;&#160;&#160;is&#160;<br/>
disease&#160;phenotypes that&#160;typically require clinical investigation&#160;<br/>
a biochemical event such as a nucleotide change, deletion,&#160;<br/>
to&#160;be&#160;recognized, whereas restriction&#160;fragment length poly-<br/>
or&#160;insertion that&#160;has produced a new allele. Many&#160;changes&#160;<br/>
morphisms (RFLPs), simple sequence length polymorphisms&#160;<br/>
in the DNA sequence of&#160;a gene, such as those within introns&#160;<br/>
(SSLPs), and SNPs&#160;are molecular&#160;biologic phenotypes that&#160;can&#160;<br/>
or&#160;at&#160;the third “wobble” position of&#160;codons&#160;for particular&#160;<br/>
be&#160;detected only&#160;with&#160;a laboratory&#160;test.&#160;&#160;<br/>
<b>&#160;PENETRANCE&#160;&amp;&#160;EXPRESSIVITY&#160; &#160;</b><br/>
&#160;One of&#160;the most important principles of&#160;human genetics is&#160;<br/>
on&#160;a bone density scan&#160;in conjunction&#160;with&#160;laboratory&#160;tests&#160;<br/>
that&#160;two individuals with&#160;the same mutated gene may have&#160;dif-<br/>
for abnormal collagen synthesis. &#160;<b>Reduced penetrance</b>&#160;&#160;or&#160;&#160;<b>age-</b><br/>
ferent&#160;phenotypes. For example, in the autosomal dominant&#160;<br/>
<b>dependent penetrance</b>&#160;&#160;is a common feature of&#160;dominantly&#160;<br/>
condition&#160;called type I osteogenesis imperfecta, pedigrees may&#160;<br/>
inherited conditions that&#160;have&#160;a relatively&#160;high &#160;<b>fi&#160;tness</b>&#160;&#160;&#160;(the&#160;<br/>
occur in which there is both&#160;an&#160;aff&#160;ected grandparent&#160;and an&#160;<br/>
extent to&#160;which individuals carrying a mutant&#160;allele produce&#160;<br/>
aff&#160;ected grandchild even though&#160;the obligate&#160;carrier parent&#160;is&#160;<br/>
off&#160;spring&#160;relative&#160;to&#160;individuals who do not carry a mutant&#160;<br/>
asymptomatic (&#160;Figure 2–1&#160;). Given a set of&#160;defi&#160;ned criteria, rec-<br/>
allele); Huntington&#160;disease&#160;and polycystic kidney disease&#160;are&#160;<br/>
ognition of&#160;the condition&#160;in individuals known to&#160;carry the&#160;<br/>
examples.&#160;<br/>
mutated gene is described as &#160;<b>penetrance</b>.&#160;&#160;In&#160;other words, if&#160;<br/>
&#160;When the same mutated gene gives rise&#160;to&#160;a diff&#160;erent&#160;spec-<br/>
7 of&#160;10 individuals older than&#160;40 with&#160;the type I osteogenesis&#160;<br/>
trum of&#160;phenotypes, the situation is referred to&#160;as &#160;<b>variable&#160;</b><br/>
imperfecta&#160;mutation&#160;have&#160;an&#160;abnormal&#160;bone&#160;density&#160;scan,&#160;<br/>
<b>expressivity</b>.&#160;&#160;For example, blue scleras and short&#160;stature may&#160;<br/>
the condition&#160;is said to&#160;be&#160;70% penetrant&#160;by&#160;that&#160;criterion.&#160;<br/>
be&#160;the only&#160;manifestations&#160;of&#160;type I osteogenesis imperfecta&#160;in&#160;<br/>
Penetrance may vary&#160;both&#160;with&#160;age and according to&#160;the set of&#160;<br/>
a particular individual,&#160;whereas a sibling who carries the iden-<br/>
criteria being used; for example, type I osteogenesis imperfecta&#160;<br/>
tical mutation may be&#160;confi&#160;ned to&#160;a wheelchair as a result of&#160;<br/>
may be&#160;90% penetrant&#160;at&#160;age 40 when the conclusion is based&#160;<br/>
multiple fractures and deformities. Th<br/>
&#160;&#160;e mutation is&#160;penetrant&#160;<br/>
<hr/>
<a name=5></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 7<br/>
Mild short<br/>
&gt; 10 fractures<br/>
Premature<br/>
Reduced<br/>
stature<br/>
in childhood<br/>
hearing loss<br/>
bone density<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–1&#160;&#160;</b>&#160;Penetrance and expressivity in type I osteogenesis imperfecta. In&#160;this schematic pedigree of the autosomal dominant&#160;<br/>condition type I osteogenesis imperfecta, nearly all of the aﬀ&#160;ected individuals exhibit diﬀ&#160;erent phenotypic features that vary in severity&#160;<br/>(variable expressivity). As&#160;is shown, type I osteogenesis imperfecta is fully penetrant, because every individual who transmits&#160;the mutation&#160;<br/>is phenotypically aﬀ&#160;ected to&#160;some degree.&#160;However,&#160;if mild short stature in the individual indicated with the arrow&#160;had been considered to&#160;<br/>be a normal variant, then the condition would have&#160;been nonpenetrant in this individual.&#160;Thus, in this example, judgments about&#160;penetrance&#160;<br/>or nonpenetrance depend on the criteria for normal and abnormal stature.&#160;<br/>
in both&#160;individuals, but its expression is variable. Both&#160;reduced&#160;<br/>
diff&#160;erences between these individuals must be&#160;due to&#160;the&#160;<br/>
penetrance and variable expressivity may occur in individu-<br/>
eff&#160;ects of&#160;other “modifi&#160;er” genes, to&#160;environmental interac-<br/>
als who carry the same mutated allele; therefore,&#160;phenotypic&#160;<br/>
tions, or&#160;to&#160;chance.&#160;&#160;<br/>
<b>&#160;MECHANISMS&#160;OF&#160;MUTATION&#160;&amp;&#160;INHERITANCE&#160;PATTERNS&#160;&#160;</b><br/>
&#160;<br/>
Mutations&#160;can be&#160;characterized both&#160;by&#160;their molecular&#160;<br/>
causes the disease&#160;phenotype&#160;(in males and females); X-linked&#160;<br/>
nature—nucleotide deletion, insertion, substitution—and by&#160;<br/>
recessive&#160;inheritance occurs&#160;when two copies of&#160;a mutant&#160;gene&#160;<br/>
their eff&#160;ects on&#160;gene activity (ie, no eff&#160;ect [neutral or&#160;silent],&#160;<br/>
cause the disease&#160;phenotype&#160;(in females). Because most muta-<br/>
complete loss of&#160;function [amorphic mutation], partial loss of&#160;<br/>
tions&#160;are amorphic or&#160;hypomorphic, however,&#160;one copy&#160;of&#160;an&#160;<br/>
function [hypomorphic mutation], gain of&#160;function [hyper-<br/>
X-linked mutant&#160;allele in males is not “balanced” with&#160;a non-<br/>
morphic mutation], or&#160;acquisition of&#160;a new property [neo-<br/>
mutant&#160;allele, as it&#160;would be&#160;in females; therefore,&#160;in X-linked&#160;<br/>
morphic mutation]). Geneticists who study experimental&#160;<br/>
recessive&#160;inheritance, one copy&#160;of&#160;a mutant&#160;allele is suffi<br/>
&#160; cient&#160;<br/>
organisms frequently use specifi&#160;c deletions&#160;to&#160;ensure that&#160;a&#160;<br/>
to&#160;produce a disease&#160;phenotype&#160;in males, a situation referred&#160;<br/>
mutated allele causes a loss of&#160;function, but human geneti-<br/>
to&#160;as &#160;<b>hemizygosity</b>. &#160;<br/>
cists rely&#160;on&#160;biochemical or&#160;cell culture studies. Amorphic and&#160;<br/>hypomorphic mutations&#160;are probably&#160;the most frequent type&#160;<br/>of&#160;mutation in human genetic disease&#160;because there are many&#160;<br/>
<b>&#160; RECESSIVE&#160;&#160;INHERITANCE&#160;&#160;&amp;&#160;</b><br/>
ways to&#160;interfere with&#160;a protein’s&#160;function.&#160;<br/>
<b>LOSSOFFUNCTION&#160;MUTATIONS&#160;</b><br/>
&#160;For autosomal genes, the fundamental&#160;diff&#160;erence&#160;between&#160;<br/>
dominant&#160;and recessive&#160;inheritance is that, with&#160;dominant&#160;<br/>
&#160;Most recessive&#160;mutations&#160;are due to&#160;loss of&#160;function of&#160;the&#160;<br/>
inheritance, the disease&#160;state or&#160;trait&#160;being measured is appar-<br/>
gene product, which can occur from&#160;a variety of&#160;diff&#160;erent&#160;<br/>
ent when one copy&#160;of&#160;the mutated allele and one copy&#160;of&#160;the&#160;<br/>
causes, including failure of&#160;the gene to&#160;be&#160;transcribed or&#160;trans-<br/>
normal allele are present. With&#160;recessive&#160;inheritance, two cop-<br/>
lated and failure of&#160;the translated gene product to&#160;function&#160;<br/>
ies of&#160;the mutated allele must be&#160;present for the disease&#160;state&#160;<br/>
correctly.&#160;Th<br/>
&#160;&#160;ere are two general principles to&#160;keep in mind&#160;<br/>
or&#160;trait&#160;to&#160;be&#160;apparent. However,&#160;for genes that&#160;lie on&#160;the X&#160;<br/>
when considering loss-of-function&#160;mutations. First, because&#160;<br/>
chromosome,&#160;the situation is slightly&#160;diff&#160;erent because females&#160;<br/>
expression from&#160;the nonmutant allele usually does not change&#160;<br/>
have&#160;two X chromosomes and males have&#160;only&#160;one.&#160;X-linked&#160;<br/>
(i.e., there is no &#160;<b>dosage compensation</b>&#160;), gene expression in a&#160;<br/>
dominant&#160;inheritance occurs&#160;when one copy&#160;of&#160;a mutant&#160;gene&#160;<br/>
heterozygous carrier of&#160;a loss-of-function&#160;allele is reduced to&#160;<br/>
<hr/>
<a name=6></a>8 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
<b>&#160;TABLE&#160;&#160;22&#160;&#160;Phenotype, inheritance,&#160;and prevalence of selected genetic disorders.&#160;</b><br/>
<b>Disorder</b><br/>
<b>Phenotype</b><br/>
<b>Genetic Mechanism</b><br/>
<b>Incidence</b><br/>
Down syndrome<br/>
Mental and growth retardation, dysmorphic&#160;<br/>
Chromosomal imbalance; caused by&#160;<br/>
≈1:800; increased risk with&#160;<br/>
features, internal organ anomalies<br/>
trisomy 21<br/>
advanced maternal age<br/>
Fragile X–associated&#160;<br/>
Mental retardation, characteristic facial&#160;<br/>
X-linked; progressive expansion of&#160;<br/>
≈1:1500 males; can be manifested&#160;<br/>
mental retardation<br/>
features, large testes<br/>
unstable DNA causes failure to&#160;express&#160;<br/>
in females; multistep mechanism<br/>
gene encoding RNA-binding protein<br/>
Sickle cell anemia<br/>
Recurrent painful crises, increased&#160;<br/>
Autosomal recessive; caused by&#160;a single&#160;&#160;≈1:400 blacks<br/>
susceptibility to&#160;infections<br/>
missense mutation in beta-globin<br/>
Cystic ﬁ&#160;brosis<br/>
Recurrent pulmonary infections, exocrine&#160;<br/>
Autosomal recessive; caused by&#160;a&#160;<br/>
≈1:2000 whites; very&#160;rare in Asians<br/>
pancreatic insuﬃ<br/>
&#160; ciency,&#160;infertility<br/>
multiple loss-of-function mutations in a&#160;<br/>chloride channel<br/>
Leber hereditary optic&#160;&#160;Acute or subacute blindness, occasional&#160;<br/>
Mutation of electron transport chain&#160;<br/>
≈1:50,000–1:10,000<br/>
neuropathy<br/>
myopathy or neurodegeneration<br/>
encoded by&#160;mtDNA<br/>
Myoclonic epilepsy&#160;<br/>
Uncontrolled periodic jerking, muscle&#160;<br/>
Mutation of mitochondrial tRNA in&#160;<br/>
≈1:100,000–1:50,000<br/>
with ragged red ﬁ&#160;bers<br/>
weakness<br/>
mtDNA<br/>
Neuroﬁ&#160;bromatosis<br/>
Multiple café-au-lait spots, neuroﬁ&#160;bromas,&#160;<br/>
Autosomal dominant; caused by&#160;<br/>
≈1:3000;&#160;≈50% are new mutations<br/>
increased tumor susceptibility<br/>
multiple loss-of-function mutations in a&#160;<br/>signaling molecule<br/>
Duchenne muscular&#160;<br/>
Muscular weakness and degeneration<br/>
X-linked recessive; caused by&#160;multiple&#160;<br/>
≈1:3000 males;&#160;≈33% are new&#160;<br/>
dystrophy<br/>
loss-of-function mutations in muscle&#160;<br/>
mutations<br/>
protein<br/>
Osteogenesis&#160;<br/>
Increased susceptibility to&#160;fractures,&#160;<br/>
Phenotypically and genetically&#160;<br/>
≈1:10,000<br/>
imperfecta<br/>
connective tissue fragility,&#160;blue scleras<br/>
heterogeneous<br/>
Phenylketonuria<br/>
Mental and growth retardation<br/>
Autosomal recessive; caused by&#160;<br/>
≈1:10,000<br/>
multiple loss-of-function mutations in&#160;<br/>phenylalanine hydroxylase<br/>
50% of&#160;normal. Second, for most biochemical pathways, a 50%&#160;<br/>
cause of&#160;very&#160;short&#160;stature,&#160;is usually described as autosomal&#160;<br/>
reduction in enzyme concentration&#160;is not suffi<br/>
&#160; cient&#160;to&#160;produce&#160;<br/>
dominant. However,&#160;rare&#160;matings between two aff&#160;ected&#160;indi-<br/>
a disease&#160;state. Th<br/>
&#160;&#160;us, most diseases resulting&#160;from&#160;enzyme&#160;<br/>
viduals have&#160;a 25% probability of&#160;producing off&#160;spring&#160;&#160;with&#160;<br/>
defi&#160;ciencies such as phenylketonuria (&#160;Table 2–2&#160;) are inherited&#160;<br/>
two copies of&#160;the mutant&#160;gene. Th<br/>
&#160;&#160;is results in homozygous&#160;<br/>
in a recessive&#160;fashion.&#160;&#160;<br/>
achondroplasia, a condition&#160;that&#160;is very&#160;severe and usually&#160;<br/>fatal in the perinatal period; thus, achondroplasia exhibits&#160;<br/>
<b>&#160; DOMINANT&#160;&#160;INHERITANCE&#160;&#160;&amp;&#160;</b><br/>
semidominant&#160;inheritance. Huntington&#160;disease, a dominantly&#160;<br/>
<b>LOSSOFFUNCTION&#160;MUTATIONS&#160;</b><br/>
inherited&#160;neurologic disease, is the only&#160;known human condi-<br/>tion in which the homozygous mutant&#160;phenotype&#160;is identical&#160;<br/>to&#160;the heterozygous mutant&#160;phenotype&#160;(sometimes referred to&#160;<br/>
&#160;If&#160;50% of&#160;a particular product is not enough for the cell or&#160;tis-<br/>
as a “true dominant”).&#160;&#160;<br/>
sue to&#160;function normally,&#160;then a loss-of-function&#160;mutation in&#160;<br/>this gene produces a dominantly&#160;inherited&#160;phenotype. Such&#160;<br/>mutations&#160;oft&#160;en occur in structural proteins; an&#160;example is&#160;<br/>
<b>&#160;DOMINANT&#160;NEGATIVE&#160;GENE&#160;ACTION&#160;</b><br/>
type I osteogenesis imperfecta, which is considered in detail&#160;<br/>later.&#160;Most dominantly&#160;inherited phenotypes are actually&#160;<br/>
&#160;A special kind of&#160;pathophysiologic mechanism, referred to&#160;<br/>
&#160;<b>semidominant</b>,&#160;&#160;which means that&#160;an&#160;individual who car-<br/>
as dominant&#160;negative, occurs&#160;frequently in human genetic&#160;<br/>
ries two copies of&#160;the mutant&#160;allele is aff&#160;ected more&#160;severely&#160;<br/>
diseases that&#160;involve proteins that&#160;form&#160;oligomeric or&#160;poly-<br/>
than&#160;someone who carries one mutant&#160;and one normal copy.&#160;<br/>
meric complexes. In&#160;these disorders, the mutant&#160;allele gives&#160;<br/>
However,&#160;for most dominantly&#160;inherited&#160;conditions, homo-<br/>
rise&#160;to&#160;a structurally abnormal protein that&#160;interferes with&#160;the&#160;<br/>
zygous mutant&#160;individuals are rarely&#160;observed.&#160;For example,&#160;<br/>
function of&#160;the normal allele. Note&#160;that&#160;any molecular&#160;lesion&#160;<br/>
inheritance of&#160;achondroplasia, the most common genetic&#160;<br/>
(ie, deletion, nonsense, missense, or&#160;splicing) can produce a&#160;<br/>
<hr/>
<a name=7></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 9<br/>
loss-of-function&#160;allele. However,&#160;only&#160;molecular&#160;lesions&#160;that&#160;<br/>
alteration itself cannot, strictly speaking, be&#160;dominant&#160;or&#160;<br/>
yield a protein product (ie, splicing, missense, or&#160;nonsense&#160;<br/>
recessive. Th<br/>
&#160;&#160;e terms are instead appropriate to&#160;the eff&#160;ect of&#160;a&#160;<br/>
mutations) can result in a dominant&#160;negative&#160;allele. Type&#160;II&#160;<br/>
mutation on&#160;a particular trait. Th<br/>
&#160;&#160;erefore,&#160;in characterizing a&#160;<br/>
osteogenesis imperfecta, described later,&#160;is an&#160;example of&#160;a&#160;<br/>
particular mutation as “recessive,”&#160;one is referring&#160;to&#160;the eff&#160;ect&#160;<br/>
dominant&#160;negative&#160;mutation.&#160;<br/>
of&#160;the mutation on&#160;the trait&#160;being studied.&#160;&#160;<br/>
&#160;Although&#160;the terms “dominant” and “recessive” are occa-<br/>
sionally used to&#160;describe specifi&#160;c mutations, a DNA sequence&#160;<br/>
<b>&#160;MUTATION&#160;RATE&#160;&amp;&#160;THE&#160;PREVALENCE&#160;OF&#160;GENETIC&#160;DISEASE&#160;&#160;</b><br/>
&#160;At&#160;the level of&#160;DNA sequence, nucleotide mutations&#160;(substitu-<br/>
genes (ie, mendelian disorders) is approximately&#160;1% of&#160;the&#160;<br/>
tions, small insertions, or&#160;small deletions) in humans&#160;occur at&#160;<br/>
general population.&#160;<br/>
a rate&#160;of&#160;approximately&#160;2&#160;×&#160;10&#160;−8&#160;&#160;per nucleotide per human gen-<br/>
&#160;Table 2–2&#160;&#160;lists the major symptoms, genetic mechanisms,&#160;<br/>
eration, or&#160;150 new mutations&#160;per diploid genome. However,&#160;<br/>
and prevalence of&#160;the diseases considered in this chapter as&#160;<br/>
only&#160;about 5% of&#160;the human genome is functional, so&#160;most&#160;<br/>
well as of&#160;several others. Th<br/>
&#160;&#160;e most common conditions, such&#160;<br/>
new mutations&#160;have&#160;no eff&#160;ect. Still, with approximately 23,000&#160;<br/>
as neurofi&#160;bromatosis, cystic fi&#160;brosis, and fragile X–associated&#160;<br/>
genes in the human genome and an&#160;estimated deleterious&#160;<br/>
mental retardation syndrome,&#160;will be&#160;encountered at&#160;some&#160;<br/>
“per locus”&#160;mutation rate&#160;of&#160;10&#160;−5&#160;&#160;per generation, the chance&#160;<br/>
time by&#160;most health&#160;care&#160;professionals regardless of&#160;their&#160;<br/>
of&#160;a new deleterious mutation in any one individual is about&#160;<br/>
fi&#160;eld of&#160;interest. Other conditions such as Huntington&#160;disease&#160;<br/>
20%. Furthermore, assuming 10 billion new births&#160;in the last&#160;<br/>
and adenosine deaminase defi&#160;ciency,&#160;although&#160;of&#160;intellectual&#160;<br/>
millennium, every gene in the human genome has probably&#160;<br/>
and pathophysiologic interest, are not likely to&#160;be&#160;seen by&#160;most&#160;<br/>
been mutated (in a deleterious manner) about 100,000 diff&#160;er-<br/>
practitioners.&#160;<br/>
ent times. However,&#160;from&#160;a clinical perspective,&#160;only&#160;about&#160;<br/>
&#160;<br/>
Many&#160;common conditions such as atherosclerosis and&#160;<br/>
5000 single-gene disorders have&#160;been recognized to&#160;cause a&#160;<br/>
breast cancer that&#160;do not show strictly mendelian inheri-<br/>
human disease. In&#160;considering possible explanations&#160;for this&#160;<br/>
tance patterns&#160;have&#160;a genetic component evident from&#160;famil-<br/>
disparity, it&#160;seems likely that&#160;deleterious mutations&#160;of&#160;many&#160;<br/>
ial aggregation or&#160;twin studies. Th<br/>
&#160;&#160;ese conditions are usually&#160;<br/>
single genes are lethal very&#160;early in development and thus not&#160;<br/>
described as &#160;<b>multifactorial</b>,&#160;&#160;which means that&#160;the eff&#160;ects&#160;of&#160;<br/>
clinically apparent, whereas deleterious mutations&#160;in other&#160;<br/>
one or&#160;more&#160;mutated genes and environmental diff&#160;erences&#160;all&#160;<br/>
genes do not cause an&#160;easily recognizable phenotype. Th<br/>
&#160;e&#160;<br/>
contribute&#160;to&#160;the likelihood&#160;that&#160;a given individual will mani-<br/>
overall frequency of&#160;disease&#160;attributable to&#160;defects in single&#160;<br/>
fest the phenotype.&#160;&#160;<br/>
<b>&#160;ISSUES&#160;IN&#160;CLINICAL&#160;GENETICS&#160;&#160;</b><br/>
&#160;Most patients with&#160;genetic disease&#160;present during&#160;early child-<br/>
common single-gene disorders such as Duchenne muscu-<br/>
hood&#160;with&#160;symptoms that&#160;ultimately&#160;give&#160;rise&#160;to&#160;a diagnosis&#160;<br/>
lar dystrophy, cystic fi&#160;brosis, and hemophilia. Some forms of&#160;<br/>
such as fragile X–associated mental retardation or&#160;Down syn-<br/>
therapy&#160;are directed at&#160;replacing the mutant&#160;protein, whereas&#160;<br/>
drome.&#160;Th<br/>
&#160;&#160;e major clinical issues at&#160;presentation are arriving&#160;<br/>
others are directed at&#160;ameliorating its eff&#160;ects.&#160;<br/>
at&#160;the correct diagnosis and counseling the patient and family&#160;<br/>
&#160;<br/>
regarding the natural history and prognosis of&#160;the condition.&#160;<br/>It&#160;is important to&#160;assess the likelihood&#160;that&#160;the same condi-<br/>
<b>&#160;CHECKPOINT&#160;</b><br/>
tion will occur again in the family and determine whether it&#160;<br/>can be&#160;diagnosed prenatally.&#160;Th<br/>
&#160;&#160;ese issues are the subject mat-<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; &#160;1. &#160;&#160;</b></i>Deﬁ&#160;ne gene, locus, allele, mutation, heterozygosity,&#160;<br/>
ter of&#160;genetic counseling by&#160;medical geneticists and genetic&#160;<br/>
hemizygosity,&#160;polymorphism, and phenotype.&#160;<br/>
counselors.&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 2. &#160;&#160;</b></i>How is it possible for two individuals with the same mu-<br/>
&#160;<br/>
Understanding the pathophysiology of&#160;genetic diseases&#160;<br/>
tation to&#160;have&#160;diﬀ&#160;erences in the severity of an abnormal&#160;<br/>
that&#160;interfere with&#160;specifi&#160;c metabolic pathways—so-called&#160;<br/>
phenotype?&#160;<br/>
inborn&#160;errors&#160;of&#160;metabolism—has led to&#160;eff&#160;ective&#160;treatments&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 3. &#160;&#160;</b></i>Explain the pathophysiologic diﬀ&#160;erence&#160;between&#160;muta-<br/>
for selected conditions such as phenylketonuria, maple syrup&#160;<br/>
tions that act via loss of function and those that act via&#160;<br/>
urine disease, and homocystinuria. Many&#160;of&#160;these diseases&#160;<br/>
dominant negative gene action.&#160;&#160;<br/>
are rare, but eff&#160;orts are underway to&#160;develop treatments for&#160;<br/>
<hr/>
<a name=8></a>10 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
<b>&#160;PATHOPHYSIOLOGY&#160;OF&#160;SELECTED&#160;GENETIC&#160;DISEASES&#160;&#160;</b><br/>
<b>&#160; OSTEOGENESIS&#160;&#160;IMPERFECTA&#160;</b><br/>
from&#160;the perspective of&#160;patients, caregivers, or&#160;molecular&#160;<br/>geneticists.&#160;<br/>
&#160;Osteogenesis imperfecta&#160;is a condition&#160;inherited&#160;in mendelian&#160;<br/>
&#160;All forms of&#160;osteogenesis imperfecta&#160;are characterized by&#160;<br/>
fashion that&#160;illustrates many&#160;principles of&#160;human genetics. It&#160;<br/>
increased susceptibility to&#160;fractures (“brittle bones”), but&#160;<br/>
is a heterogeneous and pleiotropic group of&#160;disorders char-<br/>
there is considerable phenotypic heterogeneity, even within&#160;<br/>
acterized by&#160;a tendency toward&#160;fragility of&#160;bone. Advances&#160;<br/>
individual subtypes. Individuals with&#160;type I or&#160;type IV osteo-<br/>
in the last two decades demonstrate&#160;two genetically diff&#160;erent&#160;<br/>
genesis imperfecta&#160;present in early childhood&#160;with&#160;one or&#160;<br/>
groups: the “classical” group,&#160;in which more&#160;than&#160;90% of&#160;cases&#160;<br/>
a few fractures of&#160;long&#160;bones in response&#160;to&#160;minimal or&#160;no&#160;<br/>
are caused by&#160;a mutation of&#160;the &#160;<i>COL1A1</i>&#160;&#160;or&#160;&#160;<i>COL1A2</i>&#160;&#160;&#160;genes,&#160;<br/>
trauma; x-ray fi&#160;lms reveal mild osteopenia, little or&#160;no bony&#160;<br/>
which encode the subunits of&#160;type I collagen, proα1(I) and&#160;<br/>
deformity, and oft&#160;en evidence of&#160;earlier subclinical fractures.&#160;<br/>
proα2(I), respectively, and a newer group,&#160;caused by&#160;loss-of-<br/>
However,&#160;most individuals with&#160;type I or&#160;type IV osteogene-<br/>
function mutations&#160;in proteins required for proper folding,&#160;<br/>
sis imperfecta&#160;do not have&#160;fractures in utero.&#160;Type&#160;I and type&#160;<br/>
processing, and secretion of&#160;collagen. More&#160;than&#160;100 diff&#160;erent&#160;<br/>
IV osteogenesis imperfecta&#160;are distinguished by&#160;the sever-<br/>
mutant&#160;alleles have&#160;been described for osteogenesis imper-<br/>
ity (less in type I than&#160;in type IV) and by&#160;scleral hue,&#160;which&#160;<br/>
fecta; the relationships between diff&#160;erent DNA sequence&#160;<br/>
indicates the thickness of&#160;this tissue and the deposition of&#160;<br/>
alterations&#160;and the type of&#160;disease&#160;(genotype-phenotype&#160;<br/>
type I collagen. Individuals with&#160;type I osteogenesis imper-<br/>
correlations) illustrate&#160;several pathophysiologic principles in&#160;<br/>
fecta have&#160;blue scleras, whereas the scleras of&#160;those with&#160;type&#160;<br/>
human genetics.&#160;<br/>
IV are normal or&#160;slightly&#160;gray.&#160;In&#160;type I, the typical number&#160;<br/>of&#160;fractures during&#160;childhood&#160;is 10–20; fracture&#160;incidence&#160;<br/>
<b>&#160; Clinical&#160;&#160;Manifestations&#160;</b><br/>
decreases aft&#160;er puberty,&#160;and the main features in adult life&#160;<br/>are mild short&#160;stature,&#160;a tendency toward&#160;conductive&#160;hearing&#160;<br/>
&#160;Th<br/>
&#160;e clinical and genetic characteristics of&#160;osteogenesis&#160;<br/>
loss, and occasionally dentinogenesis imperfecta. Individuals&#160;<br/>
imperfecta&#160;are summarized in &#160;Table 2–3&#160;, in which the tim-<br/>
with&#160;type IV osteogenesis imperfecta&#160;generally experience&#160;<br/>
ing and severity of&#160;fractures, radiologic fi&#160;ndings, and pres-<br/>
more&#160;fractures than&#160;those with&#160;type I and have&#160;signifi&#160;cant&#160;<br/>
ence of&#160;additional clinical features help to&#160;distinguish four&#160;<br/>
short&#160;stature caused by&#160;a combination&#160;of&#160;long&#160;bone and&#160;<br/>
diff&#160;erent subtypes. Th<br/>
&#160;is&#160;classifi&#160;cation was presented more&#160;<br/>
spinal deformities, but they&#160;oft&#160;en are able to&#160;walk indepen-<br/>
than&#160;30 years ago.&#160;Over the past decade, it&#160;has become clear&#160;<br/>
dently.&#160;Approximately&#160;one fourth&#160;of&#160;the cases of&#160;type I or&#160;<br/>
that&#160;there are more&#160;than&#160;a dozen diff&#160;erent genes in which&#160;<br/>
type IV osteogenesis imperfecta&#160;represent new mutations; in&#160;<br/>
mutations&#160;can cause osteogenesis imperfecta, and that&#160;the&#160;<br/>
the remainder, the history and examination&#160;of&#160;other family&#160;<br/>
utility of&#160;alternative or&#160;more&#160;extended nosologic approaches&#160;<br/>
members&#160;reveal fi&#160;ndings consistent with&#160;autosomal domi-<br/>
depends on&#160;whether the condition&#160;is being considered&#160;<br/>
nant&#160;inheritance.&#160;<br/>
<b>&#160;TABLE&#160;&#160;23&#160;&#160;Subtypes of dominant osteogenesis imperfecta.&#160;</b><br/>
<b>Type</b><br/>
<b>Phenotype</b><br/>
<b>Genetics</b><br/>
<b>Molecular Pathophysiology</b><br/>
Type I<br/>
&#160;<b>Mild:</b>&#160;&#160;Short stature,&#160;postnatal fractures,&#160;<br/>
Autosomal dominant<br/>
Loss-of-function mutation in proα1(I) chain&#160;<br/>
little or no deformity,&#160;blue scleras,&#160;<br/>
resulting in decreased amount of mRNA; quality&#160;<br/>
premature hearing loss<br/>
of collagen is normal; quantity is reduced twofold<br/>
Type II<br/>
&#160;<b>Perinatal lethal:</b>&#160;&#160;Severe&#160;prenatal fractures,&#160;&#160;Sporadic (autosomal dominant)<br/>
Structural mutation in proα1(I) or proα2(I) chain&#160;<br/>
abnormal bone formation, severe&#160;<br/>
that has mild eﬀ&#160;ect on heterotrimer assembly;&#160;<br/>
deformities, blue scleras, connective tissue&#160;<br/>
quality of collagen is severely abnormal; quantity&#160;<br/>
fragility<br/>
often reduced also<br/>
Type III<br/>
&#160;<b>Progressive deforming:</b>&#160;&#160;&#160;Prenatal&#160;<br/>
Autosomal dominant&#160;&#160;1&#160;&#160;<br/>
Structural mutation in proα1(I) or proα2(I) chain&#160;<br/>
fractures, deformities usually present&#160;<br/>
that has mild eﬀ&#160;ect on heterotrimer assembly;&#160;<br/>
at birth, very&#160;short stature,&#160;usually&#160;<br/>
quality of collagen is severely abnormal; quantity&#160;<br/>
nonambulatory,&#160;blue scleras, hearing loss<br/>
can be normal<br/>
Type IV<br/>
&#160;<b>Deforming with normal scleras:</b>&#160;<br/>
Autosomal dominant<br/>
Structural mutation in the proα2(I), or, less&#160;<br/>
Postnatal fractures, mild-to-moderate&#160;<br/>
frequently, proα1(I) chain that has little or no eﬀ&#160;ect&#160;<br/>
deformities, premature hearing&#160;<br/>
on heterotrimer assembly; quality of collagen is&#160;<br/>
loss, normal or gray&#160;scleras, dental&#160;<br/>
usually abnormal; quantity can be normal<br/>
abnormalities imperfect<br/>
&#160;1&#160;Autosomal recessive in rare cases.<br/>
<hr/>
<a name=9></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 11<br/>
&#160;Type&#160;II osteogenesis imperfecta&#160;presents at&#160;or&#160;before&#160;birth&#160;<br/>
Proline and lysine hydroxylation<br/>
(diagnosed by&#160;prenatal imaging) with&#160;multiple fractures, bony&#160;<br/>
Amino terminal<br/>
to facilitate helix formation<br/>
H<br/>
propeptide<br/>
deformities, increased fragility of&#160;nonbony connective&#160;tis-<br/>
2N<br/>
Oligosaccharide<br/>
sue, and blue scleras and usually results in death in infancy.&#160;<br/>
Three<br/>
Two typical radiologic fi&#160;ndings are the presence of&#160;isolated&#160;<br/>
proα&#160;chains<br/>
COOH<br/>
“islands”&#160;of&#160;mineralization in the skull (wormian bones) and a&#160;<br/>beaded appearance to&#160;the ribs. Nearly&#160;all cases of&#160;type II osteo-<br/>
H<br/>
COOH<br/>
2N<br/>
genesis imperfecta&#160;represent a new dominant&#160;mutation, and&#160;<br/>
COOH<br/>
there is no family history.&#160;Death&#160;usually results from&#160;respira-<br/>tory&#160;diffi<br/>
&#160; culties.&#160;<br/>
Carboxyl terminal<br/>
&#160;Type&#160;III osteogenesis imperfecta&#160;presents at&#160;birth or&#160;in&#160;<br/>
propeptide<br/>
infancy with&#160;progressive&#160;bony&#160;deformities, multiple fractures,&#160;<br/>
H2N<br/>
Interchain disulfide<br/>
and blue scleras. It&#160;is intermediate&#160;in severity between types II&#160;<br/>
bond<br/>
Intrachain disulfide<br/>
and IV; most aff&#160;ected individuals will require multiple correc-<br/>
bond<br/>
Collagen molecule<br/>
tive&#160;surgeries and lose the ability to&#160;ambulate&#160;by&#160;early adult-<br/>
COOH<br/>
hood. Unlike other forms of&#160;osteogenesis imperfecta, which&#160;<br/>
H2N<br/>
Triple helical domains<br/>
are nearly&#160;always due to&#160;mutations&#160;that&#160;act dominantly, type&#160;<br/>
COOH<br/>
H2N<br/>
III may be&#160;inherited, very&#160;rarely, in a recessive&#160;manner.&#160;<br/>
&#160;Although&#160;&#160;diff&#160;erent subtypes of&#160;osteogenesis imperfecta&#160;<br/>
COOH<br/>
H<br/>
Non-triple<br/>
can oft&#160;en be&#160;distinguished biochemically,&#160;the classifi&#160;ca-<br/>
2N<br/>
helical domains<br/>
tion presented in &#160;Table 2–3&#160;&#160;is primarily&#160;clinical rather than&#160;<br/>
Procollagen<br/>
molecular, and the disease&#160;phenotypes for each&#160;subtype&#160;<br/>show a spectrum of&#160;severities that&#160;overlap one another. For&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–2&#160;&#160;</b>&#160;Molecular assembly of type I pro-collagen.&#160;<br/>
example, a few individuals diagnosed with&#160;type II osteogen-<br/>
Type I procollagen is assembled in the endoplasmic reticulum from&#160;<br/>
esis imperfecta&#160;based on&#160;the presence of&#160;severe bony&#160;defor-<br/>
three proα&#160;chains that associate with each other beginning at their&#160;<br/>carboxyl terminals. An important requirement for proper assembly&#160;<br/>
mities in utero will survive&#160;for many&#160;years and thus overlap&#160;<br/>
of the triple helix is the presence of a glycine residue at every third&#160;<br/>
the type III subtype. Similarly,&#160;some individuals with&#160;type IV&#160;<br/>
position in each of the proα&#160;chains. After secretion, the amino and&#160;<br/>
osteogenesis imperfecta&#160;have&#160;fractures in utero and develop&#160;<br/>
carboxyl terminal propeptides are proteolytically cleaved,&#160;leaving&#160;<br/>
deformities that&#160;lead to&#160;loss of&#160;ambulation. Distinguishing&#160;<br/>
a rigid triple helical collagen molecule with very&#160;short non–triple-<br/>
this presentation from&#160;type III osteogenesis imperfecta&#160;may&#160;<br/>
helical domains at both ends.&#160;(Modiﬁ&#160;ed and reproduced, with permission,&#160;<br/>
be&#160;possible only&#160;if other aff&#160;ected family members&#160;exhibit&#160;a&#160;<br/>
from Alberts BA. &#160;<i>Molecular Biology of the Cell</i>,&#160;&#160;3rd ed. Garland Science,&#160;1994.)&#160;&#160;<br/>
milder course.&#160;<br/>
&#160;Additional subtypes of&#160;osteogenesis imperfecta&#160;have&#160;been&#160;<br/>
suggested&#160;for individuals that&#160;do not match&#160;types I–IV, and&#160;<br/>there are additional disorders associated with&#160;congenital&#160;<br/>
two&#160;α1 chains&#160;and one&#160;α2 chain, encoded by&#160;the &#160;<i>COL1A1</i>&#160;<br/>
fractures that&#160;are usually not considered to&#160;be&#160;“classic” osteo-<br/>
and&#160;&#160;<i>COL1A2</i>&#160;&#160;genes, respectively&#160;(&#160;Figure 2–2&#160;).&#160;&#160;The&#160;&#160;α1 and&#160;<br/>
genesis imperfecta. In&#160;particular,&#160;work over the past several&#160;<br/>
α2 chains&#160;are synthesized as larger precursors&#160;with&#160;amino&#160;<br/>
years has identifi&#160;ed 10 additional genes in which mutations&#160;<br/>
and carboxyl&#160;terminal “propeptide” extensions, assemble&#160;<br/>
can cause autosomal recessive&#160;osteogenesis imperfecta&#160;and&#160;<br/>
with&#160;each&#160;other inside the cell, and are ultimately&#160;secreted&#160;<br/>
has provided additional insight&#160;into&#160;the genetic pathophysiol-<br/>
as a heterotrimeric type I procollagen molecule.&#160;During&#160;<br/>
ogy.&#160;In&#160;general, recessively&#160;inherited&#160;osteogenesis imperfect is&#160;<br/>
intracellular assembly, the three chains&#160;wind around each&#160;<br/>
caused by&#160;loss-of-function&#160;mutations&#160;in genes whose protein&#160;<br/>
other in a triple helix that&#160;is stabilized by&#160;interchain interac-<br/>
product is required for proper protein folding, intracellular&#160;<br/>
tions&#160;between hydroxylated proline and adjacent carbonyl&#160;<br/>
processing, and traffi<br/>
&#160;&#160;cking of&#160;type I collagen.&#160;&#160;<br/>
residues. There is a dynamic relationship between the post-<br/>translational action of&#160;prolyl hydroxylase and assembly&#160;of&#160;<br/>
<b>&#160; Pathophysiology&#160;</b><br/>
the triple helix, which begins at&#160;the carboxyl&#160;terminal end&#160;<br/>of&#160;the molecule.&#160;Increased levels of&#160;hydroxylation result in a&#160;<br/>
&#160;Osteogenesis imperfecta&#160;is a disease&#160;of&#160;type I collagen,&#160;<br/>
more&#160;stable helix, but helix formation prevents further pro-<br/>
which constitutes the major extracellular protein in the&#160;<br/>
lyl hydroxylation. The nature&#160;of&#160;the triple helix causes the&#160;<br/>
body.&#160;It&#160;is the major collagen in the dermis, the connec-<br/>
side chain of&#160;every third amino acid to&#160;point inward, and&#160;<br/>
tive&#160;tissue capsules of&#160;most organs, and the vascular and&#160;<br/>
steric constraints allow only&#160;a proton&#160;in this position. Thus,&#160;<br/>
gastrointestinal (GI) adventitia and is the only&#160;collagen in&#160;<br/>
the amino acid sequence of&#160;virtually all collagen chains&#160;in&#160;<br/>
bone. A mature&#160;type I collagen fibril is a rigid structure&#160;<br/>
the triple-helical portion is (Gly-X-Y)&#160;&#160;, where Y is proline&#160;<br/>
n<br/>
that&#160;contains&#160;multiple type I collagen molecules packed in&#160;<br/>
about one third of&#160;the time.&#160;<br/>
a staggered array and stabilized by&#160;intermolecular covalent&#160;<br/>
&#160;Th<br/>
&#160;e fundamental defect in most individuals with&#160;type I&#160;<br/>
cross-links. Each&#160;mature&#160;type I collagen molecule contains&#160;<br/>
osteogenesis imperfecta&#160;is reduced synthesis of&#160;type I collagen&#160;<br/>
<hr/>
<a name=10></a>12 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
proα1<br/>proα1<br/>proα1<br/>
<b>Nonmutant</b><br/>
proα1<br/>proα2<br/>proα2<br/>
proα1<br/>
<b>Type I OI</b><br/>
proα1<br/>
50%&#160;↓&#160;in type I collagen<br/>
proα2<br/>proα2<br/>
Excess proα2 chains are not assembled<br/>
proα1*<br/>proα1*<br/>
<b>Type II OI</b><br/>
proα1<br/>
75%&#160;↓&#160;in normal type I collagen<br/>
proα1<br/>proα2<br/>
Partially assembled heterotrimers<br/>
proα2<br/>
Excess post-translational<br/>modification<br/>
Activation of unfolded<br/>
Procollagen chains<br/>
Collagen molecules<br/>
protein stress response<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–3&#160;&#160;</b>&#160;Molecular pathogenesis of type I and type II osteogenesis imperfecta (OI).&#160;The &#160;<i>COL1A1</i>&#160;&#160;gene normally produces twice as&#160;<br/>many proα&#160;chains as the &#160;<i>COL1A2</i>&#160;&#160;gene.&#160;Therefore,&#160;in nonmutant cells, the ratio of proα1 to&#160;proα2 chains is 2:1, which corresponds to&#160;the ratio&#160;<br/>of&#160;α1 and&#160;α2 chains in intact collagen molecules. In&#160;type I osteogenesis imperfecta, a mutation (X) in one of the &#160;<i>COL1A1</i>&#160;&#160;alleles (*) results in&#160;<br/>failure to&#160;produce proα1 chains, leading to&#160;a 50% reduction in the total number of proα1 chains, a 50% reduction in the production of intact&#160;<br/>type I collagen molecules, and an excess of unassembled proα2 chains, which are degraded inside the cell. In&#160;type II osteogenesis imperfecta,&#160;<br/>a mutation in one of the &#160;<i>COL1A1</i>&#160;&#160;alleles results in a structural alteration that blocks triple-helix formation and secretion of partially assembled&#160;<br/>collagen molecules containing the mutant chain.&#160;(Adapted from&#160;Thompson MW et al.&#160;&#160;<i>Genetics in Medicine,</i>&#160;&#160;5th ed. Saunders, 1991.)&#160;<br/>
resulting&#160;from&#160;loss-of-function&#160;mutations&#160;in &#160;<br/>
<i>COL1A1</i>. &#160;&#160;In&#160;<br/>
mRNA precursors&#160;that&#160;carry the nonsense&#160;codon are recog-<br/>
most cases, the mutant&#160;&#160;<i>COL1A1</i>&#160;&#160;allele gives rise&#160;to&#160;greatly&#160;<br/>
nized and degraded by&#160;the cell. With&#160;collagen and many&#160;other&#160;<br/>
reduced (partial loss-of-function) or&#160;no (complete loss-of-<br/>
genes, production of&#160;a truncated protein (as might&#160;be&#160;pre-<br/>
function) mRNA. Because the nonmutant &#160;<br/>
<i>COL1A1</i>&#160;&#160;&#160;allele&#160;<br/>
dicted from&#160;a nonsense&#160;mutation) would be&#160;more&#160;damaging to&#160;<br/>
continues to&#160;produce mRNA at&#160;a normal rate&#160;(ie, there is no&#160;<br/>
the cell than&#160;production of&#160;no protein at&#160;all. Th<br/>
&#160;us,&#160;nonsense-<br/>
dosage compensation), heterozygosity for a complete loss-<br/>
mediated decay,&#160;which has been observed to&#160;occur for muta-<br/>
of-function&#160;mutation results in a 50% reduction in the total&#160;<br/>
tions&#160;in many&#160;diff&#160;erent multiexon&#160;genes, serves as a protective&#160;<br/>
rate&#160;of&#160;proα1(I) mRNA synthesis, whereas heterozygosity&#160;<br/>
phenomenon and is an&#160;important component of&#160;the genetic&#160;<br/>
for a partial loss-of-function&#160;mutation results in a less severe&#160;<br/>
pathophysiology.&#160;<br/>
reduction. A reduced concentration&#160;of&#160;proα1(I) chains&#160;limits&#160;<br/>
&#160;An example of&#160;these principles is apparent&#160;from&#160;considering&#160;<br/>
the production of&#160;type I procollagen, leading to&#160;(1) a reduced&#160;<br/>
type II osteogenesis imperfecta, which is caused by&#160;structur-<br/>
amount&#160;of&#160;structurally normal type I collagen and (2) an&#160;<br/>
ally abnormal forms of&#160;type I collagen and is more&#160;severe than&#160;<br/>
excess of&#160;unassembled proα2(I) chains, which are degraded&#160;<br/>
type I osteogenesis imperfecta. Mutations&#160;in type II osteogen-<br/>
inside the cell (&#160;Figure 2–3&#160;).&#160;<br/>
esis imperfecta&#160;can be&#160;caused by&#160;defects in either &#160;<i>COL1A1</i>&#160;<br/>
&#160;Th<br/>
&#160;&#160;ere are several potential molecular&#160;defects responsible for&#160;<br/>
or&#160;<i>&#160;COL1A2</i>&#160;&#160;and usually are missense&#160;alterations&#160;of&#160;a glycine&#160;<br/>
&#160;<i>COL1A1</i>&#160;&#160;mutations&#160;in type I osteogenesis imperfecta, includ-<br/>
residue that&#160;allow the mutant&#160;peptide chain to&#160;bind to&#160;nor-<br/>
ing alterations&#160;in a regulatory&#160;region leading to&#160;reduced tran-<br/>
mal chains&#160;in the initial steps of&#160;trimer assembly&#160;(&#160;Figure 2–3&#160;).&#160;<br/>
scription, splicing abnormalities leading to&#160;reduced steady&#160;<br/>
However,&#160;triple-helix formation is ineff&#160;ective,&#160;&#160;oft&#160;en&#160;because&#160;<br/>
state levels of&#160;RNA, and deletion of&#160;the entire &#160;<i>COL1A1</i>&#160;&#160;&#160;gene.&#160;<br/>
amino acids with&#160;large&#160;side chains&#160;are substituted for glycine.&#160;<br/>
However,&#160;in many&#160;cases, the underlying&#160;defect is a single base&#160;<br/>
Ineff&#160;ective&#160;triple-helix formation leads to&#160;increased post-<br/>
pair change&#160;that&#160;creates a premature&#160;stop&#160;codon (also known&#160;<br/>
translational modifi&#160;cation by&#160;prolyl hydroxylase,&#160;a reduced&#160;<br/>
as a &#160;<b>“nonsense mutation”</b>&#160;) in an&#160;internal exon. In&#160;a process&#160;<br/>
rate&#160;of&#160;secretion, and activation of&#160;the unfolded protein stress&#160;<br/>
referred to&#160;as nonsense-mediated decay,&#160;partially synthesized&#160;<br/>
response. Th<br/>
&#160;&#160;ese appear&#160;to&#160;be&#160;critical events in the cellular&#160;<br/>
<hr/>
<a name=11></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 13<br/>
pathogenesis of&#160;type II osteogenesis imperfecta, because gly-<br/>
and nonmutant &#160;<i>COL1A1</i>&#160;&#160;alleles using closely linked DNA-<br/>
cine substitutions&#160;toward&#160;the carboxyl&#160;terminal end of&#160;the&#160;<br/>
based&#160;polymorphisms, even though&#160;the causative molecular&#160;<br/>
molecule are generally more&#160;severe than&#160;those at&#160;the amino&#160;<br/>
defect is not known. Once this information is established for&#160;<br/>
terminal end.&#160;<br/>
a particular family,&#160;inheritance of&#160;the mutant&#160;allele can be&#160;<br/>
&#160;Th<br/>
&#160;&#160;ese considerations&#160;help to&#160;explain why type II osteogen-<br/>
predicted in future&#160;pregnancies.&#160;<br/>
esis imperfecta&#160;is more&#160;severe than&#160;type I and exemplify the&#160;<br/>
&#160;For types III and IV osteogenesis imperfecta, mutations&#160;can&#160;<br/>
principle of&#160;dominant&#160;negative&#160;gene action. Th<br/>
&#160;e&#160;eff&#160;ects of&#160;an&#160;<br/>
occur in &#160;<i>COL1A1</i>&#160;&#160;or&#160;&#160;<i>COL1A2</i>&#160;&#160;(ie, &#160;<b>locus heterogeneity</b>&#160;),&#160;&#160;and&#160;<br/>
amino acid substitution in a proα1(I) peptide chain are ampli-<br/>
in this situation, linkage analysis is more&#160;diffi<br/>
&#160; cult&#160;because&#160;one&#160;<br/>
fi&#160;ed at&#160;the levels of&#160;both&#160;triple-helix assembly&#160;and fi&#160;bril&#160;for-<br/>
cannot be&#160;sure which locus is abnormal.&#160;<br/>
mation. Because every type I procollagen molecule has two&#160;<br/>
&#160;For both&#160;type I and type IV osteogenesis imperfecta, the&#160;<br/>
proα1(I) chains, only&#160;25% of&#160;type I procollagen molecules will&#160;<br/>
most important question in the clinical setting oft&#160;en&#160;relates&#160;<br/>
contain two normal proα1(I) chains&#160;even though&#160;only&#160;one of&#160;<br/>
to&#160;the natural history of&#160;the illness. For example, reproductive&#160;<br/>
the two &#160;<i>COL1A1</i>&#160;&#160;alleles is mutated.&#160;Furthermore, activation&#160;<br/>
decision making in families at&#160;risk for osteogenesis imperfecta&#160;<br/>
of&#160;the unfolded protein stress response&#160;appears to&#160;be&#160;a key&#160;<br/>
is infl&#160;uenced greatly by&#160;the relative&#160;likelihood&#160;of&#160;producing a&#160;<br/>
event in the pathophysiology of&#160;the disease, as discussed&#160;fur-<br/>
child who will never walk and will require multiple orthopedic&#160;<br/>
ther below.&#160;Finally,&#160;because each&#160;molecule in a fi&#160;bril&#160;interacts&#160;<br/>
operations&#160;versus a child whose major problems will be&#160;a few&#160;<br/>
with&#160;several others, incorporation of&#160;an&#160;abnormal molecule&#160;<br/>
long&#160;bone fractures and an&#160;increased risk of&#160;mixed sensori-<br/>
can have&#160;disproportionately&#160;large&#160;eff&#160;ects on&#160;fi&#160;bril&#160;&#160;structure&#160;<br/>
neural and conductive&#160;hearing loss in childhood&#160;and adult-<br/>
and integrity.&#160;<br/>
hood. As&#160;evident from&#160;the prior discussion, diff&#160;erent&#160;mutant&#160;<br/>
&#160;Collagen mutations&#160;that&#160;cause type III and type IV osteo-<br/>
genes and diff&#160;erent mutant&#160;alleles, as well as other genes that&#160;<br/>
genesis imperfecta&#160;are diverse and include glycine substitu-<br/>
modify the osteogenesis imperfecta&#160;phenotype, can contribute&#160;<br/>
tions&#160;in the amino terminal portion of&#160;the collagen triple helix,&#160;<br/>
to&#160;this &#160;<b>phenotypic heterogeneity</b>. &#160;<br/>
a few internal deletions&#160;of&#160;&#160;<i>COL1A1</i>&#160;&#160;and &#160;<i>COL1A2</i>&#160;&#160;that&#160;do not&#160;<br/>
&#160;In&#160;type II osteogenesis imperfecta, a single copy&#160;of&#160;the&#160;<br/>
signifi&#160;cantly&#160;disturb triple helix formation, and some unusual&#160;<br/>
mutant&#160;allele causes the abnormal phenotype&#160;and,&#160;therefore,&#160;<br/>
alterations&#160;in the non–triple-helical extensions&#160;at&#160;the amino&#160;<br/>
has a dominant&#160;mechanism of&#160;action. Although&#160;the type II&#160;<br/>
and carboxyl&#160;terminals of&#160;proα&#160;chains.&#160;<br/>
phenotype&#160;itself is never inherited, there are rare&#160;situations&#160;in&#160;<br/>
&#160;Recessively&#160;inherited osteogenesis imperfect can be&#160;caused&#160;<br/>
which a phenotypically normal individual harbors a COL1A1&#160;<br/>
by&#160;loss of&#160;function for a key prolyl hydroxylase encoded by&#160;the&#160;<br/>
mutant&#160;allele among his or&#160;her germ&#160;cells. Th<br/>
&#160;ese&#160;individu-<br/>
&#160;<i>PLOD2</i>&#160;&#160;gene, one of&#160;three genes, &#160;<i>CRTAP,&#160;LEPRE1, PPIB,</i>&#160;&#160;&#160;that&#160;<br/>
als with so-called &#160;<b>gonadal mosaicis</b>&#160;<b>m</b>&#160;&#160;can produce multiple&#160;<br/>
encode members&#160;of&#160;a protein complex that&#160;resides within the&#160;<br/>
off&#160;spring&#160;with&#160;type II osteogenesis imperfecta&#160;(&#160;Figure 2–4&#160;),&#160;<br/>
rough endoplasmic reticulum and facilitates the folding and&#160;<br/>
a pattern of&#160;segregation that&#160;can be&#160;confused with reces-<br/>
processing of&#160;type I collagen, as well as several additional genes&#160;<br/>
sive&#160;inheritance. In&#160;fact, many&#160;other mutations, includ-<br/>
whose protein products are required for intracellular traffi<br/>
&#160; ck-<br/>
ing Duchenne muscular dystrophy, which is X linked, and&#160;<br/>
ing and secretion of&#160;type I collagen. A common pathway for&#160;<br/>
type 1 neurofi&#160;bromatosis, which is autosomal dominant, also&#160;<br/>
all types of&#160;osteogenesis imperfect involves a combination&#160;<br/>
occasionally show unusual inheritance patterns&#160;explained by&#160;<br/>
of&#160;reduced production of&#160;type I collagen in the extracellular&#160;<br/>
gonadal&#160;&#160;mosaicism. &#160; &#160;&#160;<br/>
matrix and/or dysfunctional intracellular collagen processing&#160;<br/>and maturation.&#160;&#160;<br/>
<b>&#160; Genetic&#160;&#160;Principles&#160;<br/></b>&#160;<br/>
As&#160;already&#160;described, most cases of&#160;type I osteogenesis&#160;<br/>imperfecta&#160;are caused by&#160;partial or&#160;complete loss-of-func-<br/>tion mutations&#160;in &#160;<br/>
<i>COL1A1.</i>&#160;<br/>
&#160;However,&#160;in approximately&#160;<br/>
one-third of&#160;aff&#160;ected individuals, the disease&#160;is caused by&#160;a&#160;<br/>
Type II OI<br/>
new mutation; in addition, there are many&#160;ways in which&#160;<br/>DNA sequence alterations&#160;can reduce gene expression.&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–4&#160;&#160;</b>&#160;Gonadal mosaicism for type II osteogenesis&#160;<br/>
Consequently,&#160;there is a wide range&#160;of&#160;mutant&#160;alleles (ie,&#160;<br/>
imperfecta. In&#160;this idealized pedigree,&#160;the phenotypically normal&#160;<br/>
&#160;<b>allelic heterogeneity</b>&#160;), which represents a challenge&#160;for the&#160;<br/>
father (indicated with the arrow) has had two children by&#160;diﬀ&#160;erent&#160;<br/>mates, each of whom is aﬀ&#160;ected with autosomal dominant type II&#160;<br/>
development of&#160;molecular&#160;diagnostic tests. In&#160;a family in&#160;<br/>
osteogenesis imperfecta (OI). Analysis of the father showed that&#160;<br/>
which type I osteogenesis imperfecta&#160;is known to&#160;occur clini-<br/>
some of his spermatozoa carried a &#160;<i>COL1A1</i>&#160;&#160;mutation, indicating that&#160;<br/>
cally and a proband seeks a diagnostic test for the purposes&#160;<br/>
the explanation for this unusual pedigree is germline mosaicism.&#160;<br/>
of&#160;reproductive&#160;planning, it&#160;is possible in most cases to&#160;use&#160;<br/>
(Adapted from Cohn DH et al. Recurrence of lethal osteogenesis imperfecta due&#160;<br/>
linkage analysis at&#160;the &#160;<i>COL1A1</i>&#160;&#160;locus. In&#160;this approach, one&#160;<br/>
to&#160;parental mosaicism for a dominant mutation in a human type I collagen gene&#160;<br/>
distinguishes between chromosomes that&#160;carry the mutant&#160;<br/>
[&#160;<i>COL1A1</i>&#160;]. Am J Hum Genet. 1990;46:591.)&#160;<br/>
<hr/>
<a name=12></a>14 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
regardless of&#160;fetal genotype.&#160;Th<br/>
&#160;&#160;e number of&#160;pregnancies at&#160;risk&#160;<br/>
<b>&#160;CHECKPOINT&#160;</b><br/>
has risen in proportion to&#160;the successful treatment of&#160;phenyl-<br/>ketonuria and represents a challenge&#160;to&#160;public health&#160;offi<br/>
&#160; cials,&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; &#160;4. &#160;&#160;</b></i>When and how does type II osteogenesis imperfecta&#160;<br/>
physicians, and geneticists in the future.&#160;<br/>
present?&#160;To&#160;what do these individuals succumb?&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 5. &#160;&#160;</b></i>What are two typical radiologic ﬁ&#160;ndings in type II osteo-<br/>
genesis imperfecta?&#160;<br/>
<b>&#160; Clinical&#160;&#160;Manifestations&#160;</b><br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 6. &#160;&#160;</b></i>Explain how nonsense-mediated decay can help pro-<br/>
&#160;Th<br/>
&#160;&#160;e incidence of&#160;hyperphenylalaninemia varies among diff&#160;er-<br/>
tect&#160;individuals aﬀ&#160;ected by&#160;a genetic disease.&#160;&#160;<br/>
ent populations. In&#160;African Americans, it&#160;is about 1:50,000; in&#160;<br/>Yemenite Jews, about 1:5000; and in most Northern European&#160;<br/>populations, about 1:10,000. Post-natal growth&#160;retardation,&#160;<br/>moderate-to-severe mental retardation, recurrent seizures,&#160;<br/>
<b>&#160; PHENYLKETONURIA&#160;</b><br/>
hypopigmentation, and eczematous skin rashes constitute&#160;<br/>the major phenotypic features of&#160;untreated phenylketonuria.&#160;<br/>
&#160;Phenylketonuria presents one of&#160;the most dramatic examples&#160;<br/>
However,&#160;with&#160;the advent&#160;of&#160;widespread newborn screening&#160;<br/>
of&#160;how the relationship between genotype and phenotype&#160;can&#160;<br/>
programs&#160;for hyperphenylalaninemia, the major phenotypic&#160;<br/>
depend on&#160;environmental variables. Phenylketonuria was fi&#160;rst&#160;<br/>
manifestations&#160;of&#160;phenylketonuria today occur when treat-<br/>
recognized as an&#160;inherited cause of&#160;mental retardation in 1934,&#160;<br/>
ment is partial or&#160;when it&#160;is terminated prematurely&#160;during&#160;<br/>
and systematic attempts to&#160;treat the condition&#160;were&#160;initiated in&#160;<br/>
late&#160;childhood&#160;or&#160;adolescence. In&#160;these cases, there is usually a&#160;<br/>
the 1950s. Th<br/>
&#160;&#160;e term&#160;“phenylketonuria”&#160;denotes elevated lev-<br/>
slight&#160;but signifi&#160;cant&#160;decline in IQ, an&#160;array of&#160;specifi&#160;c&#160;perfor-<br/>
els of&#160;urinary&#160;phenylpyruvate&#160;and phenylacetate,&#160;which occur&#160;<br/>
mance and perceptual defects, and an&#160;increased frequency of&#160;<br/>
when circulating phenylalanine levels, normally between 0.06&#160;<br/>
learning and behavioral problems.&#160;<br/>
and 0.1 mmol/L, rise&#160;above 1.2 mmol/L. Th<br/>
&#160;&#160;us, the primary&#160;<br/>
&#160;Newborn screening for phenylketonuria is performed on&#160;a&#160;<br/>
defect in phenylketonuria is &#160;<b>hyperphenylalaninemia</b>, &#160;&#160;which&#160;<br/>
small amount&#160;of&#160;dried blood&#160;obtained at&#160;24–72 hours of&#160;age.&#160;<br/>
itself has a number of&#160;distinct genetic causes.&#160;<br/>
From&#160;the initial screen, there is about a 1% incidence of&#160;posi-<br/>
&#160;Th<br/>
&#160;&#160;e pathophysiology of&#160;phenylketonuria illustrates several&#160;<br/>
tive&#160;or&#160;indeterminate&#160;test results, and a more&#160;quantitative&#160;mea-<br/>
important principles in human genetics. Hyperphenylalanin-<br/>
surement of&#160;plasma phenylalanine is then performed before&#160;<br/>
emia itself is caused by&#160;&#160;<b>substrate accumulation</b>,&#160;&#160;which occurs&#160;<br/>
2 weeks of&#160;age.&#160;In&#160;neonates who undergo&#160;a second round of&#160;<br/>
when a normal intermediary&#160;metabolite fails to&#160;be&#160;eliminated&#160;<br/>
testing, the diagnosis of&#160;phenylketonuria is ultimately&#160;con-<br/>
properly and its concentrations become elevated to&#160;levels that&#160;<br/>
fi&#160;rmed in about 1%, providing an&#160;estimated phenylketonuria&#160;<br/>
are toxic. As&#160;described later,&#160;the most common cause of&#160;hyper-<br/>
prevalence of&#160;1:10,000, although&#160;there is great geographic and&#160;<br/>
phenylalaninemia is defi&#160;ciency of&#160;the enzyme phenylalanine&#160;<br/>
ethnic variation (see prior discussion). Th<br/>
&#160;&#160;e false-negative&#160;rate&#160;<br/>
hydroxylase,&#160;which catalyzes the conversion of&#160;phenylala-<br/>
of&#160;phenylketonuria newborn screening programs&#160;is approxi-<br/>
nine to&#160;tyrosine. Individuals with&#160;mutations&#160;in phenylalanine&#160;<br/>
mately&#160;1:70; phenylketonuria in these unfortunate&#160;individuals&#160;<br/>
hydroxylase usually do not suff&#160;er from&#160;the absence of&#160;tyrosine&#160;<br/>
is usually not detected until developmental delay and seizures&#160;<br/>
because this amino acid can be&#160;supplied to&#160;the body by&#160;mecha-<br/>
during&#160;infancy or&#160;early childhood&#160;prompt&#160;a systematic evalu-<br/>
nisms that&#160;are independent of&#160;phenylalanine hydroxylase.&#160;In&#160;<br/>
ation for an&#160;inborn&#160;error of&#160;metabolism.&#160;<br/>
other forms of&#160;phenylketonuria, however,&#160;additional disease&#160;<br/>
&#160;Infants in whom&#160;a diagnosis of&#160;phenylketonuria is con-<br/>
manifestations&#160;occur as a result of&#160;&#160;<b>end-product&#160;defi&#160;ciency</b>, &#160;<br/>
fi&#160;rmed are usually placed on&#160;a dietary regimen in which a&#160;<br/>
which occurs&#160;when the downstream product of&#160;a particular&#160;<br/>
semisynthetic formula low in phenylalanine can be&#160;combined&#160;<br/>
enzyme is required for a key physiologic process.&#160;<br/>
with regular breast feeding. Th<br/>
&#160;&#160;is regimen is adjusted empiri-<br/>
&#160;A discussion of&#160;phenylketonuria also helps to&#160;illustrate&#160;the&#160;<br/>
cally to&#160;maintain a plasma phenylalanine concentration&#160;at&#160;<br/>
rationale for,&#160;and application&#160;of, population-based screening pro-<br/>
or&#160;below 1 mmol/L, which is still several times greater than&#160;<br/>
grams&#160;for genetic disease. More&#160;than&#160;10 million newborn infants&#160;<br/>
normal but similar to&#160;levels observed in so-called &#160;<b>benign&#160;</b><br/>
per year&#160;are tested for phenylketonuria, and the focus today in&#160;<br/>
<b>hyperphenylalaninemia</b>&#160;&#160;(see later discussion), a biochemi-<br/>
treatment has shift&#160;ed in several respects. First, “successful” treat-<br/>
cal diagnosis which is not associated with&#160;phenylketonuria&#160;<br/>
ment of&#160;phenylketonuria by&#160;dietary restriction&#160;of&#160;phenylalanine&#160;<br/>
and has no clinical consequences. Phenylalanine is an&#160;essen-<br/>
is, in general, accompanied by&#160;subtle neuropsychologic defects&#160;<br/>
tial amino acid, and even individuals with&#160;phenylketonuria&#160;<br/>
that&#160;have&#160;been recognized only&#160;in the last decade. Th<br/>
&#160;us,&#160;current&#160;<br/>
must consume small amounts to&#160;avoid protein starvation and&#160;<br/>
investigations&#160;focus on&#160;alternative treatment strategies such as&#160;<br/>
a catabolic state.&#160;Most children require 25–50 mg/kg/d of&#160;<br/>
somatic gene therapy&#160;as well as on&#160;the social and psychologic fac-<br/>
phenylalanine, and these requirements are met by&#160;combining&#160;<br/>
tors&#160;that&#160;aff&#160;ect compliance with&#160;dietary management. Second, a&#160;<br/>
natural foods with&#160;commercial products designed for phenyl-<br/>
generation of&#160;females treated for phenylketonuria are now bear-<br/>
ketonuria treatment. When dietary treatment programs&#160;were&#160;<br/>
ing children, and the phenomenon of&#160;&#160;<b>maternal phenylketon-</b><br/>
fi&#160;rst implemented,&#160;it&#160;was hoped that&#160;the risk of&#160;neurologic&#160;<br/>
<b>uria</b>&#160;&#160;has been recognized in which in utero exposure to&#160;maternal&#160;<br/>
damage from&#160;the hyperphenylalaninemia of&#160;phenylketonuria&#160;<br/>
hyperphenylalaninemia results in congenital abnormalities&#160;<br/>
would have&#160;a limited window and that&#160;treatment could be&#160;<br/>
<hr/>
<a name=13></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 15<br/>
stopped&#160;aft&#160;er childhood. However,&#160;it&#160;now appears that&#160;even&#160;<br/>
can also inhibit&#160;the transport&#160;of&#160;neutral amino acids across&#160;<br/>
mild hyperphenylalaninemia in adults (&gt;1.2 mmol/L) is asso-<br/>
the blood-brain barrier, leading to&#160;a selective&#160;amino acid defi&#160;-<br/>
ciated with neuropsychologic and cognitive&#160;defi&#160;cits;&#160;therefore,&#160;<br/>
ciency in the cerebrospinal fl&#160;uid.&#160;Th<br/>
&#160;&#160;us, the neurologic mani-<br/>
dietary treatment of&#160;phenylketonuria should probably&#160;be&#160;con-<br/>
festations&#160;of&#160;phenylketonuria are felt&#160;to&#160;be&#160;due to&#160;a general&#160;<br/>
tinued indefi&#160;nitely.&#160;<br/>
eff&#160;ect of&#160;substrate&#160;accumulation&#160;on&#160;cerebral metabolism. Th<br/>
&#160;e&#160;<br/>
&#160;As&#160;an&#160;increasing number of&#160;treated females with&#160;phenylke-<br/>
pathophysiology of&#160;the eczema seen in untreated or&#160;partially&#160;<br/>
tonuria reach childbearing&#160;age,&#160;a new problem—fetal hyper-<br/>
treated phenylketonuria is not well understood, but eczema&#160;<br/>
phenylalaninemia via intrauterine exposure—has become&#160;<br/>
is a common feature of&#160;other inborn&#160;errors&#160;of&#160;metabolism in&#160;<br/>
apparent. Newborn infants in such cases exhibit&#160;microcephaly&#160;<br/>
which plasma concentrations of&#160;branched-chain amino acids&#160;<br/>
and growth&#160;retardation of&#160;prenatal onset, congenital heart&#160;<br/>
are elevated.&#160;Hypopigmentation in phenylketonuria is prob-<br/>
disease, and severe developmental delay regardless of&#160;the fetal&#160;<br/>
ably&#160;caused by&#160;an&#160;inhibitory eff&#160;ect of&#160;excess phenylalanine on&#160;<br/>
genotype.&#160;Rigorous control of&#160;maternal phenylalanine con-<br/>
the production of&#160;dopaquinone in melanocytes, which is the&#160;<br/>
centrations from&#160;before&#160;conception until birth reduces the&#160;<br/>
rate-limiting step in melanin synthesis.&#160;&#160;<br/>
incidence of&#160;fetal abnormalities in maternal phenylketonuria,&#160;<br/>
&#160;Approximately&#160;90% of&#160;infants with&#160;persistent hyperphenylal-<br/>
but the level of&#160;plasma phenylalanine that&#160;is “safe” for a devel-<br/>
aninemia detected by&#160;newborn screening have&#160;typical phenyl-<br/>
oping fetus is 0.12–0.36 mmol/L—signifi&#160;cantly&#160;lower than&#160;<br/>
ketonuria caused by&#160;a defect in phenylalanine hydroxylase (see&#160;<br/>
what&#160;is considered acceptable for phenylketonuria-aff&#160;ected&#160;<br/>
later discussion). Of the remainder, most have&#160;benign hyper-<br/>
children or&#160;adults on&#160;phenylalanine-restricted diets.&#160;&#160;<br/>
phenylalaninemia, in which circulating levels of&#160;phenylalanine&#160;<br/>are between 0.1 mmol/L and 1 mmol/L. However,&#160;approxi-<br/>
<b>&#160; Pathophysiology&#160;</b><br/>
mately&#160;1% of&#160;infants with&#160;persistent hyperphenylalaninemia&#160;<br/>have&#160;defects in the metabolism of&#160;tetrahydrobiopterin (BH&#160;&#160;),&#160;<br/>
&#160;Th<br/>
&#160;&#160;e normal metabolic fate&#160;of&#160;free phenylalanine is incorpora-<br/>
4<br/>
which is a stoichiometric cofactor for the hydroxylation reac-<br/>
tion into&#160;protein or&#160;hydroxylation by&#160;phenylalanine hydroxy-<br/>
tion (&#160;Figure 2–6&#160;). Unfortunately, BH&#160;&#160;&#160;is required not only&#160;for&#160;<br/>
lase to&#160;form&#160;tyrosine (&#160;Figure 2–5&#160;). Because tyrosine, but not&#160;<br/>
4<br/>
phenylalanine hydroxylase but also for tyrosine hydroxylase&#160;<br/>
phenylalanine, can be&#160;metabolized to&#160;produce fumarate&#160;and&#160;<br/>
and tryptophan&#160;hydroxylase.&#160;Th<br/>
&#160;&#160;e products of&#160;these latter two&#160;<br/>
acetoacetate,&#160;hydroxylation of&#160;phenylalanine can be&#160;viewed&#160;<br/>
enzymes are catecholaminergic and serotonergic neurotrans-<br/>
both&#160;as a means of&#160;making tyrosine a nonessential amino acid&#160;<br/>
mitters; thus, individuals with&#160;defects in BH&#160;&#160;&#160;metabolism suff&#160;er&#160;<br/>
and as a mechanism for providing energy&#160;via gluconeogen-<br/>
4<br/>
not only&#160;from&#160;phenylketonuria (substrate&#160;accumulation) but&#160;<br/>
esis during&#160;states of&#160;protein starvation. In&#160;individuals with&#160;<br/>
also from&#160;absence of&#160;important neurotransmitters (end-product&#160;<br/>
mutations&#160;in phenylalanine hydroxylase,&#160;tyrosine becomes an&#160;<br/>
defi&#160;ciency).&#160;Aff&#160;ected individuals develop a severe neurologic&#160;<br/>
essential amino acid. However,&#160;the clinical manifestations&#160;of&#160;<br/>
disorder in early childhood&#160;manifested&#160;by&#160;hypotonia, inactiv-<br/>
the disease&#160;are caused not by&#160;absence of&#160;tyrosine (most people&#160;<br/>
ity,&#160;and developmental regression and are treated not only&#160;with&#160;<br/>
get enough tyrosine in the diet in any case) but by&#160;accumu-<br/>
dietary restriction&#160;of&#160;phenylalanine but also with&#160;dietary sup-<br/>
lation of&#160;phenylalanine. Transamination&#160;of&#160;phenylalanine to&#160;<br/>
plementation with&#160;BH&#160;&#160;, dopa, and 5-hydroxytryptophan.&#160;&#160;<br/>
form&#160;phenylpyruvate&#160;normally does not occur unless circulat-<br/>
4<br/>
ing concentrations exceed 1.2 mmol/L, but the pathogenesis of&#160;<br/>central nervous system (CNS) abnormalities in phenylketon-<br/>
<b>&#160; Genetic&#160;&#160;Principles&#160;</b><br/>
uria is related more&#160;to&#160;phenylalanine itself than&#160;to&#160;its metabo-<br/>
&#160;Phenylketonuria is one of&#160;several mendelian conditions that&#160;<br/>
lites. In&#160;addition to&#160;a direct eff&#160;ect of&#160;elevated phenylalanine&#160;<br/>
have&#160;a relatively&#160;high incidence, others being cystic fi&#160;bro-<br/>
levels on&#160;energy&#160;production, protein synthesis, and neurotrans-<br/>
sis, Duchenne muscular dystrophy, neurofi&#160;bromatosis&#160;&#160;type&#160;<br/>
mitter homeostasis in the developing&#160;brain, phenylalanine&#160;<br/>
I, and sickle cell anemia (&#160;Table 2–2&#160;).&#160;&#160;Th<br/>
&#160;&#160;ese conditions share&#160;<br/>
no single feature: Some are recessive, some dominant, some&#160;<br/>autosomal, and some X linked, some are lethal in early child-<br/>hood, but others have&#160;very&#160;little eff&#160;ect on&#160;reproduction (and&#160;<br/>
Tyrosine<br/>
Melanin<br/>
transmission of&#160;mutant&#160;genes to&#160;subsequent generations). In&#160;<br/>
catecholamines<br/>
Phenylalanine<br/>
fact, the incidence of&#160;a mendelian condition&#160;is determined by&#160;<br/>
hydroxylase<br/>
a balance of&#160;factors, including the rate&#160;at&#160;which new mutations&#160;<br/>
Dietary<br/>
Ketone bodies<br/>
occur,&#160;and the likelihood&#160;that&#160;an&#160;individual carrying a muta-<br/>
phenylalanine<br/>
tion will transmit it&#160;to&#160;his or&#160;her off&#160;spring.&#160;Th<br/>
&#160;&#160;e latter character-<br/>
istic—the probability, compared with&#160;the general population,&#160;<br/>
Protein synthesis<br/>
Gluconeogenesis<br/>
of&#160;transmitting one’s genes to&#160;the next generation—is called&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–5&#160;&#160;</b>&#160;Metabolic fates of phenylalanine. Because&#160;<br/>
&#160;<b>fi&#160;tness</b>.&#160;&#160;Reduced fi&#160;tness exhibited by&#160;many&#160;genetic conditions&#160;<br/>
catabolism of phenylalanine must proceed via tyrosine, the absence&#160;<br/>
such as Duchenne muscular dystrophy&#160;or&#160;type 1 neurofi&#160;bro-<br/>
of phenylalanine hydroxylase leads to&#160;accumulation of phenylalanine.&#160;<br/>
matosis is balanced by&#160;an&#160;appreciable &#160;<b>new mutation&#160;rate</b>, &#160;&#160;so&#160;<br/>
Tyrosine is also a biosynthetic precursor for melanin and certain&#160;<br/>neurotransmitters, and the absence of phenylalanine hydroxylase&#160;<br/>
that&#160;the incidence of&#160;the condition&#160;remains constant&#160;in succes-<br/>
causes tyrosine to&#160;become an essential amino acid.&#160;&#160;<br/>
sive&#160;generations.&#160;<br/>
<hr/>
<a name=14></a>16 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
Phenylalanine<br/>
hydroxylase<br/>
Transamination<br/>
Phenylalanine<br/>
Tyrosine<br/>
BH<br/>
qBH<br/>
4<br/>
2<br/>
Phenylpyruvate<br/>
Dihydropteridine<br/>
Tyrosine<br/>
reductase<br/>
6-PTS<br/>
hydroxylase<br/>
Phenylacetate<br/>
GTP<br/>
Tyrosine<br/>
Dopa<br/>
cyclohydrolase<br/>
Phenylketones<br/>
BH<br/>
qBH<br/>
4<br/>
2<br/>
GTP<br/>
accumulated in<br/>plasma and urine<br/>
Dihydropteridine<br/>
when [Phe] &gt; 1.2 mmol/L<br/>
reductase<br/>
Tryptophan<br/>
hydroxylase<br/>
Tryptophan<br/>
5-Hydroxytryptophan<br/>
BH<br/>
qBH<br/>
4<br/>
2<br/>
Dihydropteridine<br/>
reductase<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–6&#160;&#160;</b>&#160;Normal and abnormal phenylalanine metabolism.&#160;Tetrahydrobiopterin (BH&#160;&#160;) is a cofactor for phenylalanine&#160;<br/>
4<br/>
hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase. Consequently, defects in the biosynthesis of BH&#160;&#160;&#160;or its metabolism result&#160;<br/>
4<br/>
in a failure of all three hydroxylation reactions.&#160;The absence of phenylalanine hydroxylation has phenotypic eﬀ&#160;ects because of substrate&#160;<br/>accumulation, but the absence of tyrosine or tryptophan hydroxylation has phenotypic eﬀ&#160;ects as a result of end-product deﬁ&#160;ciency.&#160;<br/>(6-PTS, 6-pyruvoyltetrahydrobiopterin synthetase; qBH&#160;&#160;, quinonoid dihydrobiopterin.)&#160;&#160;<br/>
2<br/>
&#160;For recessive&#160;conditions like phenylketonuria or&#160;sickle cell&#160;<br/>
treatments. Each&#160;of&#160;these conditions is caused by&#160;loss of&#160;func-<br/>
anemia (or X-linked&#160;recessive&#160;conditions such as Duchenne&#160;<br/>
tion for an&#160;enzyme expressed specifi&#160;cally in the liver;&#160;there-<br/>
muscular dystrophy), another factor that&#160;can infl&#160;uence&#160;&#160;dis-<br/>
fore, attempts to&#160;deliver a normal gene to&#160;aff&#160;ected&#160;individuals&#160;<br/>
ease&#160;incidence is whether heterozygous carriers experience a&#160;<br/>
have&#160;focused on&#160;strategies to&#160;express the gene in hepatocytes.&#160;<br/>
selective&#160;advantage or&#160;disadvantage compared with&#160;homozy-<br/>
However,&#160;as is the case for benign hyperphenylalaninemia,&#160;<br/>
gous nonmutant individuals. For example, the relatively&#160;high&#160;<br/>
individuals with&#160;very&#160;low levels of&#160;enzymatic activity are clini-<br/>
incidence of&#160;sickle cell anemia in individuals of&#160;West African&#160;<br/>
cally normal, and successful gene therapy&#160;might, therefore,&#160;<br/>
ancestry is due in part&#160;to&#160;&#160;<b>heterozygote&#160;advantage</b>, &#160;&#160;confer-<br/>
be&#160;accomplished by&#160;expressing the target gene in only&#160;a small&#160;<br/>
ring&#160;resistance to&#160;malaria. Because the detrimental eff&#160;ects&#160;of&#160;<br/>
proportion of&#160;hepatic cells.&#160;&#160;<br/>
homozygosity for the hemoglobin B sickle allele (&#160;<i>HBB&#160;S</i><b>&#160;</b>&#160;)&#160;&#160;are&#160;<br/>balanced by&#160;the benefi&#160;cial&#160;eff&#160;ects of&#160;heterozygosity, the overall&#160;<br/>frequency of&#160;the&#160;<i>&#160;HBB&#160;S</i><b>&#160;</b>&#160;allele has increased over time in popu-<br/>
<b>&#160;CHECKPOINT&#160;</b><br/>
lations&#160;where malaria is endemic.&#160;<br/>
&#160;A&#160;&#160;fi&#160;nal factor that&#160;may contribute&#160;to&#160;the high incidence of&#160;a&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; &#160;7. &#160;&#160;</b></i>What are the primary defects in phenylketonuria?&#160;<br/>
mendelian disease&#160;is &#160;<b>genetic drift&#160;</b>,&#160;&#160;which refers&#160;to&#160;the fl&#160;uctua-<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 8. &#160;&#160;</b></i>Why is dietary modiﬁ&#160;cation a less than satisfactory&#160;<br/>
tion of&#160;gene frequencies due to&#160;random sampling over many&#160;<br/>
treatment of this condition?&#160;<br/>
generations. Th<br/>
&#160;&#160;e extent of&#160;fl&#160;uctuation is greatest in very&#160;small&#160;<br/>
<i><b>&#160;</b></i><br/>
<i><b>&#160; 9. &#160;&#160;</b></i>Explain how strategies of dietary treatment for inborn&#160;<br/>
populations. A related phenomenon is the &#160;<b>founder eff&#160;ect</b>, &#160;<br/>
errors of metabolism depend on whether the patho-<br/>
which occurs&#160;when a population founded by&#160;a small number&#160;<br/>
physiology is caused by&#160;substrate accumulation or end-<br/>
of&#160;ancestors has, by&#160;chance, a high frequency of&#160;a deleterious&#160;<br/>
product deﬁ&#160;ciency.&#160;<br/>
gene. A founder eff&#160;ect and genetic drift&#160;&#160;can operate&#160;together&#160;<br/>
<i><b>&#160;&#160;&#160; 10. &#160;&#160;</b></i>Explain the phenomenon of maternal phenylketonuria.&#160;&#160;<br/>
to&#160;produce large&#160;changes in the incidence of&#160;mendelian dis-<br/>eases, especially in small populations&#160;founded by&#160;a small num-<br/>ber of&#160;ancestors. In&#160;the case of&#160;phenylketonuria, the fi&#160;tness of&#160;<br/>aff&#160;ected individuals has until recently been very&#160;low,&#160;and new&#160;<br/>
<b>&#160; FRAGILE&#160;&#160;XASSOCIATED&#160;&#160;MENTAL&#160;</b><br/>
mutations&#160;are exceedingly rare; however,&#160;population genetic&#160;<br/>
<b>RETARDATION&#160;SYNDROME&#160;</b><br/>
studies provide evidence for both&#160;a founder eff&#160;ect and hetero-<br/>zygote advantage.&#160;<br/>
&#160;<br/>
Fragile X–associated mental retardation syndrome pro-<br/>
&#160;Phenylketonuria is also representative&#160;of&#160;a class of&#160;mende-<br/>
duces a combination&#160;of&#160;phenotypic features that&#160;aff&#160;ect&#160;the&#160;<br/>
lian conditions for which eff&#160;orts are under way to&#160;develop gene&#160;<br/>
CNS, the testes, and the cranial skeleton. Th<br/>
&#160;ese&#160;features&#160;<br/>
therapy, such as hemophilia and ornithine transcarbamoylase&#160;<br/>
were&#160;recognized as a distinct clinical entity more&#160;than&#160;50&#160;<br/>
defi&#160;ciency.&#160;A thorough&#160;understanding of&#160;the pathophysiology&#160;<br/>
years ago.&#160;A laboratory&#160;test for the syndrome was devel-<br/>
of&#160;these conditions is an&#160;important prerequisite&#160;to&#160;developing&#160;<br/>
oped during&#160;the 1970s, when it&#160;was recognized that&#160;most&#160;<br/>
<hr/>
<a name=15></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 17<br/>
aff&#160;ected individuals exhibit&#160;a cytogenetic abnormality of&#160;<br/>
and subject to&#160;additional amplifi&#160;cation, leading to&#160;typical&#160;<br/>
the X chromosome: failure of&#160;the region between bands&#160;<br/>
features of&#160;the syndrome (&#160;Figures 2–8&#160;&#160;and &#160;2–9&#160;).&#160;<br/>
Xq27 and Xq28 to condense&#160;at&#160;metaphase. Instead, this&#160;<br/>region appears in the microscope&#160;as a thin constriction that&#160;<br/>
<b>&#160; Clinical&#160;&#160;Manifestations&#160;</b><br/>
is subject to&#160;breakage during&#160;preparation, which accounts&#160;<br/>for the designation “fragile X.” Advances in the last decade&#160;<br/>
&#160;Fragile X–associated mental retardation syndrome is usually&#160;<br/>
have&#160;helped to&#160;explain both&#160;the presence of&#160;the fragile site&#160;<br/>
recognized in aff&#160;ected boys because of&#160;developmental delay&#160;<br/>
and the unique pattern of&#160;inheritance exhibited by&#160;the&#160;<br/>
apparent&#160;by&#160;1–2 years of&#160;age,&#160;small joint hyperextensibility,&#160;<br/>
syndrome.&#160;In&#160;some respects, fragile X–associated mental&#160;<br/>
mild hypotonia, and a family history of&#160;mental retardation&#160;<br/>
retardation syndrome is similar to&#160;other genetic conditions&#160;<br/>
in maternally related males. Aff&#160;ected females generally have&#160;<br/>
caused by&#160;X-linked mutations: Aff&#160;ected males are impaired&#160;<br/>
either mild mental retardation or&#160;only&#160;subtle impairments&#160;<br/>
more&#160;severely than aff&#160;ected females, and the condition&#160;is&#160;<br/>
of&#160;visuospatial ability, and the condition&#160;may not be&#160;evident&#160;<br/>
never transmitted from&#160;father to&#160;son. However,&#160;the syn-<br/>
or&#160;diagnosed&#160;until it&#160;is suspected aft&#160;er&#160;identifi&#160;cation&#160;of&#160;an&#160;<br/>
drome breaks the rules of&#160;mendelian transmission in that&#160;at&#160;<br/>
aff&#160;ected male relative. In&#160;late&#160;childhood&#160;or&#160;early adoles-<br/>
least 20% of&#160;carrier males manifest no signs of&#160;it. Daughters&#160;<br/>
cence, aff&#160;ected males begin to&#160;exhibit&#160;large&#160;testes and char-<br/>
of&#160;these nonpenetrant&#160;but “transmitting males” are them-<br/>
acteristic facial features, including mild coarsening, large&#160;<br/>
selves nonpenetrant&#160;but produce aff&#160;ected&#160;&#160;off&#160;spring,&#160;&#160;male&#160;<br/>
ears, a prominent forehead and mandible, a long&#160;face, and&#160;<br/>
and female, with&#160;frequencies close to&#160;mendelian expecta-<br/>
relative&#160;macrocephaly (considered in relation to&#160;height). Th<br/>
&#160;e&#160;<br/>
tions&#160;(&#160;Figure 2–7&#160;). About a third of&#160;carrier females (those&#160;<br/>
syndrome is extremely common and aff&#160;ects about 1:1500–<br/>
with&#160;one normal and one abnormal X chromosome) exhibit&#160;<br/>
1:1000 males. Virtually all aff&#160;ected males are born&#160;to&#160;females&#160;<br/>
a signifi&#160;cant&#160;degree of&#160;mental retardation. Th<br/>
&#160;ese&#160;unusual&#160;<br/>
who are either aff&#160;ected or&#160;carry the premutation, and there&#160;<br/>
features of&#160;the syndrome were&#160;explained when the subchro-<br/>
are no well-recognized cases of&#160;new premutations&#160;in males&#160;<br/>
mosomal region spanning the fragile site&#160;was isolated and&#160;<br/>
or&#160;females.&#160;<br/>
shown to&#160;contain a segment in which the triplet sequence&#160;<br/>
&#160;Th<br/>
&#160;e inheritance of&#160;fragile X–associated mental retarda-<br/>
CGG was repeated many&#160;times: (CGG)&#160;&#160;.&#160;&#160;Th<br/>
&#160;&#160;e number of&#160;<br/>
tion syndrome exhibits several unusual features and is oft&#160;en&#160;<br/>
n<br/>
triplet repeats is very&#160;polymorphic but normally less than&#160;<br/>
described in terms of&#160;empiric risk fi&#160;gures&#160;(&#160;Figure 2–7&#160;). In&#160;par-<br/>
60. A repeat&#160;size between 60 and 200 does not cause a clini-<br/>
ticular, the likelihood&#160;that&#160;an&#160;individual carrying an&#160;abnormal&#160;<br/>
cal phenotype&#160;or&#160;a cytogenetic fragile site&#160;but is unstable&#160;<br/>
chromosome will manifest clinical features depends on&#160;the&#160;<br/>
I<br/>
1<br/>
II<br/>
1<br/>
2<br/>
3<br/>
4<br/>
9%<br/>
5%<br/>
III<br/>
1<br/>
2<br/>
3<br/>
4<br/>
40%<br/>
16%<br/>
IV<br/>
1<br/>
2<br/>
3<br/>
4<br/>
50%<br/>
28%<br/>
40%<br/>
16%<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–7&#160;&#160;</b>&#160;Likelihood of fragile X–associated mental retardation syndrome in an artiﬁ&#160;cial pedigree.&#160;The percentages shown indicate the&#160;<br/>likelihood of clinical manifestation according to&#160;position in the pedigree.&#160;Because individuals carrying the abnormal X chromosome have&#160;a 50%&#160;<br/>chance of passing it to&#160;their oﬀ&#160;spring, penetrance is twice that of the values depicted.&#160;Penetrance increases with each successive generation&#160;<br/>owing to&#160;the progressive expansion of a triplet repeat element (see text). Expansion is dependent on maternal inheritance of the abnormal&#160;<br/>allele; thus, daughters of normal transmitting males (indicated with a&#160;T in II-4) are nonpenetrant. Obligate carrier females are indicated with&#160;<br/>a central dot.&#160;(Reproduced, with permission, from Nussbaum and Ledbetter. Fragile X syndrome: a unique mutation in man. Annu Rev Genet. 1986;20:109.) &#160;<br/>
<hr/>
<a name=16></a>18 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
Xq27.3<br/>
number of&#160;generations&#160;through which the abnormal chromo-<br/>some has been transmitted and the sex of&#160;the transmitting&#160;<br/>parent. For example, nonpenetrant&#160;transmitting males tend to&#160;<br/>
CpG island<br/>
FMR-1<br/>
occur in the same sibship with&#160;each&#160;other and with&#160;nonpen-<br/>etrant&#160;carrier females. Th<br/>
&#160;&#160;is is refl&#160;ected in low risk fi&#160;gures&#160;for&#160;<br/>
brothers and sisters of&#160;transmitting males: 9% and 5%, respec-<br/>
...(CGG)n&#160;...&#160;ATG ...<br/>
...&#160;TGA&#160;...<br/>
tively, compared with&#160;40% and 16% for their maternal grand-<br/>
Genotype<br/>
CpG island<br/>
...(CGG)n&#160;...<br/>
FMR-1 mRNA<br/>
sons&#160;and granddaughters. Th<br/>
&#160;&#160;is latter observation, in which the&#160;<br/>
penetrance or&#160;expressivity (or both) of&#160;a genetic disease&#160;seems&#160;<br/>
Nonmutant<br/>
Unmethylated<br/>
n = 30&#160;±&#160;25<br/>
Expressed<br/>
to&#160;increase&#160;in successive&#160;generations, is sometimes referred to&#160;<br/>
(active X)<br/>
more&#160;generally as &#160;<b>genetic anticipation</b>. &#160;<br/>
Nonmutant<br/>
Methylated<br/>
n = 30&#160;±&#160;25<br/>
Not expressed<br/>
&#160;Genetic anticipation in fragile X–associated mental retar-<br/>
(inactive X)<br/>
dation syndrome is caused by&#160;progressive&#160;expansion of&#160;the&#160;<br/>
Premutation<br/>
Unmethylated<br/>
55&#160;≤&#160;n&#160;≤&#160;200<br/>
Expressed<br/>
triplet repeat. A similar phenomenon occurs&#160;in several neu-<br/>
Full mutation<br/>
Methylated<br/>
n&#160;≥&#160;200<br/>
Not expressed<br/>
rodegenerative&#160;disorders such as Huntington&#160;disease&#160;and&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–8&#160;&#160;</b>&#160;Molecular genetics of fragile X–associated mental&#160;<br/>
spinocerebellar ataxia (ie, grandchildren are aff&#160;ected&#160;&#160;more&#160;<br/>
retardation syndrome.&#160;The cytogenetic fragile site at Xq27.3 is&#160;<br/>
severely than&#160;grandparents). Th<br/>
&#160;e neurodegenerative&#160;disor-<br/>
located close to&#160;a small region of DNA that contains a CpG island&#160;<br/>
ders are caused by&#160;production of&#160;abnormal proteins; fragile&#160;<br/>
(see text) and the &#160;<i>FMR1</i>&#160;&#160;gene.&#160;Within the 5′&#160;untranslated region&#160;<br/>
X–associated mental retardation is caused by&#160;failure to&#160;pro-<br/>
of the &#160;<i>FMR1</i>&#160;&#160;gene lies an unstable segment of repetitive DNA&#160;<br/>
duce a normal protein. Although&#160;the biochemical mecha-<br/>
5′–(CGG)&#160;&#160;&#160;–3′.&#160;The table shows&#160;the methylation status of the CpG&#160;<br/>
n<br/>
nisms are diff&#160;erent, the underlying&#160;molecular&#160;causes of&#160;genetic&#160;<br/>
island, the size of the triplet repeat, and whether the FMR1 mRNA&#160;<br/>
anticipation are identical and involve progressive&#160;expansion&#160;<br/>
is expressed depending on the genotype of the X chromosome.&#160;<br/>
of&#160;an&#160;unstable triplet repeat.&#160;<br/>
Note that the inactive X chromosome in nonmutant females has a&#160;<br/>
&#160;In&#160;addition to&#160;triplet repeat&#160;expansion, genetic anticipa-<br/>
methylated CpG island and does not express the FMR1 mRNA.&#160;The&#160;<br/>
tion can be&#160;caused by&#160;&#160;<b>bias of&#160;ascertainment</b>,&#160;&#160;which occurs&#160;<br/>
methylation and expression status of &#160;<i>FMR1</i>&#160;&#160;in premutation and full&#160;<br/>
when a mild or&#160;variably&#160;expressed condition&#160;fi&#160;rst diagnosed&#160;in&#160;<br/>
mutation alleles applies to&#160;males and to&#160;the &#160;active X chromosome&#160;<br/>of females; premutation and full mutation alleles on the inactive X&#160;<br/>
grandchildren from&#160;a three generation pedigree is then easily&#160;<br/>
chromosome of females exhibit methylation of the CpG island and&#160;<br/>
recognized in siblings of&#160;the grandchildren who are available&#160;<br/>
fail to&#160;express the FMR1 mRNA.&#160;<br/>
for examination&#160;and testing. In&#160;contrast to&#160;genetic anticipation&#160;<br/>caused by&#160;expansion of&#160;a triplet repeat, anticipation caused&#160;<br/>by&#160;bias of&#160;ascertainment aff&#160;ects the &#160;<i>apparent</i>&#160;&#160;rather than&#160;the&#160;<br/>actual penetrance.&#160;<br/>
<b>&#160; Pathophysiology&#160;</b><br/>
Transmitting males<br/>
Carrier females<br/>
&#160;Amplifi&#160;cation of&#160;the (CGG)&#160;&#160;&#160;repeat&#160;at&#160;the fraXq27.3 site&#160;<br/>
n<br/>
Premutation<br/>
Premutation<br/>
Full mutation<br/>
aff&#160;ects both&#160;methylation&#160;and expression of&#160;the &#160;<i>FMR1</i>&#160;&#160;&#160;gene.&#160;<br/>
(father)<br/>
(mother)<br/>
(mother)<br/>
Th<br/>
&#160;&#160;is gene and the unstable DNA responsible for the expan-<br/>
sion were&#160;isolated on&#160;the basis of&#160;their proximity to&#160;the cyto-<br/>
<b>Spermatogenesis</b><br/>
<b>Oogenesis</b><br/>
<b>Oogenesis</b><br/>
genetic fragile site&#160;in Xq27.3. &#160;<i>FMR1</i>&#160;&#160;encodes an&#160;RNA-binding&#160;<br/>protein that&#160;regulates translation&#160;of&#160;mRNA molecules car-<br/>
Premutation<br/>
Expanded<br/>
Full mutation<br/>
(all daughters)<br/>
premutation<br/>
(son or daughter)<br/>
rying a characteristic sequence in which four guanine resi-<br/>
(son or daughter)<br/>
dues can form intramolecular bonds, a so-called G quartet&#160;<br/>
(Daughters)<br/>
structure.&#160;<br/>
&#160;Th<br/>
&#160;e&#160;(CGG)&#160;&#160;&#160;repeat&#160;is located in the 5′&#160;untranslated region of&#160;<br/>
Nonmutant<br/>
FMR<br/>
n<br/>
phenotype<br/>
phenotype<br/>
the&#160;&#160;<i>FMR1</i>&#160;&#160;gene&#160;(&#160;Figure 2–8&#160;).&#160;&#160;Th<br/>
&#160;&#160;is segment is highly variable&#160;<br/>
in length; the number of&#160;repeats, n, is equal to&#160;about 30&#160;±&#160;25 in&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–9&#160;&#160;</b>&#160; &#160;Transmission&#160;&#160;and&#160;&#160;ampliﬁ&#160;cation of the fragile&#160;<br/>
individuals who are neither aff&#160;ected with&#160;nor carriers for&#160;<br/>
X–&#160;associated mental retardation triplet repeat.&#160;The heavy&#160;arrows&#160;<br/>
fragile X–associated mental retardation syndrome.&#160;In&#160;trans-<br/>
show expansion of the triplet repeat, which is thought to&#160;occur&#160;<br/>
mitting males and in unaff&#160;ected carrier females, the number&#160;<br/>
postzygotically after the pre-mutation or full mutation is transmitted&#160;<br/>
of&#160;repeats is usually between 70 and 100. Remarkably, alleles&#160;<br/>
through the female germline.&#160;The dashed arrows represent potential&#160;<br/>
with&#160;fewer than&#160;50 repeats are very&#160;stable and almost always&#160;<br/>
phenotypic consequences. Daughters with the full mutation may&#160;<br/>
transmitted without a change&#160;in repeat&#160;number. However,&#160;<br/>
not express the fragile X–associated mental retardation phenotype,&#160;<br/>
alleles with&#160;55 or&#160;more&#160;repeats are unstable and oft&#160;en&#160;exhibit&#160;<br/>
depending on the proportion of cells in which the mutant allele&#160;<br/>
expansion aft&#160;er maternal transmission; these individuals are&#160;<br/>
happens to&#160;lie on the inactive X chromosome.&#160;(Adapted from&#160;Tarleton JC&#160;<br/>et al. Molecular genetic advances in fragile X syndrome. J Pediatr. 1993;122:169.)&#160;&#160;<br/>
said to&#160;carry a &#160;<b>premutation</b>.&#160;&#160;Although&#160;premutation carriers&#160;<br/>
<hr/>
<a name=17></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 19<br/>
do not develop a typical fragile X–associated mental retar-<br/>
by&#160;alterations&#160;to&#160;chromatin structure&#160;that&#160;include modifi&#160;ca-<br/>
dation syndrome,&#160;studies indicate&#160;that&#160;female premutation&#160;<br/>
tion of&#160;DNA by&#160;methylation&#160;and modifi&#160;cation&#160;of&#160;histones&#160;by&#160;<br/>
carriers exhibit&#160;a 20% incidence of&#160;premature&#160;ovarian failure,&#160;<br/>
methylation&#160;and/or acetylation. For example, globin should be&#160;<br/>
whereas male premutation carriers are at&#160;increased risk for&#160;<br/>
expressed only&#160;in reticulocytes; albumin should be&#160;expressed&#160;<br/>
a tremor/ataxia syndrome.&#160;In&#160;both&#160;cases, the mechanism is&#160;<br/>
only&#160;in hepatocytes; and insulin should be&#160;expressed only&#160;by&#160;<br/>
likely to&#160;be&#160;explained by&#160;somatic expansion of&#160;the premuta-<br/>
pancreatic B cells. During gametogenesis and immediately&#160;<br/>
tion (see later discussion). Th<br/>
&#160;&#160;e degree of&#160;expansion is related&#160;<br/>
aft&#160;er fertilization, specifi&#160;c patterns&#160;of&#160;chromatin modifi&#160;ca-<br/>
to&#160;the number of&#160;repeats; premutation alleles with&#160;a repeat&#160;<br/>
tion characteristic of&#160;diff&#160;erentiated cells are erased, only&#160;to&#160;be&#160;<br/>
number less than&#160;60 rarely&#160;are amplifi&#160;ed to&#160;a full mutation,&#160;<br/>
reestablished in fetal development. In&#160;this way,&#160;DNA methyla-<br/>
but premutation alleles with&#160;a repeat&#160;number greater than&#160;<br/>
tion and other chromatin modifi&#160;cations&#160;provide a reversible&#160;<br/>
90 are usually amplifi&#160;ed to&#160;a full mutation. Th<br/>
&#160;&#160;e number of&#160;<br/>
change&#160;in gene structure&#160;that&#160;can be&#160;inherited during&#160;mito-<br/>
repeats in the full mutation—observed both&#160;in aff&#160;ected&#160;males&#160;<br/>
sis of&#160;diff&#160;erentiated cells yet erased&#160;during&#160;meiosis and early&#160;<br/>
and in aff&#160;ected females—is always greater than&#160;200 but is&#160;<br/>
development. Th<br/>
&#160;&#160;is type of&#160;alteration—a heritable phenotypic&#160;<br/>
generally heterogeneous, suggesting that&#160;once this thresh-<br/>
change&#160;that&#160;is not determined by&#160;DNA sequence—is broadly&#160;<br/>
old is reached, additional amplifi&#160;cation occurs&#160;frequently in&#160;<br/>
referred to&#160;as &#160;<b>epigenetic</b>. &#160;<br/>
somatic cells.&#160;<br/>
&#160;Analysis of&#160;fragile X–associated mental retardation syn-<br/>
&#160;Expansion from&#160;a premutation to&#160;a full mutation has two&#160;<br/>
drome pedigrees reveals that&#160;one of&#160;the most important fac-<br/>
important eff&#160;ects:&#160;&#160;&#160;<i>FMR1</i>&#160;&#160;gene transcription&#160;is shut&#160;off&#160;,&#160;&#160;and&#160;<br/>
tors&#160;infl&#160;uencing whether a premutation allele is subject to&#160;<br/>
DNA surrounding the transcriptional start site&#160;of&#160;the &#160;<i>FMR1</i>&#160;<br/>
postzygotic expansion is the sex of&#160;the parent&#160;who transmits&#160;<br/>
gene becomes methylated.&#160;Th<br/>
&#160;&#160;e clinical phenotype&#160;is caused&#160;<br/>
the premutation allele (&#160;Figures 2–7&#160;&#160;and &#160;2–9&#160;). As&#160;discussed, a&#160;<br/>
by&#160;failure to&#160;produce FMR1; in addition, methylation&#160;of&#160;sur-<br/>
premutation allele transmitted by&#160;a female expands to&#160;a full&#160;<br/>
rounding DNA has important implications for molecular&#160;<br/>
mutation with&#160;a likelihood&#160;proportionate&#160;to&#160;the length of&#160;<br/>
diagnosis. Methylation occurs&#160;in a so-called &#160;<b>CpG island</b>, &#160;&#160;a&#160;<br/>
the premutation. Premutation alleles with&#160;a repeat&#160;number&#160;<br/>
several hundred base pair segment just upstream of&#160;the &#160;<i>FMR1</i>&#160;<br/>
between 52 and 60 rarely&#160;expand to&#160;a full mutation, and those&#160;<br/>
transcriptional start site&#160;that&#160;contains&#160;a high frequency of&#160;<br/>
with&#160;a repeat&#160;number greater than&#160;90 nearly&#160;always expand. In&#160;<br/>
5′-CG-3′&#160;dinucleotides compared with&#160;the rest of&#160;the genome.&#160;<br/>
contrast, a premutation allele transmitted by&#160;a male rarely&#160;if&#160;<br/>
Methylation of&#160;the CpG island and expansion of&#160;the triplet&#160;<br/>
ever expands to&#160;a full mutation regardless of&#160;the length of&#160;the&#160;<br/>
repeat&#160;can be&#160;easily detected with molecular&#160;biologic tech-<br/>
repeat&#160;number.&#160;<br/>
niques, which are the basis of&#160;the common diagnostic tests for&#160;<br/>
&#160;Th<br/>
&#160;e notion that&#160;alleles of&#160;the same DNA sequence can&#160;<br/>
individuals at&#160;risk.&#160;&#160;<br/>
behave&#160;very&#160;diff&#160;erently depending on&#160;the sex of&#160;the parent&#160;<br/>who transmitted them is closely related to&#160;the concept of&#160;<br/>
<b>&#160; Genetic&#160;&#160;Principles&#160;</b><br/>
&#160;<b>gametic imprinting</b>,&#160;&#160;which is used to&#160;describe the situation&#160;<br/>that&#160;occurs&#160;when expression of&#160;a particular gene depends on&#160;<br/>
&#160;In&#160;addition to&#160;the tendency of&#160;(CGG)&#160;&#160;&#160;premutation alleles&#160;<br/>
the sex of&#160;the parent&#160;who transmitted it. Gametic imprinting&#160;<br/>
n<br/>
to&#160;undergo&#160;further amplifi&#160;cations&#160;in length, the molecular&#160;<br/>
aff&#160;ects a handful of&#160;genes involved in fetal or&#160;placental growth,&#160;<br/>
genetics of&#160;fragile X–associated mental retardation syndrome&#160;<br/>
including insulin-like growth&#160;factor 2 (IGF2) and the type 2&#160;<br/>
exhibits several unusual features. As&#160;described previously,&#160;<br/>
IGF receptor (IGF2R); for example, the &#160;<i>IGF2</i>&#160;&#160;gene is expressed&#160;<br/>
each&#160;phenotypically aff&#160;ected individual carries a full mutation&#160;<br/>
only&#160;on&#160;the paternally derived chromosome,&#160;whereas in some&#160;<br/>
defi&#160;ned by&#160;a repeat&#160;number greater than&#160;200, but the exact&#160;<br/>
individuals the &#160;<i>IGF2R</i>&#160;&#160;gene&#160;&#160;is&#160;&#160;expressed&#160;&#160;only&#160;&#160;on&#160;&#160;the&#160;&#160;mater-<br/>
repeat&#160;number exhibits considerable heterogeneity in diff&#160;erent&#160;<br/>
nally derived chromosome.&#160;Th<br/>
&#160;&#160;e mechanisms responsible for&#160;<br/>
cells and tissues.&#160;<br/>
gametic imprinting depend on&#160;biochemical modifi&#160;cations&#160;<br/>
&#160;Diagnostic testing for the number of&#160;CGG repeats is usu-<br/>
to&#160;the chromosome that&#160;occur during&#160;gametogenesis; these&#160;<br/>
ally performed on&#160;lymphocytes taken from&#160;a small amount&#160;<br/>
modifi&#160;cations&#160;do not aff&#160;ect the actual DNA sequence but are&#160;<br/>
of&#160;peripheral blood. In&#160;individuals who carry a repeat&#160;num-<br/>
stably&#160;transmitted for a certain number of&#160;cell divisions&#160;(ie,&#160;<br/>
ber less than&#160;50, each&#160;cell has the same number of&#160;repeats.&#160;<br/>
they&#160;are epigenetic and contribute&#160;to&#160;the pathogenesis of&#160;cer-<br/>
However,&#160;in phenotypically aff&#160;ected males or&#160;females (ie,&#160;<br/>
tain types of&#160;cancer).&#160;&#160;<br/>
those with&#160;a repeat&#160;number greater than&#160;200), many&#160;of&#160;the&#160;<br/>cells may have&#160;a diff&#160;erent number of&#160;repeats. Th<br/>
&#160;is&#160;situation,&#160;<br/>
oft&#160;en referred to&#160;as &#160;<b>somatic mosaicism</b>,&#160;&#160;indicates that&#160;at&#160;least&#160;<br/>
<b>&#160;CHECKPOINT&#160;</b><br/>
some of&#160;the amplifi&#160;cation is&#160;&#160;<br/>
<b>postzygotic</b>,&#160;<br/>
&#160;meaning that&#160;it&#160;<br/>
occurs&#160;in cells of&#160;the developing&#160;embryo&#160;aft&#160;er fertilization. In&#160;<br/>
<i><b>&#160;&#160;&#160; &#160;11. &#160;&#160;</b></i>Explain why fragile X syndrome exhibits an unusual pat-<br/>
addition to&#160;the DNA methylation&#160;associated with&#160;an&#160;abnormal&#160;<br/>
tern of inheritance.&#160;<br/>
&#160;<i>FMR1</i>&#160;&#160;gene, methylation&#160;of&#160;many&#160;genes is a normal process&#160;<br/>
<i><b>&#160;&#160;&#160; 12. &#160;&#160;</b></i>What is genetic anticipation?&#160;What are two explanations&#160;<br/>
during&#160;development and diff&#160;erentiation&#160;that&#160;helps to&#160;regu-<br/>
for it?&#160;<br/>
late&#160;gene expression. Cells in which a particular gene should&#160;<br/>
<i><b>&#160;&#160;&#160; 13. &#160;&#160;</b></i>What is an epigenetic change?&#160;&#160;<br/>
not be&#160;expressed frequently shut&#160;off&#160;&#160;that&#160;gene’s&#160;expression&#160;<br/>
<hr/>
<a name=18></a>20 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
<b>&#160; LEBER&#160;&#160;HEREDITARY&#160;&#160;OPTIC&#160;</b><br/>
<b>&#160; Pathophysiology&#160;</b><br/>
<b>NEUROPATHY,&#160;MITOCHONDRIAL&#160;</b><br/>
&#160;Th<br/>
&#160;e central energy-producing machinery of&#160;the mitochon-<br/>
<b>ENCEPHALOMYOPATHY&#160;WITH&#160;</b><br/>
dria, complexes I–V of&#160;the electron&#160;transport&#160;chain, contains&#160;<br/>
<b>RAGGED&#160;RED&#160;FIBERS,&#160;&amp;&#160;OTHER&#160;</b><br/>
approximately&#160;90 polypeptides. Th<br/>
&#160;&#160;e majority are encoded by&#160;<br/>
the nuclear genome and,&#160;like proteins required for replication,&#160;<br/>
<b>MITOCHONDRIAL&#160;DISEASES&#160;</b><br/>
transcription, and translation&#160;of&#160;the mitochondrial genome,&#160;<br/>are imported into&#160;the mitochondria aft&#160;er translation. Th<br/>
&#160;e&#160;mito-<br/>
&#160;In&#160;nearly&#160;every cell in the body,&#160;the indispensable job of&#160;turn-<br/>
chondrial genome itself (mtDNA) is 16,569 bp&#160;in length and&#160;<br/>
ing nutrients into&#160;energy&#160;takes place in mitochondria, ubiqui-<br/>
encodes 13 polypeptides that&#160;are transcribed and translated in&#160;<br/>
tous subcellular&#160;organelles with&#160;their own genomes and unique&#160;<br/>
mitochondria; mtDNA also encodes mitochondrial ribosomal&#160;<br/>
rules of&#160;gene expression. Over the past decade, defects in&#160;<br/>
RNA and 22 mitochondrial tRNA species. Complexes 1, III, IV,&#160;<br/>
mitochondrial function have&#160;become increasingly recognized&#160;<br/>
and V of&#160;the electron&#160;transport&#160;chain contain subunits encoded&#160;<br/>
as important human causes of&#160;diseases, from&#160;rare&#160;conditions&#160;<br/>
by&#160;both&#160;mtDNA and the nuclear genome, whereas the proteins&#160;<br/>
whose study has led to&#160;a deeper understanding of&#160;pathophysio-<br/>
that&#160;form&#160;complex II are encoded entirely in the nuclear genome.&#160;<br/>
logic mechanisms to&#160;common conditions such as diabetes and&#160;<br/>
&#160;<br/>
LHON&#160;and MERRF are both&#160;caused by&#160;mutations&#160;in&#160;<br/>
deafness. On one level,&#160;the consequences of&#160;defective&#160;mito-<br/>
mtDNA; LHON&#160;is caused by&#160;mutations&#160;in a component of&#160;the&#160;<br/>
chondrial function are predictable and nonspecifi&#160;c:&#160;&#160;Inability&#160;<br/>
electron&#160;transport&#160;chain, whereas MERRF is caused by&#160;muta-<br/>
to&#160;generate&#160;suffi<br/>
&#160;&#160;cient adenosine triphosphate&#160;(ATP) leads to&#160;<br/>
tions&#160;of&#160;mitochondrial tRNA, usually tRNA&#160;Lys&#160;.&#160;&#160;Th<br/>
&#160;us,&#160;from&#160;a&#160;<br/>
accumulation&#160;of&#160;lactic acid, weakness, and,&#160;eventually,&#160;cell&#160;<br/>
biochemical perspective,&#160;LHON&#160;is caused by&#160;a specifi&#160;c&#160;inability&#160;<br/>
death. However,&#160;every mitochondrion contains&#160;multiple mito-<br/>
to&#160;generate&#160;ATP,&#160;whereas MERRF is caused by&#160;a general defect&#160;<br/>
chondrial genomes; every cell contains&#160;multiple mitochondria;&#160;<br/>
in mitochondrial protein synthesis. However,&#160;the pathophysi-<br/>
the requirements for energy&#160;production vary&#160;from&#160;one tissue&#160;<br/>
ologic mechanisms that&#160;lead from&#160;defective&#160;mitochondrial&#160;<br/>
to&#160;another; and,&#160;most importantly,&#160;mutations&#160;in mitochondrial&#160;<br/>
function to&#160;specifi&#160;c organ abnormalities are not completely&#160;<br/>
DNA&#160;aff&#160;ect only&#160;a fraction of&#160;mitochondrial genomes within&#160;<br/>
understood. In&#160;general, organ systems aff&#160;ected&#160;by&#160;mitochon-<br/>
a given individual.&#160;Because of&#160;these characteristics, defects in&#160;<br/>
drial diseases are those in which ATP production plays a critical&#160;<br/>
mitochondrial function present clinically with symptoms and&#160;<br/>
role, such as skeletal muscle and the CNS. In&#160;addition, defects&#160;<br/>
signs that&#160;are both&#160;specifi&#160;c and protean. In&#160;addition, mitochon-<br/>
in electron&#160;transport&#160;can cause excessive&#160;production of&#160;toxic&#160;<br/>
drial DNA is transmitted by&#160;eggs but not by&#160;sperm, leading to&#160;a&#160;<br/>
free radicals, leading to&#160;oxidative&#160;damage and cell death, and&#160;<br/>
unique and characteristic pattern of&#160;inheritance.&#160;<br/>
may contribute&#160;to&#160;age-related dementia. Finally,&#160;several pro-<br/>teins that&#160;normally reside within mitochondria play&#160;key roles in&#160;<br/>
<b>&#160; Clinical&#160;&#160;Manifestations&#160;</b><br/>
the control of&#160;apoptosis; thus, primary&#160;abnormalities in mito-<br/>chondrial integrity can contribute&#160;to&#160;disease&#160;both&#160;by&#160;decreasing&#160;<br/>
&#160;First described by&#160;a German&#160;physician in 1871, Leber heredi-<br/>
energy&#160;production and by&#160;increasing programmed cell death.&#160;<br/>
tary&#160;optic neuropathy&#160;(LHON) presents as painless bilateral&#160;<br/>loss of&#160;vision that&#160;occurs&#160;in young adults, more&#160;commonly in&#160;<br/>
<b>&#160; Genetic&#160;&#160;Principles&#160;</b><br/>
males. Loss of&#160;vision can be&#160;sudden and complete or&#160;subacute&#160;<br/>and progressive, proceeding from&#160;central scotomas to&#160;blind-<br/>
&#160;For mitochondrial proteins encoded by&#160;the nuclear genome&#160;<br/>
ness over 1–2 years and usually aff&#160;ecting both eyes within&#160;<br/>
and imported into&#160;mitochondria aft&#160;er translation, defects that&#160;<br/>
1–2 months. Th<br/>
&#160;e condition&#160;is occasionally associated with&#160;<br/>
cause disease&#160;are inherited&#160;in a typical mendelian fashion.&#160;<br/>
neurologic fi&#160;ndings, including ataxia, dysarthria, or&#160;symptoms&#160;<br/>
mtDNA, however,&#160;is transmitted by&#160;the egg and not the sperm,&#160;<br/>
of&#160;demyelinating&#160;disease, and may be&#160;associated also with&#160;car-<br/>
in part&#160;because the egg contains&#160;more&#160;than&#160;1000 times more&#160;<br/>
diac conduction abnormalities. Ophthalmologic examina-<br/>
mtDNA molecules than&#160;the sperm. Th<br/>
&#160;&#160;erefore,&#160;for diseases like&#160;<br/>
tion shows peripapillary&#160;telangiectasia, microangiopathy,&#160;and&#160;<br/>
LHON&#160;and MERRF caused by&#160;defects in mtDNA, the condi-<br/>
vascular tortuosity; in patients with&#160;neurologic fi&#160;ndings&#160;(and&#160;<br/>
tions&#160;show a characteristic pattern of&#160;maternal inheritance&#160;<br/>
some without), CNS imaging studies may reveal abnormalities&#160;<br/>
(&#160;Figure 2–10&#160;) in which all off&#160;spring&#160;of&#160;an&#160;aff&#160;ected female are&#160;<br/>
of&#160;the basal ganglia and corpus striatum.&#160;<br/>
at&#160;risk but aff&#160;ected males never transmit the condition.&#160;<br/>
&#160;By&#160;contrast to&#160;LHON, mitochondrial encephalomyopathy&#160;<br/>
&#160;A second unique feature of&#160;diseases caused by&#160;mutations&#160;in&#160;<br/>
with&#160;ragged red fi&#160;bers&#160;(MERRF) was recognized as a distinct&#160;<br/>
mtDNA is the mosaic nature&#160;of&#160;the mutation within individual&#160;<br/>
clinical entity relatively&#160;recently.&#160;Th<br/>
&#160;e presenting symptoms&#160;<br/>
cells. Typically,&#160;a single cell contains&#160;10–100 separate&#160;mtDNA&#160;<br/>
are usually periodic jerking and progressive&#160;skeletal weak-<br/>
molecules; in the case of&#160;an&#160;mtDNA mutation, only&#160;a fraction&#160;<br/>
ness, but the onset and severity of&#160;the symptoms are variable.&#160;<br/>
of&#160;the molecules carry the mutation, a situation referred to&#160;as&#160;<br/>
Th<br/>
&#160;&#160;e term&#160;“ragged red fi&#160;bers” refers&#160;to&#160;the histologic appear-<br/>
&#160;<b>heteroplasmy</b>. &#160;&#160;Th<br/>
&#160;&#160;e levels of&#160;heteroplasmy may vary&#160;consider-<br/>
ance of&#160;muscle from&#160;aff&#160;ected individuals, in which abnormal&#160;<br/>
ably&#160;among diff&#160;erent individuals and among diff&#160;erent&#160;tissues;&#160;<br/>
mitochondria accumulate&#160;and aggregate&#160;in individual muscle&#160;<br/>
furthermore, a female primordial germ&#160;cell with&#160;a mixture of&#160;<br/>
fi&#160;bers. Other symptoms may include sensorineural hearing&#160;<br/>
normal and mutated mtDNA molecules can transmit diff&#160;erent&#160;<br/>
loss, ataxia, cardiomyopathy, and dementia.&#160;&#160;<br/>
proportions&#160;to&#160;daughter eggs (&#160;Figure 2–11&#160;). For both&#160;LHON&#160;<br/>
<hr/>
<a name=19></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 21<br/>
and MERRF, levels of&#160;mutant&#160;mtDNA may vary&#160;from&#160;about&#160;<br/>50% to&#160;about 90%; in general, the severity of&#160;the condition&#160;<br/>correlates with&#160;the extent of&#160;heteroplasmy.&#160;<br/>
&#160; A&#160;&#160;fi&#160;nal principle that&#160;is apparent&#160;from&#160;the pathophysiology&#160;<br/>
of&#160;mitochondrial diseases is genetic interaction between the&#160;<br/>nuclear and mitochondrial genomes. One of&#160;the best examples&#160;<br/>is the sex diff&#160;erence in LHON, which aff&#160;ects four to&#160;fi&#160;ve&#160;times&#160;<br/>as many&#160;males as females. Th<br/>
&#160;&#160;is observation&#160;suggests that&#160;there&#160;<br/>
may be&#160;a gene on&#160;the X chromosome that&#160;modifi&#160;es the sever-<br/>ity of&#160;a mitochondrial tRNA&#160;Lys&#160;&#160;mutation and underscores the&#160;<br/>observation&#160;that, even though&#160;mtDNA itself encodes for a set&#160;<br/>of&#160;key mitochondrial components, most mitochondrial pro-<br/>
Blindness<br/>
Hearing loss<br/>
teins are encoded by&#160;the nuclear genome.&#160;&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–10&#160;&#160;</b>&#160;Maternal inheritance.&#160;An idealized pedigree&#160;<br/>&#160;illustrating maternal inheritance,&#160;which occurs in disease caused&#160;<br/>
<b>&#160; DOWN&#160;&#160;SYNDROME&#160;</b><br/>
by&#160;mutations in mitochondrial DNA. Mothers transmit the mutated&#160;<br/>mtDNA to&#160;all of their oﬀ&#160;spring, but fathers do not.&#160;Variable&#160;<br/>
&#160;Th<br/>
&#160;&#160;e clinical features of&#160;Down syndrome were&#160;described over&#160;<br/>
expressivity and reduced penetrance are a consequence of diﬀ&#160;erent&#160;<br/>
a century&#160;ago.&#160;Although&#160;the underlying&#160;cause—an extra copy&#160;<br/>
levels of heteroplasmy.&#160;<br/>
of&#160;chromosome 21—has been known for more&#160;than&#160;4 decades,&#160;<br/>
Mutant mtDNA<br/>
Normal mtDNA<br/>
Liver<br/>
Heart<br/>
Brain<br/>
Germ cells<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–11&#160;&#160;</b>&#160;Heteroplasmy and variable expressivity.&#160;The fraction of mutated mtDNA molecules within a cell is determined by&#160;a combination&#160;<br/>of random chance and selection at the cellular level during embryonic development. Adult tissues are mosaic for cells with diﬀ&#160;erent fractions of&#160;<br/>mutated mtDNA molecules, which helps to&#160;explain why mitochondrial dysfunction can produce diﬀ&#160;erent phenotypes and diﬀ&#160;erent levels of severity.&#160;<br/>
<hr/>
<a name=20></a>22 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
the nearly&#160;complete DNA sequence of&#160;chromosome 21—some&#160;<br/>
<b>&#160; Clinical&#160;&#160;Manifestations&#160;</b><br/>
33,546,361 base pairs—was determined only&#160;4 years ago,&#160;and&#160;<br/>
&#160;Down syndrome occurs&#160;approximately&#160;once in every 700 live&#160;<br/>
the relationship of&#160;genotype to&#160;phenotype&#160;is just beginning&#160;<br/>
births&#160;and accounts for approximately&#160;one-third of&#160;all cases of&#160;<br/>
to&#160;be&#160;understood. Down syndrome is broadly representative&#160;<br/>
mental retardation. Th<br/>
&#160;&#160;e likelihood&#160;of&#160;conceiving a child with&#160;<br/>
of&#160;&#160;<b>aneuploid</b>&#160;&#160;conditions, or&#160;those that&#160;are caused by&#160;a devia-<br/>
Down syndrome is related exponentially to&#160;increasing maternal&#160;<br/>
tion from&#160;the normal chromosome complement (&#160;<b>euploidy</b>&#160;).&#160;<br/>
age.&#160;Historically,&#160;because screening programs&#160;were&#160;off&#160;ered&#160;to&#160;<br/>
Chromosome 21, which contains&#160;a little less than&#160;2% of&#160;the&#160;<br/>
pregnant&#160;women older than&#160;35 years (&#160;Figure 2–13&#160;), most chil-<br/>
total genome, is one of&#160;the &#160;<b>acrocentric</b>&#160;&#160;autosomes (the oth-<br/>
dren with&#160;Down syndrome have&#160;been born&#160;to&#160;women younger&#160;<br/>
ers are 13, 14, 15, and 22), which means one in which nearly&#160;<br/>
than&#160;35 years. Recent advances in noninvasive&#160;prenatal test-<br/>
all the DNA lies on&#160;one side of&#160;the centromere.&#160;In&#160;general,&#160;<br/>
ing, however,&#160;have led most obstetricians&#160;to off&#160;er&#160;prenatal&#160;test-<br/>
aneuploidy&#160;may involve part&#160;or&#160;all of&#160;an&#160;autosome or&#160;sex&#160;<br/>
ing for Down syndrome and other aneuploidies to&#160;all women.&#160;<br/>
chromosome.&#160;Most individuals with&#160;Down syndrome have&#160;47&#160;<br/>
When not identifi&#160;ed prenatally,&#160;Down syndrome is&#160;usually sus-<br/>
chromosomes (ie, one extra chromosome 21, or&#160;&#160;<b>trisomy 21</b>&#160;)&#160;<br/>
pected&#160;shortly aft&#160;er birth from&#160;the presence of&#160;characteristic&#160;<br/>
and are born&#160;to&#160;parents with&#160;normal karyotypes. Th<br/>
&#160;&#160;is type&#160;of&#160;<br/>
facial and dysmorphic features such as brachycephaly,&#160;epican-<br/>
aneuploidy is usually caused&#160;by&#160;&#160;<b>nondisjunction</b>&#160;&#160;during&#160;mei-<br/>
thal folds, small ears, transverse palmar creases, and hypoto-<br/>
otic segregation, which means failure of&#160;two homologous chro-<br/>
nia (&#160;Table 2–4&#160;). Approximately&#160;50% of&#160;aff&#160;ected children have&#160;<br/>
mosomes to&#160;separate&#160;(disjoin) from&#160;each&#160;other at&#160;anaphase.&#160;In&#160;<br/>
congenital heart defects that&#160;come to&#160;medical attention in the&#160;<br/>
contrast, aneuploid conditions that&#160;aff&#160;ect part of&#160;an&#160;autosome&#160;<br/>
immediate&#160;perinatal period&#160;because of&#160;cardiorespiratory&#160;prob-<br/>
or&#160;sex chromosome must at&#160;some point involve DNA break-<br/>
lems. Strong&#160;suspicion of&#160;the condition&#160;on&#160;clinical grounds is&#160;<br/>
age and reunion. DNA rearrangements are an&#160;infrequent but&#160;<br/>
usually confi&#160;rmed by&#160;molecular&#160;testing within 2–3 days.&#160;<br/>
important cause of&#160;Down syndrome and are usually evident&#160;<br/>
&#160;A great many&#160;minor and major abnormalities occur with&#160;<br/>
as a karyotype with&#160;46 chromosomes in which one chromo-<br/>
increased frequency in Down syndrome,&#160;yet two aff&#160;ected&#160;indi-<br/>
some 21 is fused via its centromere to&#160;another acrocentric&#160;<br/>
viduals rarely&#160;have&#160;the same set of&#160;abnormalities, and many&#160;<br/>
chromosome. Th<br/>
&#160;&#160;is abnormal&#160;chromosome is described&#160;as a&#160;<br/>
single abnormalities can be&#160;seen in unaff&#160;ected individuals. For&#160;<br/>
&#160;<b>robertsonian translocation</b>&#160;&#160;and can sometimes be&#160;inherited&#160;<br/>
example, the incidence of&#160;a transverse palmar crease&#160;in Down&#160;<br/>
from&#160;a carrier parent&#160;(&#160;Figure 2–12&#160;).&#160;&#160;Th<br/>
&#160;&#160;us, Down syndrome&#160;<br/>
syndrome is about 50%, ten times that&#160;in the general popula-<br/>
may be&#160;caused by&#160;a variety of&#160;diff&#160;erent karyotypic abnormali-<br/>
tion, yet most individuals in whom&#160;transverse palmar creases&#160;<br/>
ties, which have&#160;in common a 50% increase&#160;in &#160;<b>gene dosage</b>&#160;&#160;&#160;for&#160;<br/>
are the only&#160;unusual feature do not have&#160;Down syndrome or&#160;<br/>
nearly&#160;all of&#160;the genes on&#160;chromosome 21.&#160;&#160;<br/>
any other genetic disease.&#160;<br/>
21<br/>14<br/>
14&#160;14&#160;21&#160;21<br/>
14<br/>
t<br/>
21<br/>
46, XY<br/>
45, XX, t(14q21q)<br/>
21<br/>14<br/>
t<br/>
14&#160;21&#160;21<br/>
46, XY, –14, +t (14q21q)<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–12&#160;&#160;</b>&#160;Mechanisms leading to&#160;Down syndrome. A pedigree in which the mother is phenotypically normal yet is a balanced carrier&#160;<br/>for a 14;21 robertsonian translocation. She transmits both the translocation chromosome and a normal chromosome 21 to&#160;her son,&#160;who also&#160;<br/>inherits a normal chromosome 21 from his father.&#160;Three copies of chromosome 21 in the son cause Down syndrome.&#160;(Adapted from&#160;Thompson MW&#160;<br/>et al. &#160;<i>Genetics in Medicine,</i>&#160;&#160;5th ed. Saunders, 1991.)&#160;<br/>
<hr/>
<a name=21></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 23<br/>
120<br/>
<b>&#160;TABLE&#160;&#160;24&#160;&#160;Phenotypic features of trisomy 21.&#160;&#160;1&#160;&#160;</b><br/>
110<br/>
<b>Feature</b><br/>
<b>Frequency</b><br/>
100<br/>
Upslanting palpebral ﬁ&#160;ssures<br/>
82%<br/>
90<br/>
Excess skin on back of neck<br/>
81%<br/>
80<br/>
Brachycephaly<br/>
75%<br/>
70<br/>
Hyperextensible joints<br/>
75%<br/>
60<br/>
Flat nasal bridge<br/>
68%<br/>
wn syndrome (per 1000)<br/>
50<br/>
Wide gap between ﬁ&#160;rst&#160;and&#160;<br/>
68%<br/>
second toes<br/>
40<br/>
Short, broad hands<br/>
64%<br/>
requency of Do<br/>
30<br/>
F<br/>
Epicanthal folds<br/>
59%<br/>
20<br/>
Short ﬁ&#160;fth&#160;ﬁ&#160;nger<br/>
58%<br/>
10<br/>
Incurved ﬁ&#160;fth&#160;ﬁ&#160;nger<br/>
57%<br/>
0&#160;15<br/>
20<br/>
25<br/>
30<br/>
35<br/>
40<br/>
45<br/>
50<br/>
Brushﬁ&#160;eld spots (iris hypoplasia)<br/>
56%<br/>
Maternal age (years)<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–13&#160;</b><br/>
Transverse palmar crease<br/>
53%<br/>
&#160;Relationship of Down syndrome to&#160;maternal&#160;<br/>
age.&#160;The frequency of Down syndrome rises exponentially with&#160;<br/>
Folded or dysplastic ear<br/>
50%<br/>
increasing maternal age.&#160;The frequency at amniocentesis (blue&#160;<br/>
Protruding tongue<br/>
47%<br/>
symbols) is slightly higher than in live-born infants (black symbols)&#160;<br/>because miscarriages are more likely in fetuses with Down syndrome.&#160;<br/>
&#160;1&#160;Data from Scriver CR et al, eds.&#160;<i>&#160;The Metabolic and Molecular Bases of Inherited&#160;</i><br/>
(Data from Scriver CR et al, eds.&#160;&#160;<i>The Metabolic and Molecular Bases of Inherited&#160;</i><br/>
<i>Disease&#160;</i>, 7th ed. McGraw-Hill, 1995.<br/>
<i>Disease,</i>&#160;&#160;&#160;8th&#160;&#160;ed. McGraw-Hill, 2001.)&#160;&#160;<br/>
incidence of&#160;typical neuropathologic changes—senile plaques&#160;<br/>and neurofi&#160;brillary&#160;tangles—is nearly&#160;100% by&#160;age 35. Th<br/>
&#160;e&#160;<br/>
&#160;Th<br/>
&#160;&#160;e natural history of&#160;Down syndrome in childhood&#160;is char-<br/>
major causes of&#160;morbidity in Down syndrome are congeni-<br/>
acterized mainly by&#160;developmental delay,&#160;growth&#160;retardation,&#160;<br/>
tal heart disease, infections, and leukemia. Life&#160;expectancy&#160;<br/>
and immunodefi&#160;ciency.&#160;Developmental delay is usually appar-<br/>
depends to&#160;a large&#160;extent on&#160;the presence of&#160;congenital heart&#160;<br/>
ent by&#160;3–6 months&#160;of&#160;age as failure to&#160;attain age-appropriate&#160;<br/>
disease; survival to&#160;ages 10 and 30 years is approximately&#160;60%&#160;<br/>
developmental milestones and aff&#160;ects all aspects of&#160;motor and&#160;<br/>
and 50%, respectively, for individuals with&#160;congenital heart&#160;<br/>
cognitive&#160;function. Th<br/>
&#160;&#160;e mean&#160;IQ&#160;is between 30 and 70 and&#160;<br/>
disease&#160;and approximately&#160;85% and 80%, respectively, for&#160;<br/>
declines with&#160;increasing age.&#160;However,&#160;there is a consider-<br/>
individuals without congenital heart disease.&#160;&#160;<br/>
able range&#160;in the degree of&#160;mental retardation in adults with&#160;<br/>Down syndrome,&#160;and many&#160;aff&#160;ected individuals can live&#160;semi-&#160;<br/>
<b>&#160; Pathophysiology&#160;</b><br/>
independently.&#160;In&#160;general, cognitive&#160;skills are more&#160;limited&#160;<br/>than&#160;aff&#160;ective&#160;performance,&#160;and&#160;only&#160;a&#160;minority&#160;of&#160;aff&#160;ected&#160;<br/>
&#160;Th<br/>
&#160;e advent&#160;of&#160;molecular&#160;markers for diff&#160;erent portions&#160;of&#160;<br/>
individuals are severely impaired. Retardation&#160;of&#160;linear&#160;growth&#160;<br/>
chromosome 21 provided considerable information about&#160;<br/>
is moderate,&#160;and most adults with&#160;Down syndrome have&#160;stat-<br/>
when and how the extra chromosomal material arises in Down&#160;<br/>
ures 2–3 standard&#160;deviations&#160;below that&#160;of&#160;the general popula-<br/>
syndrome; and the Human Genome Project has provided a list&#160;<br/>
tion. In&#160;contrast, weight&#160;growth&#160;in Down syndrome exhibits a&#160;<br/>
of&#160;the approximately&#160;230 genes found on&#160;chromosome 21. In&#160;<br/>
mild proportionate&#160;increase&#160;compared with&#160;that&#160;of&#160;the general&#160;<br/>
contrast, much&#160;less is known about why increased gene dos-<br/>
population, and most adults with&#160;Down syndrome are over-<br/>
age for chromosome 21 should produce the clinical features of&#160;<br/>
weight. Although&#160;increased susceptibility to&#160;infections&#160;is a&#160;<br/>
Down syndrome.&#160;<br/>
common clinical feature at&#160;all ages, the nature&#160;of&#160;the underlying&#160;<br/>
&#160;For trisomy 21 (47,XX&#160;+&#160;21 or&#160;47,XY&#160;+&#160;21), cytogenetic or&#160;<br/>
abnormality is not well understood, and laboratory&#160;abnormali-<br/>
molecular&#160;markers that&#160;distinguish between the maternal and&#160;<br/>
ties can be&#160;detected in both&#160;humoral and cellular immunity.&#160;<br/>
paternal copies of&#160;chromosome 21 can be&#160;used to&#160;determine&#160;<br/>
&#160;One of&#160;the most prevalent and dramatic clinical features of&#160;<br/>
whether the egg or&#160;the sperm contributed the extra copy&#160;of&#160;<br/>
Down syndrome—premature&#160;onset of&#160;Alzheimer disease—is&#160;<br/>
chromosome 21. Th<br/>
&#160;ere are no obvious clinical diff&#160;erences&#160;<br/>
not evident until adulthood. Although&#160;frank dementia is not&#160;<br/>
between these two types of&#160;trisomy 21 individuals, which&#160;<br/>
clinically detectable in all adults with Down syndrome,&#160;the&#160;<br/>
suggests that&#160;gametic imprinting does not play&#160;a signifi&#160;cant&#160;<br/>
<hr/>
<a name=22></a>24 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
Nondisjunction<br/>
Meiosis I<br/>
Normal<br/>
Normal<br/>
Normal<br/>
Meiosis II<br/>
Normal<br/>
Nondisjunction<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–14&#160;&#160;</b>&#160; &#160;Nondisjunction&#160;&#160;has&#160;&#160;diﬀ&#160;erent consequences depending on whether it occurs at meiosis I or meiosis II.&#160;The abnormal gamete&#160;<br/>has two copies of a particular chromosome.&#160;When nondisjunction occurs at meiosis I, each of the copies originates from a diﬀ&#160;erent&#160;chromosome;&#160;<br/>however,&#160;when nondisjunction occurs at meiosis II, each of the copies originates from the same chromosome. Both cytogenetic and&#160;molecular&#160;<br/>polymorphisms can be used to&#160;determine the stage and the parent in which nondisjunction occurred.&#160;(Reproduced, with permission, from&#160;Thompson&#160;<br/>MW et al. &#160;<i>Genetics in Medicine,</i>&#160;&#160;5th ed. Saunders, 1991.)&#160;&#160;<br/>
role in the pathogenesis of&#160;Down syndrome.&#160;If&#160;both&#160;copies of&#160;<br/>
more&#160;likely to&#160;support a trisomy 21 conceptus to&#160;term&#160;regard-<br/>
chromosome 21 carried by&#160;each&#160;parent&#160;can be&#160;distinguished,&#160;<br/>
less of&#160;which parent&#160;contributed the extra chromosome.&#160;Th<br/>
&#160;is&#160;<br/>
it&#160;is usually possible to determine whether the nondisjunction&#160;<br/>
hypothesis can explain why paternal nondisjunction errors&#160;<br/>
event leading to&#160;an&#160;abnormal gamete occurred during&#160;ana-<br/>
increase&#160;with&#160;advanced maternal age.&#160;However,&#160;it&#160;does not&#160;<br/>
phase of&#160;meiosis I or&#160;meiosis II (&#160;Figure 2–14&#160;). Studies such as&#160;<br/>
explain why the incidence of&#160;Down syndrome resulting&#160;from&#160;<br/>
these show that&#160;approximately&#160;75% of&#160;cases of&#160;trisomy 21 are&#160;<br/>
chromosomal rearrangements (see later discussion) does not&#160;<br/>
caused by&#160;an&#160;extra maternal chromosome,&#160;that&#160;approximately&#160;<br/>
increase&#160;with&#160;maternal age.&#160;<br/>
75% of&#160;the nondisjunction events (both maternal and pater-<br/>
&#160;Th<br/>
&#160;ese and other hypotheses are not mutually exclusive,&#160;<br/>
nal) occur in meiosis I, and that&#160;both&#160;maternal and paternal&#160;<br/>
and it&#160;is possible that&#160;a combination&#160;of&#160;factors is respon-<br/>
nondisjunction events increase&#160;with&#160;advanced maternal age.&#160;<br/>
sible for the relationship between the incidence of&#160;trisomy&#160;<br/>
&#160;Several theories have&#160;been proposed to&#160;explain why the&#160;<br/>
21 and advanced maternal age.&#160;A number of&#160;environmental&#160;<br/>
incidence of&#160;Down syndrome increases with&#160;advanced mater-<br/>
and genetic factors&#160;have&#160;been considered as possible causes&#160;<br/>
nal age (&#160;Figure 2–13&#160;). Most germ&#160;cell development in females&#160;<br/>
of&#160;Down syndrome,&#160;including exposure to&#160;caff&#160;eine,&#160;alcohol,&#160;<br/>
is completed before&#160;birth; oocytes arrest at&#160;prophase of&#160;meio-<br/>
tobacco, radiation, and the likelihood&#160;of&#160;carrying one or&#160;more&#160;<br/>
sis I (the &#160;<b>dictyotene</b>&#160;&#160;stage) during&#160;the second trimester of&#160;ges-<br/>
genes that&#160;would predispose to&#160;nondisjunction. Although&#160;it&#160;is&#160;<br/>
tation. One proposal suggests that&#160;biochemical abnormalities&#160;<br/>
diffi<br/>
&#160;&#160;cult&#160;to&#160;exclude all of&#160;these possibilities from&#160;consideration&#160;<br/>
that&#160;aff&#160;ect the ability of&#160;paired chromosomes to&#160;disjoin nor-<br/>
as minor factors, there is no evidence that&#160;any of&#160;these factors&#160;<br/>
mally accumulate&#160;in these cells over time and that, without a&#160;<br/>
play&#160;a role in Down syndrome.&#160;<br/>
renewable source of&#160;fresh eggs, the proportion of&#160;eggs under-<br/>
&#160;Th<br/>
&#160;&#160;e recurrence risk for trisomy 21 is not altered signifi&#160;cantly&#160;<br/>
going nondisjunction increases with&#160;maternal age. However,&#160;<br/>
by&#160;having had previous aff&#160;ected children. However,&#160;approxi-<br/>
this hypothesis does not explain why the relationship between&#160;<br/>
mately&#160;5% of&#160;Down syndrome karyotypes have&#160;46 rather than&#160;<br/>
the incidence of&#160;trisomy 21 and advanced maternal age holds&#160;<br/>
47 chromosomes as a result of&#160;robertsonian translocations&#160;<br/>
for paternal as well as maternal nondisjunction events.&#160;<br/>
that&#160;usually involve chromosomes 14 or&#160;22. As&#160;described,&#160;<br/>
&#160;Another hypothesis proposes that&#160;structural, hormonal, and&#160;<br/>
this type of&#160;abnormality is not associated with&#160;increased&#160;<br/>
immunologic changes that&#160;occur in the uterus with&#160;advanced&#160;<br/>
maternal age; however,&#160;in about 30% of&#160;such individuals,&#160;<br/>
age produce an&#160;environment less able to&#160;reject a develop-<br/>
cytogenetic evaluation of&#160;the parents reveals a so-called bal-<br/>
mentally abnormal embryo. Th<br/>
&#160;&#160;us, an&#160;older uterus would be&#160;<br/>
anced rearrangement such as 45,XX,&#160;+&#160;t(14q;21q). Because the&#160;<br/>
<hr/>
<a name=23></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 25<br/>
<b>A</b><br/>
<b>C</b><br/>
<b>B</b><br/>
Normal<br/>
Balanced<br/>
Unbalanced gametes<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–15&#160;&#160;</b>&#160;Types of gametes produced at meiosis by&#160;a carrier of a robertsonian translocation. In&#160;a balanced carrier for a robertsonian&#160;<br/>translocation, diﬀ&#160;erent types of segregation at meiosis lead to&#160;several diﬀ&#160;erent types of gametes, including ones that are completely normal (A),&#160;<br/>ones that would give&#160;rise to&#160;other balanced translocation carriers (B), and ones that would give&#160;rise to&#160;aneuploid progeny (C).&#160;<br/>
robertsonian translocation&#160;chromosome can pair with&#160;both&#160;<br/>
Nonetheless, on&#160;average,&#160;mental retardation in mosaic tri-<br/>
of&#160;its component single acrocentric chromosomes at&#160;meiosis,&#160;<br/>
somy&#160;21 is generally milder than&#160;in nonmosaic trisomy 21.&#160;&#160;<br/>
the likelihood&#160;of&#160;segregation leading to&#160;unbalanced gametes&#160;<br/>is signifi&#160;cant&#160;(&#160;Figure 2–15&#160;), and the recurrence risk to&#160;the par-<br/>
<b>&#160; Genetic&#160;&#160;Principles&#160;</b><br/>
ent with&#160;the abnormal karyotype is much&#160;higher than&#160;for tri-<br/>
&#160;A fundamental&#160;question in understanding the relationship&#160;<br/>
somy&#160;21 (&#160;Table 2–5&#160;). Approximately&#160;1% of&#160;Down syndrome&#160;<br/>
between an&#160;extra chromosome 21 and the clinical features&#160;<br/>
karyotypes show mosaicism in which some cells are normal&#160;<br/>
of&#160;Down syndrome is whether the phenotype&#160;is caused by&#160;<br/>
and some abnormal. Somatic mosaicism for trisomy 21 or&#160;<br/>
abnormal gene expression or&#160;an&#160;abnormal chromosomal&#160;<br/>
other aneuploid conditions may initially arise either prezy-<br/>
constitution. An important principle derived from&#160;studies&#160;<br/>
gotically or&#160;postzygotically,&#160;corresponding to&#160;nondisjunction&#160;<br/>
directed at&#160;this question is that&#160;of&#160;&#160;<b>gene dosage</b>,&#160;&#160;which states&#160;<br/>
in meiosis or&#160;mitosis, respectively. In&#160;the former case (one in&#160;<br/>
that&#160;the amount&#160;of&#160;a gene product produced per cell is pro-<br/>
which a zygote is conceived from&#160;an&#160;aneuploid gamete), the&#160;<br/>
portionate&#160;to&#160;the number of&#160;copies of&#160;that&#160;gene present. In&#160;<br/>
extra chromosome is then presumably&#160;lost mitotically in a&#160;<br/>
other words, the amount&#160;of&#160;protein produced by&#160;all or&#160;nearly&#160;<br/>
clone of&#160;cells during&#160;early embryogenesis. Th<br/>
&#160;&#160;e range&#160;of&#160;phe-<br/>
all genes that&#160;lie on&#160;chromosome 21 is 150% of&#160;normal in&#160;<br/>
notypes seen in mosaic trisomy 21 is great, ranging from&#160;mild&#160;<br/>
trisomy 21 cells and 50% of&#160;normal in monosomy 21 cells.&#160;<br/>
mental retardation with&#160;subtle dysmorphic features to&#160;“typi-<br/>
Th<br/>
&#160;&#160;us, unlike the X chromosome,&#160;there is no mechanism for&#160;<br/>
cal” Down syndrome,&#160;and does not correlate&#160;with&#160;the propor-<br/>
dosage compensation that&#160;operates on&#160;autosomal genes.&#160;<br/>
tion of&#160;abnormal cells detected in lymphocytes or&#160;fi&#160;broblasts.&#160;<br/>
&#160;Experimental evidence generally supports the view that&#160;the&#160;<br/>
Down syndrome phenotype&#160;is caused by&#160;increased expres-<br/>sion of&#160;specifi&#160;c genes and not by&#160;a nonspecifi&#160;c&#160;&#160;detrimental&#160;<br/>
<b>&#160;TABLE&#160;&#160;25&#160;&#160;Risk for Down syndrome depending on&#160;</b><br/>
eff&#160;ect of&#160;cellular aneuploidy. Rarely, karyotypic analysis of&#160;an&#160;<br/>
<b>parental sex and karyotype.&#160;&#160;1&#160;&#160;</b><br/>
individual with&#160;Down syndrome reveals a chromosomal rear-<br/>rangement (usually an&#160;unbalanced reciprocal translocation) in&#160;<br/>
<b>Risk of Abnormal Live-Born Progeny</b><br/>
which only&#160;a very&#160;small portion of&#160;chromosome 21 is pres-<br/>
<b>Karyotype of Parent</b><br/>
<b>&#160;Female&#160;&#160;Carrier&#160;</b><br/>
<b>&#160;Male&#160;&#160;Carrier&#160;</b><br/>
ent in three copies per cell (&#160;Figure 2–16&#160;).&#160;&#160;Th<br/>
&#160;ese&#160;observations&#160;<br/>
suggest that&#160;there may be&#160;a critical region of&#160;chromosome 21,&#160;<br/>
46,XX or 46,XY<br/>
0.5% (at age 20) to&#160;<br/>
&lt;0.5%<br/>
which, when present in triplicate,&#160;is both&#160;suffi<br/>
&#160; cient&#160;and&#160;neces-<br/>
30% (at age 30)<br/>
sary&#160;to&#160;produce Down syndrome.&#160;<br/>
Rb(Dq;21q) (mostly 14)<br/>
10%<br/>
&lt;2%<br/>
&#160;Th<br/>
&#160;&#160;e idea that&#160;altered gene dosage of&#160;a group of&#160;closely linked&#160;<br/>
genes can produce a distinct clinical phenotype&#160;is also sup-<br/>
Rb(21q;22q)<br/>
14%<br/>
&lt;2%<br/>
ported by&#160;the observation&#160;that&#160;an&#160;increasing number of&#160;con-<br/>
Rb(21q;21q)<br/>
100%<br/>
100%<br/>
genital anomaly syndromes have&#160;been found to&#160;be&#160;caused by&#160;<br/>so-called &#160;<b>copy number</b>&#160;&#160;or&#160;&#160;<b>structural variants</b>, &#160;&#160;oft&#160;en&#160;&#160;medi-<br/>
&#160;1&#160;Data from Scriver CR et al, eds.&#160;<i>&#160;The Metabolic and Molecular Bases of Inherited&#160;<br/>Disease&#160;,</i>&#160;7th ed. McGraw-Hill, 1995.<br/>
ated by&#160;homologous segments of&#160;DNA that&#160;lie at&#160;both&#160;ends&#160;<br/>
<hr/>
<a name=24></a>26 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
&#160;Carriers for robertsonian translocations that&#160;involve chro-<br/>
13<br/>
mosome 21 can produce several diff&#160;erent types of&#160;unbalanced&#160;<br/>
12<br/>
gametes (&#160;Figure 2–15&#160;). However,&#160;the empiric risk for such a&#160;<br/>
<b>21p</b><br/>
carrier bearing an&#160;infant&#160;with&#160;Down syndrome is higher than&#160;<br/>
11.2<br/>
for other aneuploid conditions, in part&#160;because embryos with&#160;<br/>
11.1<br/>
other types of&#160;aneuploidies are likely to&#160;result in miscarriages&#160;<br/>
11.1<br/>11.2<br/>
early in development. Th<br/>
&#160;&#160;us, the consequences of&#160;trisomy for&#160;<br/>
embryonic and fetal development are proportionate&#160;to&#160;the&#160;<br/>
21<br/>
number of&#160;genes expressed to&#160;150% of&#160;their normal levels.&#160;<br/>
<i>APP</i><br/>
Because monosomy for chromosome 21 (and other auto-<br/>
<b>21q</b><br/>
<i>SOD1</i><br/>
somes) is virtually never seen in live-born infants, a similar&#160;<br/>
22.1<br/>
line of&#160;reasoning suggests that&#160;a 50% reduction in gene expres-<br/>
DS critical<br/>
sion is more&#160;severe than&#160;a 50% increase. Finally,&#160;female rob-<br/>
22.2<br/>
<i>ETS2</i><br/>
region?<br/>
ertsonian translocation&#160;carriers exhibit&#160;much&#160;higher empiric&#160;<br/>
<i>CRYA1</i><br/>
22.3<br/>
<i>CBS</i><br/>
recurrence risks than&#160;male carriers, which suggests that&#160;(1)&#160;<br/>selective&#160;responses against aneuploidy&#160;can operate&#160;on&#160;gametic&#160;<br/>
<b>&#160; &#160;FIGURE&#160;&#160;2–16&#160;&#160;</b>&#160;Down syndrome (DS) critical region. Rarely,&#160;<br/>
as well as somatic cells and (2) spermatogenesis is more&#160;sensi-<br/>
individuals with Down syndrome will have&#160;chromosomal&#160;<br/>
tive&#160;to&#160;aneuploidy&#160;than&#160;oogenesis.&#160;&#160;<br/>
rearrangements that cause trisomy for just a portion of chromosome&#160;<br/>21. The&#160;&#160;<i>APP, SOD1, ETS2, CRYA1,</i>&#160;&#160;&#160;and&#160;&#160;<i>&#160;CBS</i>&#160;&#160;genes encode proteins&#160;<br/>(amyloid precursor, superoxide dismutase, the Ets2 transcription&#160;<br/>factor,&#160;crystallin, and cystathionine beta-synthase, respectively) that&#160;<br/>
<b>&#160;CHECKPOINT&#160;</b><br/>
may play a role in the pathogenesis of Down syndrome. Analysis of&#160;<br/>two sets of individuals (indicated by&#160;the two vertical lines) suggests&#160;<br/>
<i><b>&#160;&#160;&#160; &#160;14. &#160;&#160;</b></i>What are the common features of the variety of diﬀ&#160;erent&#160;<br/>
that the genes responsible for Down syndrome lie in the region of&#160;<br/>
karyotypic abnormalities resulting in Down syndrome?&#160;<br/>
overlap.&#160;(Reproduced, with permission, from&#160;Thompson MW et al. &#160;<i>Genetics in&#160;</i><br/>
<i><b>&#160;&#160;&#160; 15. &#160;&#160;</b></i>What are the major categories of abnormalities in Down&#160;<br/>
<i>Medicine,</i>&#160;&#160;5th ed. Saunders, 1991.)&#160;&#160;<br/>
syndrome, and what is their natural history?&#160;<br/>
<i><b>&#160;&#160;&#160; 16. &#160;&#160;</b></i>Explain why trisomy 21 is associated with such a wide&#160;<br/>
range of phenotypes from mild mental retardation to&#160;<br/>
of&#160;deletion and/or insertion breakpoints. Such&#160;structural&#160;<br/>
that of&#160;“typical”&#160;Down syndrome.&#160;&#160;<br/>
variants, which can be&#160;easily detected with&#160;molecular&#160;genetic&#160;<br/>techniques, result in an&#160;increase&#160;and/or decrease&#160;in gene copy&#160;<br/>number for one or&#160;more&#160;genes. &#160;<b>Contiguous gene syndromes</b>, &#160;<br/>described in &#160;Table 2–6&#160;, are generally rare, but they&#160;have&#160;played&#160;<br/>
<b>&#160;IMPACT&#160;OF&#160;THE&#160;HUMAN&#160;GENOME&#160;</b><br/>
important roles in understanding the pathophysiology of&#160;<br/>aneuploid conditions.&#160;<br/>
<b>PROJECT&#160;AND&#160;GENOME&#160;SEQUENCING&#160;</b><br/>
<b>ON&#160;PATHOPHYSIOLOGY&#160;</b><br/>
&#160;Th<br/>
&#160;&#160;e major goal of&#160;the Human Genome Project is to&#160;determine&#160;<br/>
<b>&#160;TABLE&#160;&#160;26&#160;&#160;Phenotype and karyotype of some&#160;</b><br/>
the identity and gain understanding of&#160;all the genes of&#160;human&#160;<br/>
<b>contiguous gene syndromes.&#160;</b><br/>
beings and to&#160;apply&#160;this information to&#160;the diagnosis and&#160;<br/>treatment of&#160;human disease. An international collaboration,&#160;<br/>
<b>Syndrome</b><br/>
<b>Phenotype</b><br/>
<b>Deletion</b><br/>
in which U.S. eff&#160;orts were&#160;coordinated by&#160;the National Human&#160;<br/>
Langer-Gideon<br/>
Mental retardation,&#160;<br/>
8q24.11–q24.3<br/>
Genome Research Institute,&#160;achieved a primary&#160;milestone&#160;<br/>
microcephaly, bony&#160;<br/>
in 2003 when the approximately&#160;3 billion nucleotide human&#160;<br/>
exostoses, redundant skin<br/>
genome DNA sequence was determined.&#160;<br/>
WAGR<br/>
Wilms tumor, aniridia,&#160;<br/>
11p13<br/>
&#160;Understanding the function of&#160;all of&#160;the genes of&#160;human&#160;<br/>
gonadoblastoma, mental&#160;<br/>
beings has been facilitated by&#160;determining genome sequences&#160;<br/>
retardation<br/>
for other living organisms. Some are closely related to&#160;humans&#160;<br/>
Prader-Willi<br/>
Mental and growth&#160;<br/>
15q11–q13<br/>
on&#160;an&#160;evolutionary&#160;time scale, such&#160;as&#160;the chimpanzee, whose&#160;<br/>
retardation,&#160;<br/>
genome is approximately&#160;98% the same as humans, and&#160;<br/>
hypotonia, obesity,&#160;<br/>
whose last common ancestor&#160;with&#160;humans&#160;lived approxi-<br/>
hypopigmentation<br/>
mately&#160;6 million years ago.&#160;Others are more&#160;distantly related&#160;<br/>
Miller-Dieker<br/>
Severe&#160;mental retardation&#160;&#160;17p13.3<br/>
such as the laboratory&#160;mouse,&#160;the fruitfl&#160;y,&#160;or&#160;bakers’&#160;yeast, but&#160;<br/>
absence of cortical gyri&#160;<br/>
nonetheless serve as valuable model organisms for experi-<br/>
(lissencephaly) and corpus&#160;<br/>
mental biologists. Even the laboratory&#160;mouse,&#160;whose last com-<br/>
callosum<br/>
mon ancestor&#160;with&#160;humans&#160;lived approximately&#160;100 million&#160;<br/>
<hr/>
<a name=25></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 27<br/>
years ago,&#160;shares more&#160;than&#160;95% of&#160;its genes with&#160;the human&#160;<br/>
&#160;Indeed, there is much&#160;excitement today about the potential of&#160;<br/>
genome. Th<br/>
&#160;ese considerations&#160;underscore the important&#160;<br/>
personalized genetic medicine, in part&#160;due to&#160;recent advances&#160;<br/>
genetic principle that&#160;the processes of&#160;evolution have&#160;left&#160;&#160;valu-<br/>
in several diff&#160;erent areas. First, technological advances now&#160;<br/>
able molecular&#160;footprints that&#160;can be&#160;used to&#160;learn more&#160;about&#160;<br/>
make it&#160;possible to effi<br/>
&#160;&#160;ciently measure variation at&#160;millions&#160;<br/>
human biology.&#160;<br/>
of&#160;SNPs&#160;in individual patient samples as a routine laboratory&#160;<br/>
&#160;One important advance of&#160;the Human Genome Project in&#160;<br/>
test. Th<br/>
&#160;&#160;ese kinds of&#160;tests have&#160;been applied to&#160;thousands of&#160;<br/>
the last decade has been a catalog of&#160;common human genetic&#160;<br/>
individuals in so-called case-control studies, to&#160;identify par-<br/>
variation, usually referred to&#160;as the HapMap&#160;(for&#160;Haplotype&#160;<br/>
ticular&#160;SNPs&#160;that&#160;occur more&#160;or&#160;less frequently in cases vs.&#160;<br/>
Map), in which more&#160;than&#160;3 million SNPs&#160;have&#160;been geno-<br/>
controls. Second, advances in the design and analysis of&#160;this&#160;<br/>
typed among individuals of&#160;diverse genetic ancestry,&#160;includ-<br/>
type of&#160;approach, known as a &#160;<b>genomewide&#160;association&#160;study</b>&#160;<br/>
ing populations&#160;from&#160;Asia, Africa, the Americas, and Europe.&#160;<br/>
(GWAS), have&#160;been very&#160;successful in identifying&#160;new genetic&#160;<br/>
Because common genetic diff&#160;erences are a major determi-<br/>
determinants for obesity, diabetes, infl&#160;ammatory&#160;bowel dis-<br/>
nant&#160;of&#160;susceptibility to&#160;conditions such as diabetes mellitus,&#160;<br/>
ease, coronary&#160;artery&#160;disease, and other common conditions.&#160;<br/>
hypertension, obesity, and schizophrenia, a principle goal of&#160;<br/>
&#160;A second very&#160;important advance in the Human Genome&#160;<br/>
the HapMap&#160;is to&#160;develop a molecular&#160;understanding of&#160;those&#160;<br/>
Project has been the drive to&#160;develop new technological&#160;<br/>
determinants. Importantly,&#160;the HapMap&#160;catalog of&#160;common&#160;<br/>
approaches for effi<br/>
&#160;&#160;cient and inexpensive&#160;DNA sequencing.&#160;<br/>
human genetic variation makes it&#160;possible to&#160;predict DNA&#160;<br/>
So-called &#160;<br/>
<b>next-generation sequencing</b>&#160;<br/>
&#160;instruments use an&#160;<br/>
sequence variation for specifi&#160;c segments of&#160;the genome, even&#160;<br/>
innovative&#160;combination&#160;of&#160;molecular&#160;biologic, computational,&#160;<br/>
when that&#160;sequence has not been measured directly.&#160;Th<br/>
&#160;e&#160;<br/>
and optical principles and have&#160;revolutionized our approach to&#160;<br/>
underlying&#160;reason&#160;is that&#160;in most cases, closely linked&#160;SNPs&#160;<br/>
biomedical research&#160;and medical care. Th<br/>
&#160;&#160;e scale of&#160;technologi-<br/>
are not independently distributed&#160;among humans&#160;but are non-<br/>
cal advance is staggering: Sequencing the fi&#160;rst human genome&#160;<br/>
randomly associated in clusters known as haplotype blocks.&#160;<br/>
cost several billion dollars&#160;and required the eff&#160;ort of&#160;several&#160;<br/>
For example, if two closely linked SNPs&#160;are each&#160;found at&#160;a fre-<br/>
thousand scientists over a decade; today,&#160;a single laboratory&#160;<br/>
quency of&#160;30%, chromosomes that&#160;carry both&#160;SNPs&#160;may exist&#160;<br/>
technician can sequence a genome on&#160;a benchtop&#160;instrument&#160;<br/>
at&#160;a frequency considerably&#160;diff&#160;erent from&#160;9%, which would be&#160;<br/>
for a few thousand dollars.&#160;<br/>
the prediction if the two SNPs&#160;were&#160;completely independent.&#160;<br/>
&#160;Th<br/>
&#160;&#160;e availability and low cost of&#160;genome sequencing are hav-<br/>
Th<br/>
&#160;&#160;is phenomenon, referred to&#160;as &#160;<b>allelic association</b>&#160;&#160;or&#160;&#160;<b>linkage&#160;</b><br/>
ing an&#160;enormous impact on&#160;our approach to&#160;the diagnosis&#160;<br/>
<b>disequilibrium</b>,&#160;&#160;is due to&#160;human evolutionary&#160;and population&#160;<br/>
and pathophysiologic understanding of&#160;genetic disease. For&#160;<br/>
history;&#160;the extent to&#160;which new SNPs&#160;(that arise by&#160;mutation)&#160;<br/>
example, the ability to&#160;compare entire genome sequences (or&#160;<br/>
become separated from&#160;closely adjacent SNPs&#160;(by recombina-<br/>
partial sequences of&#160;the protein-coding regions, or&#160;&#160;<b>exomes</b>&#160;)&#160;&#160;of&#160;<br/>
tion) depends on&#160;the distance between adjacent SNPs&#160;and the&#160;<br/>
individuals aff&#160;ected with&#160;rare&#160;syndromes is rapidly leading to&#160;<br/>
eff&#160;ects of&#160;population history on&#160;the chances for recombination.&#160;<br/>
the identifi&#160;cation of&#160;mutations&#160;that&#160;cause thousands of&#160;diff&#160;er-<br/>
&#160;Th<br/>
&#160;e idea that&#160;measuring human genetic variation on&#160;a&#160;<br/>
ent conditions, including recessively&#160;inherited&#160;forms of&#160;osteo-<br/>
genome-wide scale could provide insight&#160;into&#160;common dis-<br/>
genesis imperfecta, many&#160;unexplained syndromes that&#160;involve&#160;<br/>
eases such as hypertension, schizophrenia, and cancer under-<br/>
intellectual disability,&#160;and neuropsychiatric conditions such as&#160;<br/>
scores the perspective that&#160;there is a spectrum of&#160;genetic&#160;<br/>
autism. In&#160;addition, the ability to&#160;compare genome sequences&#160;<br/>
disease&#160;from&#160;rare&#160;conditions inherited&#160;in a mendelian fash-<br/>
of&#160;diff&#160;erent tissues or&#160;biopsy samples from&#160;the same individ-<br/>
ion (which have&#160;been the major subject of&#160;this chapter) to&#160;<br/>
ual allows unprecedented insight&#160;into&#160;the pathophysiology&#160;<br/>
so-called complex genetic or&#160;multifactorial conditions, for&#160;<br/>
of&#160;many&#160;cancers, identifying, for example, a catalog of&#160;DNA&#160;<br/>
which the incidence of&#160;the disease&#160;is infl&#160;uenced by&#160;a combi-<br/>
sequence alterations&#160;that&#160;have&#160;occurred and in some cases&#160;<br/>
nation of&#160;genes, environment, and chance. Identifying&#160;genetic&#160;<br/>
have&#160;helped to&#160;drive the progression of&#160;blood&#160;cancers, brain&#160;<br/>
components of&#160;multifactorial conditions is an&#160;important goal&#160;<br/>
tumors, breast cancer, prostate cancer, and melanoma.&#160;<br/>
of&#160;the&#160;fi&#160;eld of&#160;genetic epidemiology,&#160;in which epidemiology-<br/>
&#160;Th<br/>
&#160;&#160;e future&#160;of&#160;genetic medicine will be&#160;greatly informed by&#160;<br/>
based study designs are applied to&#160;populations&#160;whose famil-<br/>
these advances; many&#160;scientists envision that&#160;powerful but&#160;<br/>
ial structure&#160;is uncertain or&#160;unknown, and the measurement&#160;<br/>
inexpensive&#160;laboratory&#160;tests that&#160;measure genetic variation&#160;<br/>
of&#160;SNPs&#160;in candidate&#160;genes are treated as hypothetical risk&#160;<br/>
across the entire genome will soon&#160;be&#160;used routinely to&#160;pre-<br/>
factors. For example, the epsilon 4 allele of&#160;the apolipopro-<br/>
dict individual susceptibility to&#160;common and rare&#160;diseases and&#160;<br/>
tein E gene (&#160;<i>APOE4</i>&#160;), is found in approximately&#160;15% of&#160;the&#160;<br/>
take&#160;appropriate steps to&#160;intervene and/or modify the course&#160;<br/>
population and increases the risk of&#160;both&#160;atherosclerosis and&#160;<br/>
of&#160;those conditions. For example, individuals at&#160;high risk for&#160;<br/>
late-onset Alzheimer disease. However,&#160;&#160;<i>APOE4</i>&#160;&#160;is&#160;just&#160;one&#160;of&#160;<br/>
certain types of&#160;cancer may benefi&#160;t from&#160;aggressive&#160;screening&#160;<br/>
many&#160;genes that&#160;infl&#160;uence susceptibility to&#160;these important&#160;<br/>
programs.&#160;<br/>
conditions, and a major goal of&#160;the HapMap&#160;is to&#160;identify and&#160;<br/>
&#160;Genetic&#160;&#160;diff&#160;erences may also help identify subgroups of&#160;<br/>
characterize those genes, both&#160;to&#160;develop new treatments,&#160;<br/>
patients whose course&#160;is likely to&#160;be&#160;more&#160;or&#160;less severe&#160;<br/>
and to&#160;provide as much&#160;information as possible to&#160;physicians&#160;<br/>
and who may respond to&#160;a particular treatment. Th<br/>
&#160;e&#160;latter&#160;<br/>
and their patients regarding disease&#160;susceptibility as a func-<br/>
approach is part&#160;of&#160;the larger fi&#160;eld of&#160;pharmacogenomics,&#160;<br/>
tion of&#160;genetics.&#160;<br/>
in which sequence variation in the hundreds of&#160;genes that&#160;<br/>
<hr/>
<a name=26></a>28 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
infl&#160;uence drug absorption, metabolism, and excretion is a&#160;<br/>
particular situation might&#160;be&#160;used to&#160;help predict the patho-<br/>
major determinant&#160;of&#160;the balance between pharmacologic effi<br/>
&#160; -<br/>
physiologic response&#160;to&#160;alcoholic liver damage,&#160;type of&#160;regi-<br/>
cacy and toxicity. One might&#160;imagine, for example, that&#160;tests&#160;<br/>
men used to&#160;treat leukemia, and course&#160;of&#160;infectious diseases&#160;<br/>
for specifi&#160;c nucleotide diff&#160;erences in a set of&#160;genes unique to&#160;a&#160;<br/>
like tuberculosis or&#160;HIV infection.&#160;&#160;<br/>
<b>&#160; CASE&#160;&#160;STUDIES &#160;&#160;&#160;<br/>&#160;Yeong Kwok, MD&#160;</b><br/>
&#160;(See &#160;Chapter 25&#160;, p.&#160;695 for Answers)&#160;<br/>
<b>&#160;&#160;C&#160;A&#160;S&#160;E&#160;&#160;&#160;1&#160;</b><br/>
&#160;A 4-year-old boy is brought in with pain and swelling of the&#160;<br/>
<i><b>&#160; Questions &#160;</b></i><br/>
right thigh after a fall in the home. An x-ray ﬁ&#160;lm reveals an&#160;<br/>
<i><b>&#160; &#160;A. &#160;&#160;</b></i>What are the four types of osteogenesis imperfecta? How&#160;<br/>
acute fracture of the right femur. Questioning of the mother&#160;<br/>
are they genetically transmitted?&#160;<br/>
reveals that the boy has had two other known fractures—left&#160;<br/>
<i><b>&#160;B.&#160;&#160;</b></i>Which two types are most likely in this patient? How might&#160;<br/>
humerus and left tibia—both with minimal trauma.&#160;The fam-<br/>
they be distinguished clinically?&#160;<br/>
ily history is notable for a bone problem during childhood in&#160;<br/>
<i><b>&#160; C. &#160;&#160;</b></i>Further workup results in a diagnosis of type I osteogenesis&#160;<br/>
the boy’s father that got better as he grew into adulthood. A&#160;<br/>
imperfecta.&#160;What clinical features may the boy expect in&#160;<br/>
diagnosis of osteogenesis imperfecta is entertained.&#160;<br/>
adult life?&#160;<br/>
<i><b>&#160;D.&#160;&#160;</b></i>What is the pathogenesis of this patient’s&#160;disease?&#160;&#160;<br/>
<b>&#160;&#160;C&#160;A&#160;S&#160;E&#160;&#160;&#160;2&#160;</b><br/>
&#160;A newborn girl tests positive for phenylketonuria (PKU) on a&#160;<br/>
<i><b>&#160; Questions &#160;</b></i><br/>
newborn screening examination.&#160;The results of a conﬁ&#160;rma-<br/>
<i><b>&#160; &#160;A. &#160;&#160;</b></i>What are the metabolic defects in persons with PKU?&#160;<br/>
tory&#160;serum test done at 2 weeks of age are also positive,&#160;es-<br/>
<i><b>&#160;B.&#160;&#160;</b></i>How do these defects lead to&#160;clinical disease in persons not&#160;<br/>
tablishing the diagnosis of PKU.&#160;<br/>
treated with dietary restrictions appropriate for PKU?&#160;<br/>
<i><b>&#160; C. &#160;&#160;</b></i>What is the genetic pattern of inheritance,&#160;and what are&#160;<br/>
some possible explanations for why the gene for the condi-<br/>tion has persisted in the gene pool despite the obvious dis-<br/>advantages for the aﬀ&#160;ected&#160;&#160;individuals? &#160;&#160;<br/>
<b>&#160;&#160;C&#160;A&#160;S&#160;E&#160;&#160;&#160;3&#160;</b><br/>
&#160;A young woman is referred for genetic counseling. She has&#160;<br/>
<i><b>&#160; Questions &#160;</b></i><br/>
a 3-year-old boy with developmental delay and small joint&#160;<br/>
<i><b>&#160; &#160;A. &#160;&#160;</b></i>What is the genetic mutation responsible for fragile&#160;<br/>
hyperextensibility.&#160;The pediatrician has diagnosed fragile&#160;<br/>
X–associated mental retardation? How does it cause the&#160;<br/>
X–associated mental retardation. She is currently pregnant&#160;<br/>
clinical syndrome of developmental delay,&#160;joint hyperexten-<br/>
with her second child at 14 weeks of gestation.&#160;The family&#160;<br/>
sibility,&#160;large testes, and facial abnormalities?&#160;<br/>
history is unremarkable.&#160;<br/>
<i><b>&#160;B.&#160;&#160;</b></i>Which parent is the probable carrier of the genetic muta-<br/>
tion? Explain why this parent and the grandparents are phe-<br/>notypically unaﬀ&#160;ected.&#160;<br/>
<i><b>&#160; C. &#160;&#160;</b></i>What is the likelihood that the unborn child will be aﬀ&#160;ected? &#160;&#160;<br/>
<hr/>
<a name=27></a><b>CHAPTER 2&#160;</b>Genetic&#160;<br/>
Disease&#160; 29<br/>
<b>&#160;&#160;C&#160;A&#160;S&#160;E&#160;&#160;&#160;4&#160;</b><br/>
&#160;A 16-year-old boy presents with worsening vision for the&#160;<br/>
<i><b>&#160; Questions &#160;</b></i><br/>
past 2 months. He ﬁ&#160;rst noticed that he was having trouble&#160;<br/>
<i><b>&#160; &#160;A. &#160;&#160;</b></i>What is the central defect in Leber hereditary optic neuropa-<br/>
with central vision in his right eye,&#160;seeing a dark spot in the&#160;<br/>
thy (LHON)?&#160;<br/>
center of his visual ﬁ&#160;eld.&#160;The dark spot had gotten larger over&#160;<br/>
<i><b>&#160;B.&#160;&#160;</b></i>How is this disorder inherited, and what is the principle of&#160;<br/>
time, and he had also developed a central loss of vision in his&#160;<br/>
heteroplasmy?&#160;<br/>
left eye.&#160;Two of his maternal uncles had loss of vision, but his&#160;<br/>
<i><b>&#160; C. &#160;&#160;</b></i>What explains the fact that males are much more likely to&#160;be&#160;<br/>
mother and another maternal uncle and two maternal aunts&#160;<br/>
aﬀ&#160;ected than females?&#160;&#160;<br/>
had no visual diﬃ<br/>
&#160;&#160;culties. No one on his father’s&#160;side was af-<br/>
fected. Physical examination reveals microangiopathy and&#160;<br/>vascular tortuosity of the retina. Genetic testing conﬁ&#160;rms&#160;the&#160;<br/>diagnosis of Leber hereditary optic neuropathy.&#160;<br/>
<b>&#160;&#160;C&#160;A&#160;S&#160;E&#160;&#160;&#160;5&#160;</b><br/>
&#160;A 40-year-old woman, recently married and pregnant for&#160;<br/>
<i><b>&#160; Questions &#160;</b></i><br/>
the ﬁ&#160;rst time, comes to&#160;the clinic with a question about the&#160;<br/>
<i><b>&#160; &#160;A .&#160;&#160;</b></i>What is the rate of occurrence of Down syndrome in the&#160;<br/>
chances of having&#160;“a&#160;Down syndrome baby.”&#160;<br/>
general population?&#160;What are some of the common clinical&#160;<br/>features?&#160;<br/>
<i><b>&#160;B.&#160;&#160;</b></i>What major genetic abnormalities are associated with Down&#160;<br/>
syndrome? How might these abnormalities lead to&#160;the clini-<br/>cal features of the syndrome?&#160;<br/>
<i><b>&#160; C. &#160;&#160;</b></i>How might this woman’s&#160;age contribute to&#160;her risk of having&#160;<br/>
a child with Down syndrome?&#160;&#160;<br/>
<b>&#160; REFERENCES&#160;</b><br/>
&#160;Hartnett C et al. Long-term outcomes of&#160;blood&#160;phenylalanine con-<br/>
centrations in children with&#160;classical phenylketonuria. Mol Genet&#160;<br/>Metab.&#160;2013 Apr;108(4):255–8. [PMID: 23465864]&#160;<br/>
<b>&#160; Osteogenesis&#160;&#160;Imperfecta&#160;</b><br/>
&#160;<br/>
Prick BW&#160;et al. Maternal phenylketonuria and hyperphenylal-<br/>
&#160;Byers&#160;PH et al. Recessively&#160;inherited&#160;forms of&#160;osteogenesis imper-<br/>
aninemia in pregnancy:&#160;pregnancy complications and neonatal&#160;<br/>
fecta. Annu Rev Genet. 2012;46:475–97. [PMID: 23145505]&#160;<br/>
sequelae in untreated and treated pregnancies. Am J Clin Nutr.&#160;<br/>
&#160;Forlino A et al. New perspectives on&#160;osteogenesis imperfecta. Nat Rev&#160;<br/>
2012 Feb;95(2):374–82. [PMID: 22205310]&#160;&#160;<br/>
Endocrinol.&#160;2011 Jun 14;7(9):540–57. [PMID: 21670757]&#160;<br/>
&#160;<br/>
Ishikawa Y et al. A molecular&#160;ensemble in the rER for procol-<br/>
<b>&#160; Fragile&#160;&#160;X–Associated&#160;</b><br/>
lagen maturation. Biochim Biophys Acta. 2013 Apr 18. 2013&#160;<br/>Nov;1833:2479–91. [PMID: 23602968]&#160;&#160;<br/>
<b>Mental Retardation&#160;<br/></b>&#160;Bhakar AL et al. Th<br/>
&#160;&#160;e pathophysiology of&#160;fragile X (and what&#160;it&#160;teaches&#160;<br/>
<b>&#160; Phenylketonuria&#160;</b><br/>
us about synapses). Annu Rev Neurosci. 2012;35:417–43. [PMID:&#160;<br/>22483044]&#160;<br/>
&#160;Flydal M et al. Phenylalanine hydroxylase: function, structure,&#160;<br/>
&#160;Lee HY et al. Fragile X syndrome: mechanistic insights and therapeu-<br/>
and regulation. IUBMB Life. 2013 Apr;65(4):341–9. [PMID:&#160;<br/>
tic avenues regarding the role of&#160;potassium channels. Curr&#160;Opin&#160;<br/>
23457044]&#160;<br/>
Neurobiol.&#160;2012 Oct;22(5):887–94. [PMID: 22483378]&#160;<br/>
&#160;Giovannini M et al. Phenylketonuria: nutritional advances and&#160;<br/>
&#160;<br/>
Mclennan Y et al. Fragile X syndrome.&#160;Curr&#160;Genomics. 2011&#160;<br/>
challenges. Nutr Metab (Lond). 2012 Feb 3;9(1):7. [PMID:&#160;<br/>
May;12(3):216–24. [PMID: 22043169]&#160;<br/>
22305125]&#160;<br/>
<hr/>
<a name=28></a>30 &#160;<b>CHAPTER 2&#160;</b>Genetic Disease<br/>
&#160;Wang&#160;T et al. New perspectives on&#160;the biology of&#160;fragile X syn-<br/>
&#160;Mersy E et al. Noninvasive&#160;detection of&#160;fetal trisomy 21: systematic&#160;<br/>
drome.&#160;Curr&#160;Opin Genet Dev.&#160;2012 Jun;22(3):256–63. [PMID:&#160;<br/>
review and report&#160;of&#160;quality and outcomes of&#160;diagnostic accuracy&#160;<br/>
22382129]&#160;&#160;&#160;<br/>
studies performed between 1997 and 2012. Hum Reprod Update.&#160;<br/>2013 Jul–Aug;19(4):318–29. [PMID: 23396607]&#160;&#160;<br/>
<b>&#160; LHON,&#160;&#160;MERFF,&#160;&#160;&amp;&#160;</b><br/>
<b>Mitochondrial Diseases&#160;</b><br/>
<b>&#160;The Human Genome Project&#160;</b><br/>
&#160;Davis RL et al. Th<br/>
&#160;&#160;e genetics of&#160;mitochondrial disease. Semin Neurol.&#160;<br/>
<b>&amp; Human Genetic&#160;Variation&#160;</b><br/>
2011 Nov;31(5):519–30. [PMID: 22266889]&#160;<br/>
&#160;Alkan C et al. Genome structural variation discovery&#160;and genotyping.&#160;<br/>
&#160;Finsterer J.&#160;Inherited&#160;mitochondrial disorders. Adv Exp Med Biol.&#160;<br/>
Nat Rev Genet. 2011 May;12(5):363–76. [PMID: 21358748]&#160;<br/>
2012;942:187–213. [PMID: 22399423]&#160;<br/>
&#160;Bamshad MJ et al. Exome sequencing as a tool&#160;for Mendelian dis-<br/>
&#160;<br/>
Kirches E. LHON: mitochondrial mutations&#160;and more. Curr&#160;<br/>
ease&#160;gene discovery. Nat Rev Genet. 2011 Sep 27;12(11):745–55.&#160;<br/>
Genomics. 2011 Mar;12(1):44–54. [PMID: 21886454]&#160;&#160;<br/>
[PMID: 21946919]&#160;<br/>
&#160;Connolly JJ et al. Th<br/>
&#160;&#160;e impact of&#160;genomics on&#160;pediatric research&#160;and&#160;<br/>
<b>&#160; Down&#160;&#160;Syndrome&#160;</b><br/>
medicine. Pediatrics 2012 Jun;129(6):1150–60. [PMID: 22566424]&#160;<br/>
&#160;Gonzaga-Jauregui C et al. Human genome sequencing in health&#160;and&#160;<br/>
&#160;Haydar&#160;TF et al. Trisomy 21 and early brain development. Trends&#160;<br/>
disease. Annu Rev Med.&#160;2012;63:35–61. [PMID: 22248320]&#160;<br/>
Neurosci. 2012 Feb;35(2):81–91. [PMID: 22169531]&#160;<br/>
&#160;Shendure J et al. Th<br/>
&#160;e expanding scope of&#160;DNA sequencing. Nat&#160;<br/>
&#160;Letourneau&#160;A et al. Genomic determinants in the phenotypic vari-<br/>
Biotechnol.&#160;2012 Nov;30(1):1084–94. [PMID: 23138308]&#160;<br/>
ability of&#160;Down syndrome.&#160;Prog Brain Res. 2012;197:15–28.&#160;<br/>
&#160;Vandeweyer G et al. Detection and interpretation of&#160;genomic struc-<br/>
[PMID: 22541286]&#160;<br/>
tural variation in health&#160;and disease. Expert Rev Mol Diagn. 2013&#160;<br/>Jan;13(1):61–82.&#160;&#160;[PMID:&#160;&#160;23256704] &#160; &#160; &#160;<b>&#160;</b>&#160;<br/>
<hr/>
</body>
</html>
